drTarget portfolio target-disease associations for nervous system DrTarget’s AI-Powered Indication Expansion for Nervous System Diseases

DrTarget’s AI-Driven Insights into Nervous System Disorders

DrTarget has mapped 348 target proteins from PubChem screens to 1,146 nervous system diseases, leveraging data from Open Targets and other public databases. By integrating AI-powered analytics, machine learning models, and association scoring, we identify potential therapeutic targets for neurological conditions.

Our approach enables:

✔ Target discovery for drug repurposing
✔ Prioritization of high-confidence gene-disease associations
✔ Identification of novel therapeutic opportunities

This dataset supports drug discovery oriented to precision medicine efforts, offering valuable insights into neurodegenerative and neurological disorders.

Target-disease associations for nervous system diseases.

Check best scored target-disease associations in table by selecting scores, genes or diseases:

PubChemAssay	program	diseaseName	testedComopunds	activeCompounds	associationScore	numberOfEvidences
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	epilepsy	305610	3878	0.601110466899752	32
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	epilepsy	305610	1082	0.601110466899752	32
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	epilepsy	305609	3405	0.694388489028926	1078
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	epilepsy	305600	1644	0.694388489028926	1078
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	epilepsy	292323	567	0.700209149187544	307
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	epilepsy	104728	4230	0.708489341786052	1893
uHTS identification of small molecule modulators of NR3A	GRIN3A	epilepsy	339772	8480	0.56770916893568	14
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	stroke	335239	991	0.539927483209128	7
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	stroke	335239	695	0.539927483209128	7
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	stroke	407539	2380	0.563827088782784	12
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	stroke	364051	9106	0.563827088782784	12
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	stroke	407539	2380	0.563827088782784	12
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	stroke	335531	328	0.646209969421255	32
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	stroke	339297	1446	0.628120473874919	23
Thrombin 1536 HTS	F2_modulation	stroke	217233	557	0.745819195337535	29
uHTS identification of small molecule modulators of NR3A	GRIN3A	stroke	339772	8480	0.51828395256274	6
qHTS of TDP-43 Inhibitors	TARDBP	familial amyotrophic lateral sclerosis	403703	7150	0.91464415824384	482
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	familial amyotrophic lateral sclerosis	45163	203	0.91464415824384	482
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	familial amyotrophic lateral sclerosis	217959	923	0.699636907731946	319
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	sporadic amyotrophic lateral sclerosis	385746	932	0.892054957027048	663
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	deafness	362274	1085	0.737707430803668	111
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	deafness	96879	447	0.581946589576287	24
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	deafness	96879	207	0.581946589576287	24
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	peripheral neuropathy	42576	834	0.511377243461816	809
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	peripheral neuropathy	335239	991	0.554662029590942	19
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	peripheral neuropathy	335239	695	0.554662029590942	19
qHTS of TDP-43 Inhibitors	TARDBP	motor neuron disease	403703	7150	0.636159681085823	613
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	motor neuron disease	45163	203	0.636159681085823	613
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	pain	290355	265	0.66739120894794	1664
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	pain	86095	1442	0.502874234984747	10
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	pain	86095	1151	0.502874234984747	10
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	pain	363803	2412	0.602176088428136	20
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	pain	335239	991	0.669376737588158	4676
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	pain	335239	695	0.669376737588158	4676
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	pain	292323	567	0.575594093745969	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	pain	359518	300	0.583819867656698	15
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	pain	335652	1779	0.583819867656698	15
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	pain	362274	1056	0.583819867656698	15
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	pain	336308	6862	0.583819867656698	15
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	pain	357537	806	0.583819867656698	15
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	pain	339887	1178	0.583819867656698	15
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	pain	407539	2380	0.565948160307315	14
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	pain	364051	9106	0.565948160307315	14
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	pain	407539	2380	0.565948160307315	14
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	pain	335531	328	0.520819643474188	6
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	pain	359207	1189	0.608284957389344	18
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	pain	63676	1938	0.608284957389344	18
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	pain	359207	316	0.608284957389344	18
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	pain	63656	2179	0.608284957389344	18
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	pain	359207	4555	0.608284957389344	18
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	pain	339297	1446	0.659538183102147	110
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	pain	305610	3794	0.593212449856628	10
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	pain	339674	2841	0.593212449856628	10
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	pain	316642	617	0.675089080796179	1370
uHTS identification of small molecule modulators of NR3A	GRIN3A	pain	339772	8480	0.662857415411265	216
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	hearing loss	364053	2026	0.563348198535835	93
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	hearing loss	362274	1085	0.54644243570006	75
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	partial epilepsy	292323	567	0.592949719312303	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	vital capacity	363803	458	0.511751699353967	12
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	vital capacity	343467	1710	0.64677440372713	18
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	restless legs syndrome	335239	991	0.516582222217723	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	restless legs syndrome	335239	695	0.516582222217723	9
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	restless legs syndrome	359518	300	0.658301784622236	117
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	restless legs syndrome	335652	1779	0.658301784622236	117
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	restless legs syndrome	362274	1056	0.658301784622236	117
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	restless legs syndrome	336308	6862	0.658301784622236	117
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	restless legs syndrome	357537	806	0.658301784622236	117
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	restless legs syndrome	339887	1178	0.658301784622236	117
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	restless legs syndrome	407539	2380	0.658022198908649	108
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	restless legs syndrome	364051	9106	0.658022198908649	108
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	restless legs syndrome	407539	2380	0.658022198908649	108
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	smoking cessation	108286	1415	0.640378804205756	36
uHTS identification of small molecule modulators of NR3A	GRIN3A	suicidal ideation	339772	8480	0.574864567642163	18
uHTS identification of small molecule modulators of NR3A	GRIN3A	attempted suicide	339772	8480	0.556037572799865	6
qHTS Assay for Identification of Novel General Anesthetics	FTL	movement disorder	341499	255	0.549353067496944	104
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	movement disorder	218528	711	0.514885375373638	44
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	movement disorder	218528	770	0.514885375373638	44
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	movement disorder	218528	750	0.514885375373638	44
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	movement disorder	363803	2412	0.608815855986794	37
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	movement disorder	359518	300	0.653671582289342	258
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	movement disorder	335652	1779	0.653671582289342	258
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	movement disorder	362274	1056	0.653671582289342	258
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	movement disorder	336308	6862	0.653671582289342	258
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	movement disorder	357537	806	0.653671582289342	258
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	movement disorder	339887	1178	0.653671582289342	258
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	movement disorder	407539	2380	0.647165212846683	81
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	movement disorder	364051	9106	0.647165212846683	81
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	movement disorder	407539	2380	0.647165212846683	81
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	movement disorder	64908	366	0.555655515890195	27
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	movement disorder	61606	416	0.555655515890195	27
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	alcohol drinking	335239	991	0.51828395256274	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	alcohol drinking	335239	695	0.51828395256274	6
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	neurodegenerative disease	376029	3978	0.534883338324039	90
qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase	PKM	neurodegenerative disease	263662	892	0.50081897368671	10
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	neurodegenerative disease	290915	2982	0.502663178367153	8
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	neurodegenerative disease	359244	1307	0.502663178367153	8
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	neurodegenerative disease	72072	2464	0.608987326393621	21
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	neurodegenerative disease	73912	5649	0.608987326393621	21
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	neurodegenerative disease	319204	3065	0.564018684854049	11
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	neurodegenerative disease	316970	306	0.564018684854049	11
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	neurodegenerative disease	305609	3405	0.592672623557014	34
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	neurodegenerative disease	305600	1644	0.592672623557014	34
uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay	SENP1	neurodegenerative disease	363840	774	0.575703329789328	7
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	neurodegenerative disease	336894	489	0.589190058569869	85
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	neurodegenerative disease	359206	428	0.532226285183309	8
HTS Assay for Peg3 Promoter Inhibitors	PPP1R15A	neurodegenerative disease	359244	6145	0.511414146696408	9
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	neurodegenerative disease	194152	1342	0.537758733599517	21
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	neurodegenerative disease	359207	1432	0.577328189160672	45
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	neurodegenerative disease	46715	2829	0.595242557991075	21
qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1)	APEX1_inhibitors	neurodegenerative disease	345898	1172	0.508986414703378	19
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	neurodegenerative disease	290726	671	0.574191290410045	9
uHTS HTRF assay for identification of inhibitors of SUMOylation	UBE2I	neurodegenerative disease	290915	1039	0.515732094857419	8
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	neurodegenerative disease	57013	201	0.582665511204253	28
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	neurodegenerative disease	324747	7988	0.552731722062662	59
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	neurodegenerative disease	369953	1241	0.671502953160591	26
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6)	SENP6	neurodegenerative disease	330392	5817	0.554494817370566	9
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	neurodegenerative disease	326888	645	0.59512464250193	58
A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37	UCHL5	neurodegenerative disease	330707	1075	0.599029121048609	10
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	neurodegenerative disease	363803	458	0.538369387010613	9
uHTS Fluorescent assay for identification of activators of Apaf-1	APAF1_activators	neurodegenerative disease	331671	1041	0.599107081143662	29
uHTS Fluorescent assay for identification of inhibitors of Apaf-1	APAF1_inhibitors	neurodegenerative disease	331671	2353	0.599107081143662	29
qHTS of TDP-43 Inhibitors	TARDBP	neurodegenerative disease	403703	7150	0.642288414311277	2279
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	neurodegenerative disease	45163	203	0.642288414311277	2279
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	neurodegenerative disease	353950	4145	0.559746831113451	37
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1)	PRMT1	neurodegenerative disease	369953	4757	0.502599783695389	6
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	neurodegenerative disease	288728	10857	0.608729374700095	14
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	neurodegenerative disease	288728	10857	0.608729374700095	14
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	neurodegenerative disease	344733	7043	0.601022749475411	13
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	neurodegenerative disease	359244	2975	0.618369114146208	709
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).	TPT1	neurodegenerative disease	302663	2452	0.583074611929383	9
qHTS assay for re-activators of p53 using a Luc reporter	TP53	neurodegenerative disease	321427	201	0.652444219623287	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neurodegenerative disease	54509	528	0.652444219623287	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neurodegenerative disease	54513	338	0.652444219623287	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neurodegenerative disease	125394	1890	0.652444219623287	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	neurodegenerative disease	124022	1156	0.652444219623287	429
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	neurodegenerative disease	263421	615	0.562884079664889	9
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	neurodegenerative disease	59788	212	0.611849024230215	21
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	neurodegenerative disease	639428	9218	0.606205598209275	33
SSB-PriA antibiotic resistant target AlphaScreen	Klebsiella pneumonia SSB-PriA interaction	neurodegenerative disease	431236	2568	0.60023710564504	20
USP8 deubiquitinase inhibition: Primary qHTS	USP8	neurodegenerative disease	47480	2010	0.628428729911184	75
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	neurodegenerative disease	356517	1139	0.529943602416502	353
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	neurodegenerative disease	108286	1415	0.611164613433357	317
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.	MCL1	neurodegenerative disease	314998	2139	0.539248910974092	13
uHTS of Mcl-1/Bid interaction inhibitors	MCL1	neurodegenerative disease	218602	2129	0.539248910974092	13
uHTS of Mcl-1/Noxa interaction inhibitors	MCL1	neurodegenerative disease	217330	3334	0.539248910974092	13
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	neurodegenerative disease	93798	679	0.599474308138305	16
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	neurodegenerative disease	322361	619	0.593816422964424	6952
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	neurodegenerative disease	328860	4078	0.559303232996058	6
uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation	EIF4E_inhibition	neurodegenerative disease	217332	799	0.579549606498111	10
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	neurodegenerative disease	325630	216	0.568226999632248	24
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	generalised epilepsy	189132	4127	0.726615041643907	463
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	neurodegenerative disease	215667	993	0.51129791900956	25
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	neurodegenerative disease	218234	1620	0.51129791900956	25
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	neurodegenerative disease	326024	350	0.59508041112244	192
Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter	FXN	neurodegenerative disease	356160	1985	0.701945822331272	694
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	neurodegenerative disease	217959	923	0.690582730159146	1125
Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2)	GPT2	neurodegenerative disease	98912	236	0.614812938066516	23
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	neurodegenerative disease	217959	2616	0.565035496135817	92
Fluorescence polarization assay for PLK1 inhibitors	PLK1	neurodegenerative disease	97099	518	0.611292905266571	18
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	neurodegenerative disease	364065	10181	0.611292905266571	18
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	neurodegenerative disease	193542	587	0.588306145605832	37
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	neurodegenerative disease	386270	1331	0.544693329001652	12
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	neurodegenerative disease	194666	1772	0.576017409602427	101
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	neurodegenerative disease	194666	1722	0.576017409602427	101
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	neuropathic pain	290355	265	0.529686109361221	14
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	neuropathic pain	335239	991	0.654073840918953	89
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	neuropathic pain	335239	695	0.654073840918953	89
Allosteric Modulators of D1 Receptors: Primary Screen	D1	neurodegenerative disease	57705	3413	0.543335400131825	31
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	neurodegenerative disease	361330	3713	0.543335400131825	31
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	neurodegenerative disease	355805	11440	0.543335400131825	31
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	neurodegenerative disease	369953	2602	0.59632424455501	11
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	neurodegenerative disease	339297	1446	0.544728007188587	19
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	neurodegenerative disease	368927	4094	0.533758386789442	16
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	neurodegenerative disease	343468	3417	0.533758386789442	16
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	neurodegenerative disease	96879	811	0.608234150917648	23
HCS assay for microtubule stabilizers	TUBB	neurodegenerative disease	195821	1625	0.61128822057763	13
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	neurodegenerative disease	189882	6790	0.637927127163836	2712
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	neurodegenerative disease	48068	449	0.637927127163836	2712
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	neurodegenerative disease	220571	2380	0.637927127163836	2712
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	neurodegenerative disease	223611	305	0.637927127163836	2712
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	neurodegenerative disease	314998	2199	0.583916454689616	35
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	neurodegenerative disease	318291	483	0.586931833345308	43
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	neurodegenerative disease	369953	1596	0.674892905265714	1044
Primary cell-based high-throughput screening assay to measure PERK inhibition	PERK_inhibitors	neurodegenerative disease	217959	370	0.537983171760528	102
Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).	PPP1CA	neurodegenerative disease	314999	2841	0.588329498055209	15
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	neurodegenerative disease	43989	342	0.624690579486488	367
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).	ULK1	neurodegenerative disease	30185	575	0.603278579256237	26
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	neurodegenerative disease	194152	656	0.586380059223403	8
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	neurodegenerative disease	194152	1288	0.586380059223403	8
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	neurodegenerative disease	194152	814	0.586380059223403	8
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	neuropathic pain	316642	617	0.609134327145434	84
uHTS identification of small molecule modulators of NR3A	GRIN3A	neuropathic pain	339772	8480	0.602628172465082	20
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	neuroticism measurement	140118	236	0.529970620572164	14
qHTS of alpha-syn Inhibitors	SNCA	neuroticism measurement	368791	501	0.529970620572164	14
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	neuroticism measurement	359518	300	0.506410375043145	23
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	neuroticism measurement	335652	1779	0.506410375043145	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	neuroticism measurement	362274	1056	0.506410375043145	23
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	neuroticism measurement	336308	6862	0.506410375043145	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	neuroticism measurement	357537	806	0.506410375043145	23
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	neuroticism measurement	339887	1178	0.506410375043145	23
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	cognitive function measurement	217819	5697	0.516586227462943	16
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	status epilepticus	292323	567	0.520086420560293	11
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	neuralgia	316642	617	0.542711443815767	17
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	spinal cord disease	363803	2412	0.580512916716499	9
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	neurodevelopmental disorder with seizures and non-epileptic hyperkinetic movements	292323	567	0.785713138394098	92
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	Lopes-Maciel-Rodan syndrome	189882	6790	0.73275567258744	41
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	Lopes-Maciel-Rodan syndrome	48068	449	0.73275567258744	41
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	Lopes-Maciel-Rodan syndrome	220571	2380	0.73275567258744	41
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	Lopes-Maciel-Rodan syndrome	223611	305	0.73275567258744	41
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	Neurodevelopmental disorder	305609	3405	0.569435323605255	923
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	Neurodevelopmental disorder	305600	1644	0.569435323605255	923
qHTS Assay for Inhibitors of BAZ2B	BAZ2B_modulators	Neurodevelopmental disorder	356826	15709	0.583262943892584	18
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	Neurodevelopmental disorder	71016	346	0.60292127111447	19
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	cancer pain	335239	991	0.647690739119118	54
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	cancer pain	335239	695	0.647690739119118	54
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	intracranial vasospasm	335531	328	0.520819643474188	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	low tension glaucoma	339297	1446	0.520819643474188	6
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	cerebral palsy	363803	2412	0.577168330395272	6
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	cerebral palsy	359207	1189	0.569561257660925	6
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	cerebral palsy	63676	1938	0.569561257660925	6
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	cerebral palsy	359207	316	0.569561257660925	6
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	cerebral palsy	63656	2179	0.569561257660925	6
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	cerebral palsy	359207	4555	0.569561257660925	6
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	diabetic neuropathy	335239	991	0.591755915992814	28
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	diabetic neuropathy	335239	695	0.591755915992814	28
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	diabetic neuropathy	316642	617	0.5850204572023	73
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	Intellectual disability	64908	979	0.579381490814232	14
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	Intellectual disability	64908	278	0.579381490814232	14
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	Intellectual disability	290915	2982	0.522565290992928	6
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	Intellectual disability	359244	1307	0.522565290992928	6
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	Intellectual disability	305609	3405	0.53550223619396	42
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	Intellectual disability	305600	1644	0.53550223619396	42
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	Intellectual disability	368927	3838	0.548715545063125	50
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Intellectual disability	70898	707	0.658125365429922	17
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Intellectual disability	131324	544	0.658125365429922	17
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Intellectual disability	108286	1415	0.507442465199123	6
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	Intellectual disability	292323	567	0.547021782892492	9
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	Intellectual disability	310014	1321	0.607223771004651	138
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Intellectual disability	193542	587	0.675838335815259	63
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	Intellectual disability	43989	342	0.533070204890202	76
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Seizure	305610	3878	0.564151783716501	8
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Seizure	305610	1082	0.564151783716501	8
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	Seizure	305609	3405	0.742012328791577	104
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	Seizure	305600	1644	0.742012328791577	104
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	Seizure	292323	567	0.809233289945136	281
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	Seizure	310014	1321	0.549729739789671	12
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	Abnormality of the nervous system	218528	711	0.566476400857916	112
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	Abnormality of the nervous system	218528	770	0.566476400857916	112
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	Abnormality of the nervous system	218528	750	0.566476400857916	112
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	Seizure	104728	4230	0.509373379751668	11
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	Chronic pain	290355	265	0.648225361607717	53
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Chronic pain	335239	991	0.666248934967793	527
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Chronic pain	335239	695	0.666248934967793	527
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	Chronic pain	324747	1043	0.524065327840843	8
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Chronic pain	316642	617	0.583510030116279	12
uHTS identification of small molecule modulators of NR3A	GRIN3A	Chronic pain	339772	8480	0.609255866556582	15
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	Back pain	290355	265	0.552121233804408	21
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Back pain	335239	991	0.646964767679243	78
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Back pain	335239	695	0.646964767679243	78
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Back pain	316642	617	0.662533243340019	73
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	Low back pain	290355	265	0.620861137391453	42
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Low back pain	335239	991	0.658909432708107	138
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Low back pain	335239	695	0.658909432708107	138
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Low back pain	316642	617	0.647073385018578	35
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Cognitive impairment	335239	991	0.509396915955061	14
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Cognitive impairment	335239	695	0.509396915955061	14
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Cognitive impairment	193400	1987	0.541999650506393	1697
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Cognitive impairment	193714	1590	0.541999650506393	1697
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Cognitive impairment	404343	257	0.541999650506393	1697
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Cognitive impairment	108286	1415	0.59152190496849	179
uHTS identification of small molecule modulators of NR3A	GRIN3A	Cognitive impairment	339772	8480	0.544595988971466	25
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	cerebellar ataxia	322361	619	0.513266557507496	23
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	amblyopia	359207	1189	0.555091317350212	12
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	amblyopia	63676	1938	0.555091317350212	12
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	amblyopia	359207	316	0.555091317350212	12
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	amblyopia	63656	2179	0.555091317350212	12
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	amblyopia	359207	4555	0.555091317350212	12
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	Epileptic encephalopathy	305609	3405	0.587761656536964	194
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	Epileptic encephalopathy	305600	1644	0.587761656536964	194
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	Epileptic encephalopathy	218528	711	0.721014842095344	71
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	Epileptic encephalopathy	218528	770	0.721014842095344	71
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	Epileptic encephalopathy	218528	750	0.721014842095344	71
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Parkinson disease	363803	2412	0.636198525212416	78
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Parkinson disease	321427	201	0.511918072179894	141
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Parkinson disease	54509	528	0.511918072179894	141
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Parkinson disease	54513	338	0.511918072179894	141
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Parkinson disease	125394	1890	0.511918072179894	141
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Parkinson disease	124022	1156	0.511918072179894	141
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Parkinson disease	108286	1415	0.613478296323205	1196
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	Parkinson disease	140118	236	0.828171049197643	6136
qHTS of alpha-syn Inhibitors	SNCA	Parkinson disease	368791	501	0.828171049197643	6136
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	Parkinson disease	292323	567	0.517948677875559	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Parkinson disease	359518	300	0.685174950061005	842
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Parkinson disease	335652	1779	0.685174950061005	842
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Parkinson disease	362274	1056	0.685174950061005	842
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Parkinson disease	336308	6862	0.685174950061005	842
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Parkinson disease	357537	806	0.685174950061005	842
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Parkinson disease	339887	1178	0.685174950061005	842
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	Parkinson disease	407539	2380	0.670877516160389	746
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	Parkinson disease	364051	9106	0.670877516160389	746
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	Parkinson disease	407539	2380	0.670877516160389	746
Fluorescence polarization assay for PLK1 inhibitors	PLK1	Parkinson disease	97099	518	0.577878323850478	9
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	Parkinson disease	364065	10181	0.577878323850478	9
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Parkinson disease	359207	1189	0.730757536945714	165
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Parkinson disease	63676	1938	0.730757536945714	165
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Parkinson disease	359207	316	0.730757536945714	165
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Parkinson disease	63656	2179	0.730757536945714	165
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Parkinson disease	359207	4555	0.730757536945714	165
Glucocerebrosidase	GBA1	Parkinson disease	48118	549	0.812818197273596	1199
Allosteric Modulators of D1 Receptors: Primary Screen	D1	Parkinson disease	57705	3413	0.644792569331339	158
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	Parkinson disease	361330	3713	0.644792569331339	158
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	Parkinson disease	355805	11440	0.644792569331339	158
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	Parkinson disease	271402	1048	0.62030182859644	1115
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	Parkinson disease	267412	5703	0.62030182859644	1115
qHTS Assay for Tau Filament Binding	MAPT	Parkinson disease	69668	1391	0.62030182859644	1115
uHTS identification of small molecule modulators of NR3A	GRIN3A	Parkinson disease	339772	8480	0.662457377099708	142
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	Parkinson disease	43989	342	0.512498148428698	185
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	migraine disorder	290355	265	0.662916077246258	83
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	migraine disorder	363803	2412	0.525317902710603	73
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	Alzheimer disease	369953	2294	0.511119614331058	17
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Alzheimer disease	321427	201	0.511773771609474	12
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Alzheimer disease	54509	528	0.511773771609474	12
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Alzheimer disease	54513	338	0.511773771609474	12
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Alzheimer disease	125394	1890	0.511773771609474	12
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Alzheimer disease	124022	1156	0.511773771609474	12
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Alzheimer disease	193400	1987	0.861771076336328	1120
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Alzheimer disease	193714	1590	0.861771076336328	1120
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Alzheimer disease	404343	257	0.861771076336328	1120
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Alzheimer disease	108286	1415	0.596827949801317	14
Fluorescence polarization assay for PLK1 inhibitors	PLK1	Alzheimer disease	97099	518	0.577168330395272	6
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	Alzheimer disease	364065	10181	0.577168330395272	6
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	migraine disorder	335239	991	0.664498935640487	95
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	migraine disorder	335239	695	0.664498935640487	95
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	migraine disorder	359518	300	0.656348969587944	101
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	migraine disorder	335652	1779	0.656348969587944	101
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	migraine disorder	362274	1056	0.656348969587944	101
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	migraine disorder	336308	6862	0.656348969587944	101
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	migraine disorder	357537	806	0.656348969587944	101
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	migraine disorder	339887	1178	0.656348969587944	101
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	migraine disorder	339297	1446	0.66863024609379	163
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	migraine disorder	316642	617	0.687070847503308	335
uHTS identification of small molecule modulators of NR3A	GRIN3A	Alzheimer disease	339772	8480	0.657913251023908	81
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	Alzheimer disease	43989	342	0.509978156110572	6
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	amyotrophic lateral sclerosis	385746	932	0.820983415810258	893
qHTS of TDP-43 Inhibitors	TARDBP	amyotrophic lateral sclerosis	403703	7150	0.824971871393985	552
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	amyotrophic lateral sclerosis	45163	203	0.824971871393985	552
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	anorexia nervosa	363803	2412	0.557048668979413	32
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	anorexia nervosa	359518	300	0.627716787694477	23
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	anorexia nervosa	335652	1779	0.627716787694477	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	anorexia nervosa	362274	1056	0.627716787694477	23
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	anorexia nervosa	336308	6862	0.627716787694477	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	anorexia nervosa	357537	806	0.627716787694477	23
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	anorexia nervosa	339887	1178	0.627716787694477	23
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	amyotrophic lateral sclerosis	217959	923	0.827061532998182	1066
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	Charcot-Marie-Tooth disease type 1A	42576	834	0.900951611526078	408
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	Charcot-Marie-Tooth disease type 1E	42576	834	0.861079375757666	69
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Alzheimer disease type 1	193400	1987	0.863489229240414	90
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Alzheimer disease type 1	193714	1590	0.863489229240414	90
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Alzheimer disease type 1	404343	257	0.863489229240414	90
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	Huntington disease	189882	6790	0.731024441538217	7266
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	Huntington disease	48068	449	0.731024441538217	7266
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	Huntington disease	220571	2380	0.731024441538217	7266
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	Huntington disease	223611	305	0.731024441538217	7266
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	Charcot-Marie-Tooth disease type 3	42576	834	0.851523859619184	102
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	hereditary neuropathy with liability to pressure palsies	42576	834	0.858608783470146	360
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ataxia telangiectasia	322361	619	0.929721108758776	19098
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	X-linked adrenal hypoplasia congenita	368927	4094	0.895131822908991	639
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	X-linked adrenal hypoplasia congenita	343468	3417	0.895131822908991	639
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	HSD10 mitochondrial disease	72072	2464	0.91026921331801	81
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	HSD10 mitochondrial disease	73912	5649	0.91026921331801	81
qHTS assay for re-activators of p53 using a Luc reporter	TP53	choroid plexus papilloma	321427	201	0.555890050810532	14
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	choroid plexus papilloma	54509	528	0.555890050810532	14
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	choroid plexus papilloma	54513	338	0.555890050810532	14
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	choroid plexus papilloma	125394	1890	0.555890050810532	14
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	choroid plexus papilloma	124022	1156	0.555890050810532	14
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	childhood absence epilepsy	104728	4230	0.555369110677203	980
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	developmental and epileptic encephalopathy, 1	305609	3405	0.514339544478264	6
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	developmental and epileptic encephalopathy, 1	305600	1644	0.514339544478264	6
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	isolated focal cortical dysplasia type II	43989	342	0.901441338803717	153
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	parkinsonism-dystonia, infantile	108286	1415	0.809677753063431	616
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	intellectual disability, autosomal dominant 10	40473	1400	0.539916981653843	14
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	frontotemporal dementia and/or amyotrophic lateral sclerosis 6	217959	923	0.823020002027243	783
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	Alzheimer disease 18	369953	2294	0.640966313727322	12
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	intellectual disability, autosomal recessive 59	205582	727	0.572390863323355	12
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	Joubert syndrome and related disorders	362026	1281	0.564628920710667	36
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	Joubert syndrome and related disorders	314998	380	0.564628920710667	36
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	Charcot-Marie-Tooth disease	42576	834	0.714642276410934	828
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	malignant migrating partial seizures of infancy	189132	4127	0.719347083244386	1206
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	juvenile amyotrophic lateral sclerosis	385746	932	0.573170704033966	30
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	alternating hemiplegia of childhood	368927	4094	0.637739119574785	216
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	alternating hemiplegia of childhood	343468	3417	0.637739119574785	216
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	infantile epileptic-dyskinetic encephalopathy	305609	3405	0.514339544478264	6
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	infantile epileptic-dyskinetic encephalopathy	305600	1644	0.514339544478264	6
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ataxia - telangiectasia variant	322361	619	0.544159269596901	9
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	cerebral cortical dysplasia	43989	342	0.508992815545776	120
uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay	COPS5	Joubert syndrome	363840	1401	0.532318314379688	74
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	Charcot-Marie-Tooth disease type 1	42576	834	0.721305340964187	609
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	nonsyndromic genetic hearing loss	362274	1085	0.520611792557172	38
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	autosomal dominant nonsyndromic hearing loss	364053	2026	0.737234129322474	225
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	autosomal dominant nonsyndromic hearing loss	330392	1295	0.558404046933777	123
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	hearing loss, autosomal recessive	362274	1085	0.704448220309956	103
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	hearing loss, autosomal recessive	96879	447	0.574957700449752	11
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	hearing loss, autosomal recessive	96879	207	0.574957700449752	11
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Dutch type	193400	1987	0.678931554588663	12
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Dutch type	193714	1590	0.678931554588663	12
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Dutch type	404343	257	0.678931554588663	12
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	developmental and epileptic encephalopathy	305609	3405	0.752819952083254	2611
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	developmental and epileptic encephalopathy	305600	1644	0.752819952083254	2611
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	developmental and epileptic encephalopathy	218528	711	0.773169282096942	596
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	developmental and epileptic encephalopathy	218528	770	0.773169282096942	596
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	developmental and epileptic encephalopathy	218528	750	0.773169282096942	596
qHTS for Inhibitors of Glutaminase (GLS)	GLS	developmental and epileptic encephalopathy	405291	844	0.549037961909993	11
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	developmental and epileptic encephalopathy	189132	4127	0.624427192659521	1214
HTS for 14-3-3 protein interaction modulators	YWHAG	developmental and epileptic encephalopathy	157962	312	0.57853134759266	33
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	brain injury	108286	1415	0.561120224360147	12
uHTS identification of small molecule modulators of NR3A	GRIN3A	brain injury	339772	8480	0.595686804534385	17
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	brain injury	339297	1446	0.594910589729757	15
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	neurodevelopmental disorder with involuntary movements	218528	711	0.877979009956465	90
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	neurodevelopmental disorder with involuntary movements	218528	770	0.877979009956465	90
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	neurodevelopmental disorder with involuntary movements	218528	750	0.877979009956465	90
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	43989	342	0.786905869129326	133
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	intellectual developmental disorder with or without epilepsy or cerebellar ataxia	64908	979	0.815362549629963	102
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	intellectual developmental disorder with or without epilepsy or cerebellar ataxia	64908	278	0.815362549629963	102
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	complex neurodevelopmental disorder	305609	3405	0.540500710871587	898
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	complex neurodevelopmental disorder	305600	1644	0.540500710871587	898
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	complex neurodevelopmental disorder	310014	1321	0.696313309749674	190
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Infantile dystonia-parkinsonism	108286	1415	0.751026462125741	122
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis	193400	1987	0.761314869524214	39
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis	193714	1590	0.761314869524214	39
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis	404343	257	0.761314869524214	39
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	Dejerine-Sottas syndrome	42576	834	0.890154648768819	101
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	Roussy-LÃ©vy syndrome	42576	834	0.59205178605105	42
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	Spasticity - intellectual disability - X-linked epilepsy	305609	3405	0.514339544478264	6
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	Spasticity - intellectual disability - X-linked epilepsy	305600	1644	0.514339544478264	6
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Piedmont type	193400	1987	0.678595966853222	8
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Piedmont type	193714	1590	0.678595966853222	8
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Piedmont type	404343	257	0.678595966853222	8
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Iowa type	193400	1987	0.678595966853222	8
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Iowa type	193714	1590	0.678595966853222	8
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Iowa type	404343	257	0.678595966853222	8
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Italian type	193400	1987	0.678595966853222	8
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Italian type	193714	1590	0.678595966853222	8
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Italian type	404343	257	0.678595966853222	8
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Flemish type	193400	1987	0.678595966853222	8
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Flemish type	193714	1590	0.678595966853222	8
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Flemish type	404343	257	0.678595966853222	8
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Arctic type	193400	1987	0.678595966853222	8
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Arctic type	193714	1590	0.678595966853222	8
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Hereditary cerebral hemorrhage with amyloidosis, Arctic type	404343	257	0.678595966853222	8
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	Rare genetic deafness	362274	1085	0.504264981526539	6
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	Rare genetic deafness	331360	2760	0.540264391088458	42
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	Rare genetic deafness	642362	5830	0.540264391088458	42
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Ataxia-telangiectasia variant	322361	619	0.645586906054851	11
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency	369953	1241	0.716707964739166	14
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	Branchio-otic syndrome	364053	2026	0.890802361045508	257

Some of these associations have also gone through clinical trials.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	PLA2G7	Platelet-activating factor acetylhydrolase	diabetic retinopathy	DARAPLADIB	targetBased	2	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01506895	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	cognition	AMPHETAMINE	targetBased	2	Recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03893032	0.2		protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	pain	VERAPAMIL	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00804895	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	pain	VERAPAMIL	targetBased	4	Recruiting	02/11/2020	https://clinicaltrials.gov/study/NCT04406259	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	pain	VERAPAMIL	targetBased	2	Terminated	01/11/2013	https://clinicaltrials.gov/study/NCT02209155	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	intracranial vasospasm	VERAPAMIL	targetBased	4	Recruiting	29/08/2016	https://clinicaltrials.gov/study/NCT01996436	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	pain	DILTIAZEM	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00893100	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	orthostatic intolerance	PROPRANOLOL	targetBased	4	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02171988	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine without aura	PROPRANOLOL	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00884663	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	smoking cessation	PROPRANOLOL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00916721	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine with aura	PROPRANOLOL	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00884663	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	PROPRANOLOL	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01061190	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac196ff5-9215-402b-bc57-69aa87f8bade	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	PROPRANOLOL	targetBased	4	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT05195996	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	PROPRANOLOL	targetBased	3	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05427474	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	PROPRANOLOL	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT03401515	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	PROPRANOLOL	targetBased	2	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01322048	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	PROPRANOLOL	targetBased	2	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01202110	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	PROPRANOLOL	targetBased	4	Recruiting	29/12/2020	https://clinicaltrials.gov/study/NCT04508244	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Low back pain	PROPRANOLOL	targetBased	2	Terminated	01/09/2017	https://clinicaltrials.gov/study/NCT03364075	0.2	LoF	protect	Recruitment issue
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	movement disorder	PROPRANOLOL	targetBased	2	Withdrawn	18/09/2017	https://clinicaltrials.gov/study/NCT03254186	0.2	LoF	protect	No participants
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	retinopathy of prematurity	PROPRANOLOL	targetBased	2	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02504944	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	retinopathy of prematurity	PROPRANOLOL	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01079715	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	retinopathy of prematurity	PROPRANOLOL	targetBased	2	Recruiting	22/09/2022	https://clinicaltrials.gov/study/NCT03083431	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	retinopathy of prematurity	PROPRANOLOL	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02014454	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	retinopathy of prematurity	PROPRANOLOL	targetBased	2	Unknown status	01/03/2017	https://clinicaltrials.gov/study/NCT03038295	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	PROPRANOLOL	targetBased	2	Terminated	18/05/2015	https://clinicaltrials.gov/study/NCT02511483	0.2	LoF	protect	Difficulty with recruitment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	alcohol drinking	PROPRANOLOL	targetBased	2	Recruiting	15/09/2018	https://clinicaltrials.gov/study/NCT03588754	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Shoulder pain	PROPRANOLOL	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02620579	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hereditary hemorrhagic telangiectasia	PROPRANOLOL	targetBased	3	Completed	23/06/2020	https://clinicaltrials.gov/study/NCT04113187	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cerebral cavernous malformation	PROPRANOLOL	targetBased	2	Terminated	24/01/2018	https://clinicaltrials.gov/study/NCT03474614	0.2	LoF	protect	lack of accrual
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=888d7d37-f581-4b27-bf9a-40f05a5ceb86	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa1ec93e-35b0-43c9-81ee-69f7e8abea87	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b7b39ae-8c19-4696-a16c-716a73287d0e	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab9e5678-db53-4354-998a-ed8bf1d33e90	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ab4058c-86fa-41c8-8291-e073fd28257f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53132901-2adb-48b9-9158-5ae585c759bd	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	LABETALOL	targetBased	2	Completed	23/10/2020	https://clinicaltrials.gov/study/NCT04484350	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	LABETALOL	targetBased	2	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT02327793	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	LABETALOL	targetBased	2	Completed	17/01/2020	https://clinicaltrials.gov/study/NCT04116112	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	intracerebral hemorrhage	LABETALOL	targetBased	2	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00963976	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	intracerebral hemorrhage	LABETALOL	targetBased	2	Recruiting	01/08/2011	https://clinicaltrials.gov/study/NCT02281838	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Intellectual disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	developmental disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	developmental disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	developmental disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	developmental disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	developmental disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	developmental disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	developmental disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Intellectual disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Intellectual disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Intellectual disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Intellectual disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Intellectual disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Intellectual disability	CLOZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	BUSPIRONE	targetBased	3	Completed	17/06/2016	https://clinicaltrials.gov/study/NCT02617017	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	BUSPIRONE	targetBased	3	Completed	17/06/2016	https://clinicaltrials.gov/study/NCT02617017	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Spinal cord injury	BUSPIRONE	targetBased	2	Recruiting	22/12/2020	https://clinicaltrials.gov/study/NCT04458324	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Spinal cord injury	BUSPIRONE	targetBased	2	Recruiting	22/12/2020	https://clinicaltrials.gov/study/NCT04458324	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Spinal cord injury	BUSPIRONE	targetBased	2	Recruiting	29/11/2020	https://clinicaltrials.gov/study/NCT05041322	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Spinal cord injury	BUSPIRONE	targetBased	2	Recruiting	29/11/2020	https://clinicaltrials.gov/study/NCT05041322	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	APOMORPHINE	targetBased	4	Not yet recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05529095	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	APOMORPHINE	targetBased	4	Recruiting	16/09/2021	https://clinicaltrials.gov/study/NCT04887467	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	APOMORPHINE	targetBased	4	Recruiting	16/09/2021	https://clinicaltrials.gov/study/NCT04887467	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	APOMORPHINE	targetBased	4	Recruiting	16/09/2021	https://clinicaltrials.gov/study/NCT04887467	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	APOMORPHINE	targetBased	4	Recruiting	16/09/2021	https://clinicaltrials.gov/study/NCT04887467	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	APOMORPHINE	targetBased	4	Recruiting	16/09/2021	https://clinicaltrials.gov/study/NCT04887467	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	APOMORPHINE	targetBased	4	Recruiting	16/09/2021	https://clinicaltrials.gov/study/NCT04887467	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	APOMORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	APOMORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	APOMORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Low back pain	APOMORPHINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02969629	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	brain injury	APOMORPHINE	targetBased	2	Suspended	01/07/2010	https://clinicaltrials.gov/study/NCT00761228	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pain	HALOPERIDOL	targetBased	2	Completed	01/11/2023	https://clinicaltrials.gov/study/NCT06428084	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Alzheimer disease	HALOPERIDOL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	pain	HALOPERIDOL	targetBased	2	Completed	01/11/2023	https://clinicaltrials.gov/study/NCT06428084	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	pain	HALOPERIDOL	targetBased	2	Completed	01/11/2023	https://clinicaltrials.gov/study/NCT06428084	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	pain	HALOPERIDOL	targetBased	2	Completed	01/11/2023	https://clinicaltrials.gov/study/NCT06428084	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	pain	HALOPERIDOL	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	HALOPERIDOL	targetBased	4	Terminated	01/02/2014	https://clinicaltrials.gov/study/NCT02972502	1	LoF	protect	PI lapsed institutional training
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Alzheimer disease	THALIDOMIDE	targetBased	2	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01094340	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	amyotrophic lateral sclerosis	THALIDOMIDE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00140452	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	amyotrophic lateral sclerosis	THALIDOMIDE	targetBased	2	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00231140	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	pain	THALIDOMIDE	targetBased	2	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00121563	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	syringomyelia	THALIDOMIDE	targetBased	2	Recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT06268093	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02660229	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02660229	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE	targetBased	3	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04533243	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE	targetBased	3	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04785768	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE	targetBased	3	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04785768	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	complex regional pain syndrome	MORPHINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT02467556	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	complex regional pain syndrome	MORPHINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT02467556	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AA51	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AA51	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE	targetBased	4	Terminated	27/04/2016	https://clinicaltrials.gov/study/NCT02746263	1	GoF	protect	Business decision because enrollment was slower than expected
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE	targetBased	4	Terminated	27/04/2016	https://clinicaltrials.gov/study/NCT02746263	1	GoF	protect	Business decision because enrollment was slower than expected
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02483221	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02483221	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE	targetBased	4	Suspended	01/02/2009	https://clinicaltrials.gov/study/NCT00916890	1	GoF	protect	difficulties in patients enrolment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE	targetBased	4	Suspended	01/02/2009	https://clinicaltrials.gov/study/NCT00916890	1	GoF	protect	difficulties in patients enrolment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db9ac9e3-d761-4a99-9f34-4946ebe8f255	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db9ac9e3-d761-4a99-9f34-4946ebe8f255	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=135f85e2-f000-4ef1-98a5-9bf0ab55d2c0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=135f85e2-f000-4ef1-98a5-9bf0ab55d2c0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	MORPHINE	targetBased	4	Completed	16/01/2019	https://clinicaltrials.gov/study/NCT03761277	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	MORPHINE	targetBased	4	Completed	16/01/2019	https://clinicaltrials.gov/study/NCT03761277	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	MORPHINE	targetBased	3	Recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03825198	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	MORPHINE	targetBased	3	Recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03825198	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	MORPHINE	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01205516	1	GoF	protect	Funding agency withdrew funding due to slow recruitment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	MORPHINE	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01205516	1	GoF	protect	Funding agency withdrew funding due to slow recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	MORPHINE	targetBased	2	Unknown status	01/07/2013	https://clinicaltrials.gov/study/NCT01914042	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	MORPHINE	targetBased	2	Unknown status	01/07/2013	https://clinicaltrials.gov/study/NCT01914042	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	MORPHINE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT02804126	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	MORPHINE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT02804126	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Abdominal pain	MORPHINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01112540	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Abdominal pain	MORPHINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01112540	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	MORPHINE	targetBased	4	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01129934	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	MORPHINE	targetBased	4	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01129934	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	MORPHINE	targetBased	4	Unknown status	01/05/2016	https://clinicaltrials.gov/study/NCT02782286	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	MORPHINE	targetBased	4	Unknown status	01/05/2016	https://clinicaltrials.gov/study/NCT02782286	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	MORPHINE	targetBased	4	Completed	27/04/2018	https://clinicaltrials.gov/study/NCT04342130	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	MORPHINE	targetBased	4	Completed	27/04/2018	https://clinicaltrials.gov/study/NCT04342130	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Neck pain	CODEINE	targetBased	2	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00029770	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Neck pain	CODEINE	targetBased	2	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00029770	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=243a6aea-0f48-42a9-a85e-ff247ab94336	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a330ef47-e23a-4d30-896c-8c5f5a6e79d6	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95a33c9b-79a6-47c7-8433-fc217950b88f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=908bdfc3-ac28-44c9-aa59-39e7b9b28903	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52321fe5-c001-4e2d-8149-3197ddc13764	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f8c5c01-5859-4843-adf4-8116ddaedc90	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdea5078-b6d3-4c2b-981b-398bb1fadc40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdea5078-b6d3-4c2b-981b-398bb1fadc40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83a536d8-385d-46ed-9cd2-47b7efe96ccf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83a536d8-385d-46ed-9cd2-47b7efe96ccf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d53bf9b7-1652-4287-a0c1-e89f6f0cb7f1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d53bf9b7-1652-4287-a0c1-e89f6f0cb7f1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	CODEINE	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT02032927	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	CODEINE	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT02032927	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	CODEINE	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT02032927	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Neck pain	CODEINE	targetBased	2	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00029770	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31cce165-fdfb-434c-83c2-fcc7709c03f4	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f6dc6c1-8f0d-4ca3-a0df-ab9103f73f6d	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01782846	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce06497d-12a6-4e79-967e-378b3a7dd61d	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d53bf9b7-1652-4287-a0c1-e89f6f0cb7f1	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8f8bb34-6d61-47a8-b58b-0b6763458052	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace223cc-458e-4455-a64e-83e5cbf95f9a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace223cc-458e-4455-a64e-83e5cbf95f9a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66305a0c-caf8-414a-a30b-3ab7b73086e1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66305a0c-caf8-414a-a30b-3ab7b73086e1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca3fe6e9-21ad-4fba-a602-e1c364cf3981	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca3fe6e9-21ad-4fba-a602-e1c364cf3981	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peripheral neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peripheral neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	diabetic neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	diabetic neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	diabetic neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	diabetic neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	diabetic neuropathy	PIRENZEPINE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04005287	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	neuropathic pain	NALOXONE	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02307305	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	neuropathic pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Parkinson disease	NALOXONE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01439100	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	stroke	NALOXONE	targetBased	4	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT05301712	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	diabetic polyneuropathy	NALOXONE	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00944697	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05a17f16-c982-4a54-80cd-079959ab49a7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05a17f16-c982-4a54-80cd-079959ab49a7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a28450a0-ac93-4235-b9a6-58cdf24773cb	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a28450a0-ac93-4235-b9a6-58cdf24773cb	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6aa52f1-0ebd-4312-8a18-99ea77928c51	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6aa52f1-0ebd-4312-8a18-99ea77928c51	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Completed	05/09/2019	https://clinicaltrials.gov/study/NCT03179475	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Completed	05/09/2019	https://clinicaltrials.gov/study/NCT03179475	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT02032927	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT02032927	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01811186	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01811186	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	NALOXONE	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02307305	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	NALOXONE	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02307305	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	restless legs syndrome	NALOXONE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01112644	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	restless legs syndrome	NALOXONE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01112644	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	epilepsy	NALOXONE	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02332447	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	epilepsy	NALOXONE	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02332447	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	epilepsy	NALOXONE	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02332447	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Back pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	NALOXONE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01427270	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	NALOXONE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01427283	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	NALOXONE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01559454	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	NALOXONE	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01358526	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	restless legs syndrome	NALOXONE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01112644	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01811186	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT02032927	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALOXONE	targetBased	4	Completed	05/09/2019	https://clinicaltrials.gov/study/NCT03179475	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALOXONE	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT01971632	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Parkinson disease	NALOXONE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01439100	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Parkinson disease	NALOXONE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01439100	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE	targetBased	4	Terminated	01/12/2009	https://clinicaltrials.gov/study/NCT00921765	1	LoF	protect	Problems with patient recruitment
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=017ef042-40aa-44c9-baa8-037f06356845	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01083485	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05a17f16-c982-4a54-80cd-079959ab49a7	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6aa52f1-0ebd-4312-8a18-99ea77928c51	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=643af9ce-549e-4102-932e-f4d995816cf1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALOXONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALOXONE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01427283	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALOXONE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01559454	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALOXONE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01559454	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALOXONE	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01358526	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALOXONE	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01358526	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	NALOXONE	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00944697	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	NALOXONE	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00944697	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	stroke	NALOXONE	targetBased	4	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT05301712	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	stroke	NALOXONE	targetBased	4	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT05301712	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Cognitive impairment	RALOXIFENE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00687102	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Alzheimer disease	RALOXIFENE	targetBased	2	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00065767	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Alzheimer disease	RALOXIFENE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00368459	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hereditary hemorrhagic telangiectasia	TAMOXIFEN	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00375622	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hereditary hemorrhagic telangiectasia	TAMOXIFEN	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00375622	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pain	TAMOXIFEN	targetBased	2	Unknown status	01/11/2018	https://clinicaltrials.gov/study/NCT02801786	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pain	TAMOXIFEN	targetBased	2	Unknown status	01/11/2018	https://clinicaltrials.gov/study/NCT02801786	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Cognitive impairment	TAMOXIFEN	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00687102	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Cognitive impairment	TAMOXIFEN	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00687102	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	amyotrophic lateral sclerosis	TAMOXIFEN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00214110	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	amyotrophic lateral sclerosis	TAMOXIFEN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00214110	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	amyotrophic lateral sclerosis	TAMOXIFEN	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01257581	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	amyotrophic lateral sclerosis	TAMOXIFEN	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01257581	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	metastasis	TAMOXIFEN	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	metastasis	TAMOXIFEN	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	diabetic autonomic neuropathy	BROMOCRIPTINE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT02233023	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT02233023	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT02233023	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT02233023	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT02233023	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/06/1998	https://clinicaltrials.gov/study/NCT02233023	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01673724	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01673724	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01673724	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Intellectual disability	BROMOCRIPTINE	targetBased	2	Suspended		https://clinicaltrials.gov/study/NCT00004300	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Intellectual disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/04/1995	https://clinicaltrials.gov/study/NCT00249145	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/04/1995	https://clinicaltrials.gov/study/NCT00249145	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Neurodevelopmental disorder	RISPERIDONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00254930	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anorexia nervosa	RISPERIDONE	targetBased	4	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00140426	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anorexia nervosa	RISPERIDONE	targetBased	4	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00140426	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anorexia nervosa	RISPERIDONE	targetBased	4	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00140426	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anorexia nervosa	RISPERIDONE	targetBased	4	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00140426	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anorexia nervosa	RISPERIDONE	targetBased	4	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00140426	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anorexia nervosa	RISPERIDONE	targetBased	4	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00140426	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	developmental disability	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	developmental disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00249158	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	RISPERIDONE	targetBased	3	Terminated	01/03/2002	https://clinicaltrials.gov/study/NCT00287742	0.7	LoF	protect	A decision was made to discontinue the study due to a change in the strategic direction of the company.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/04/1995	https://clinicaltrials.gov/study/NCT00249145	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	movement disorder	RISPERIDONE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	RISPERIDONE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	RISPERIDONE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	RISPERIDONE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	RISPERIDONE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	RISPERIDONE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	RISPERIDONE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Neurodevelopmental disorder	RISPERIDONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00254930	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Neurodevelopmental disorder	RISPERIDONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00254930	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Neurodevelopmental disorder	RISPERIDONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00254930	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Neurodevelopmental disorder	RISPERIDONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00254930	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Neurodevelopmental disorder	RISPERIDONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00254930	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Neurodevelopmental disorder	RISPERIDONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00254930	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	RISPERIDONE	targetBased	4	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00140426	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	developmental disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	developmental disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	developmental disability	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	developmental disability	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	developmental disability	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	developmental disability	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	developmental disability	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	developmental disability	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Intellectual disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Intellectual disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Intellectual disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Intellectual disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Intellectual disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Intellectual disability	RISPERIDONE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	METOCLOPRAMIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355394	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	METOCLOPRAMIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355394	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	METOCLOPRAMIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355394	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	METOCLOPRAMIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355394	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	METOCLOPRAMIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355394	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	METOCLOPRAMIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00355394	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine with aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine with aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine with aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine with aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine with aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine with aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine without aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine without aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine without aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine without aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine without aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine without aura	METOCLOPRAMIDE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01596166	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT03269435	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT03269435	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT03269435	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT03269435	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT03269435	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT03269435	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peripheral neuropathy	PACLITAXEL	targetBased	2	Not yet recruiting	30/08/2023	https://clinicaltrials.gov/study/NCT05966441	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peripheral neuropathy	PACLITAXEL	targetBased	3	Active, not recruiting	01/12/2009	https://clinicaltrials.gov/study/NCT00979082	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neuropathy	PACLITAXEL	targetBased	3	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT02311907	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	pain	PACLITAXEL	targetBased	3	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT02311907	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastasis	PACLITAXEL	targetBased	2	Active, not recruiting	04/01/2019	https://clinicaltrials.gov/study/NCT03678883	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastasis	PACLITAXEL	targetBased	2	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00046514	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastasis	PACLITAXEL	targetBased	2	Recruiting	16/10/2008	https://clinicaltrials.gov/study/NCT00781612	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastasis	PACLITAXEL	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00046527	0.7	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	anterior ischemic optic neuropathy	ALPROSTADIL	targetBased	2	Unknown status	13/06/2018	https://clinicaltrials.gov/study/NCT03851562	0.2	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	anterior ischemic optic neuropathy	ALPROSTADIL	targetBased	2	Unknown status	13/06/2018	https://clinicaltrials.gov/study/NCT03851562	0.2	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	macular degeneration	ALPROSTADIL	targetBased	3	Terminated	01/07/2006	https://clinicaltrials.gov/study/NCT00619229	0.7	GoF	protect	Interim Analysis: Optimization of study design required.
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	macular degeneration	ALPROSTADIL	targetBased	3	Terminated	01/07/2006	https://clinicaltrials.gov/study/NCT00619229	0.7	GoF	protect	Interim Analysis: Optimization of study design required.
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	stroke	ALPROSTADIL	targetBased	4	Not yet recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT03252626	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	stroke	ALPROSTADIL	targetBased	4	Not yet recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT03252626	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	low tension glaucoma	TIMOLOL	targetBased	4	Unknown status	01/10/2010	https://clinicaltrials.gov/study/NCT01446497	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	low tension glaucoma	TIMOLOL	targetBased	4	Completed	05/07/2016	https://clinicaltrials.gov/study/NCT02863705	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	low tension glaucoma	TIMOLOL	targetBased	2	Completed	15/09/2021	https://clinicaltrials.gov/study/NCT04857827	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hereditary hemorrhagic telangiectasia	TIMOLOL	targetBased	2	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02484716	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hereditary hemorrhagic telangiectasia	TIMOLOL	targetBased	2	Completed	20/10/2019	https://clinicaltrials.gov/study/NCT04139018	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	TIMOLOL	targetBased	2	Completed	27/02/2017	https://clinicaltrials.gov/study/NCT03836664	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastasis	DOCETAXEL	targetBased	3	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT00190489	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastasis	DOCETAXEL	targetBased	2	Recruiting	16/10/2008	https://clinicaltrials.gov/study/NCT00781612	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Cognitive impairment	SERTINDOLE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Cognitive impairment	SERTINDOLE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Cognitive impairment	SERTINDOLE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Cognitive impairment	SERTINDOLE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Cognitive impairment	SERTINDOLE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Cognitive impairment	SERTINDOLE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Cognitive impairment	SERTINDOLE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	brain disease	VORINOSTAT	targetBased	2	Terminated	01/08/2012	https://clinicaltrials.gov/study/NCT01600742	0.2	LoF	protect	Sponsor stops to provide the study drug.
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	childhood spinal cord tumor	VORINOSTAT	targetBased	2	Completed	26/01/2011	https://clinicaltrials.gov/study/NCT01236560	0.2	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	PERGOLIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04BC02	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pain	DINOPROSTONE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01635439	0.7	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pain	DINOPROSTONE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01635439	0.7	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pain	DINOPROSTONE	targetBased	4	Not yet recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT04080349	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	pain	DINOPROSTONE	targetBased	4	Not yet recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT04080349	1	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	rhegmatogenous retinal detachment	COLCHICINE	targetBased	3	Unknown status	01/03/2004	https://clinicaltrials.gov/study/NCT00370201	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	intracranial hemorrhage	COLCHICINE	targetBased	2	Active, not recruiting	04/08/2022	https://clinicaltrials.gov/study/NCT05159219	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	amyotrophic lateral sclerosis	COLCHICINE	targetBased	2	Completed	10/04/2019	https://clinicaltrials.gov/study/NCT03693781	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Low back pain	ACETAMINOPHEN	targetBased	4	Terminated	01/03/2005	https://clinicaltrials.gov/study/NCT00210561	1		protect	Study was stopped shortly after initiation due to change in strategic direction of the company; no safety concerns were observed that impacted this decision.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Low back pain	ACETAMINOPHEN	targetBased	4	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT02836509	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Low back pain	ACETAMINOPHEN	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01422291	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Low back pain	ACETAMINOPHEN	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT01374269	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Low back pain	ACETAMINOPHEN	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01587274	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Low back pain	ACETAMINOPHEN	targetBased	4	Recruiting	07/10/2021	https://clinicaltrials.gov/study/NCT05204667	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Alzheimer disease	ACETAMINOPHEN	targetBased	4	Recruiting	01/04/2016	https://clinicaltrials.gov/study/NCT02719834	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	carpal tunnel syndrome	ACETAMINOPHEN	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01588158	1		protect	The PI of this study is leaving the institution and enrollment was progressing slowly so we decided to close the study.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	migraine disorder	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a41fa5cd-45c2-447b-b35f-aba505a67d98	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	migraine disorder	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab17d24a-57af-4d8d-ae01-7e6846107373	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	migraine disorder	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7c94695-b5ac-497d-a2de-a336e1c22459	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	migraine disorder	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8328545-437a-4591-8cdc-66d275938024	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	migraine disorder	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8845dc27-d2b3-4b0c-8fd6-5c3f872ff867	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	migraine disorder	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11690b28-5509-496a-9648-349158770ec2	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Neck pain	ACETAMINOPHEN	targetBased	2	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00029770	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ACETAMINOPHEN	targetBased	4	Completed	21/03/2017	https://clinicaltrials.gov/study/NCT04399122	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d51600e2-2f73-483c-9b2e-f142bafff16d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30e299ce-ad48-422a-bc00-4cb565390f22	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27a9570c-78cd-45f1-87b5-83eea59d5099	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60ac290f-fa72-40bc-807b-2c18ffe10eb0	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=632c566c-39fb-4321-ac56-aea83780fa02	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	brain injury	ACETAMINOPHEN	targetBased	2	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01231139	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	brain injury	ACETAMINOPHEN	targetBased	4	Completed	03/05/2018	https://clinicaltrials.gov/study/NCT03648021	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	ACETAMINOPHEN	targetBased	4	Completed	04/09/2017	https://clinicaltrials.gov/study/NCT03244540	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	ACETAMINOPHEN	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02307305	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	ACETAMINOPHEN	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT02804126	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	ACETAMINOPHEN	targetBased	2	Terminated	20/08/2018	https://clinicaltrials.gov/study/NCT03559985	0.2		protect	Recruitment difficulties
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	alcohol drinking	ACETAMINOPHEN	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00400621	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853012b8-d3b7-78d3-e053-2a91aa0ab0f2	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e4219a-a4ef-f090-f6a4-2fd2e213d397	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dad63da3-cd1f-42a8-93d5-44b39aae1268	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f1bb6e5-3de5-48b4-bf44-d4e881be5ab0	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd7b5ba3-652a-443f-b0b9-17abda148e67	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55768b45-fd98-4779-85b6-6a50c628677e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	cancer pain	ACETAMINOPHEN	targetBased	3	Recruiting	20/10/2021	https://clinicaltrials.gov/study/NCT05051735	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Abdominal pain	ACETAMINOPHEN	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02465255	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Chronic pain	ACETAMINOPHEN	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00736957	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Chronic pain	ACETAMINOPHEN	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00314340	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Chronic pain	ACETAMINOPHEN	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02085577	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Chronic pain	ACETAMINOPHEN	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT02032927	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Chronic pain	ACETAMINOPHEN	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00195728	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diabetic neuropathy	ACETAMINOPHEN	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00634543	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diabetic neuropathy	ACETAMINOPHEN	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00210847	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00329602	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00329602	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00329602	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00329602	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00329602	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00329602	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6bf28c-d6bd-169a-e053-2991aa0a4664	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6bf28c-d6bd-169a-e053-2991aa0a4664	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6bf28c-d6bd-169a-e053-2991aa0a4664	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00373542	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00373542	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00373542	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Unverricht-Lundborg syndrome	ROPINIROLE	targetBased	2	Unknown status	01/08/2007	https://clinicaltrials.gov/study/NCT00639119	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fb15b7-da35-4841-ba5d-ee3712cd94f3	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00986245	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00986245	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00986245	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	stroke	ROPINIROLE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00221390	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	PIOGLITAZONE	targetBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00736996	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	PIOGLITAZONE	targetBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00736996	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	PIOGLITAZONE	targetBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00736996	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	PIOGLITAZONE	targetBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00736996	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	PIOGLITAZONE	targetBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00736996	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	PIOGLITAZONE	targetBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00736996	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Parkinson disease	PIOGLITAZONE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01280123	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Parkinson disease	PIOGLITAZONE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01280123	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Parkinson disease	PIOGLITAZONE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01280123	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Parkinson disease	PIOGLITAZONE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01280123	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Parkinson disease	PIOGLITAZONE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01280123	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Parkinson disease	PIOGLITAZONE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01280123	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	stroke	PIOGLITAZONE	targetBased	2	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02195791	0.2	GoF	protect	Diffculty in participant enrollment
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	stroke	PIOGLITAZONE	targetBased	2	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02195791	0.2	GoF	protect	Diffculty in participant enrollment
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	stroke	PIOGLITAZONE	targetBased	2	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02195791	0.2	GoF	protect	Diffculty in participant enrollment
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	stroke	PIOGLITAZONE	targetBased	2	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02195791	0.2	GoF	protect	Diffculty in participant enrollment
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	stroke	PIOGLITAZONE	targetBased	2	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02195791	0.2	GoF	protect	Diffculty in participant enrollment
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	stroke	PIOGLITAZONE	targetBased	2	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02195791	0.2	GoF	protect	Diffculty in participant enrollment
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00827892	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00827892	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00827892	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00827892	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00827892	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00827892	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Recruiting	08/05/2023	https://clinicaltrials.gov/study/NCT05582707	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Recruiting	08/05/2023	https://clinicaltrials.gov/study/NCT05582707	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Recruiting	08/05/2023	https://clinicaltrials.gov/study/NCT05582707	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Recruiting	08/05/2023	https://clinicaltrials.gov/study/NCT05582707	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Recruiting	08/05/2023	https://clinicaltrials.gov/study/NCT05582707	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	intracerebral hemorrhage	PIOGLITAZONE	targetBased	2	Recruiting	08/05/2023	https://clinicaltrials.gov/study/NCT05582707	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	PIOGLITAZONE	targetBased	2	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00982202	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	PIOGLITAZONE	targetBased	2	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00982202	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	PIOGLITAZONE	targetBased	2	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00982202	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	PIOGLITAZONE	targetBased	2	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00982202	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	PIOGLITAZONE	targetBased	2	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00982202	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	PIOGLITAZONE	targetBased	2	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00982202	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00822614	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00459277	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00459277	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL	targetBased	3	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04533243	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL	targetBased	3	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04533243	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	subarachnoid hemorrhage	FENTANYL	targetBased	2	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01851720	0.2	GoF	protect	Inclusion criteria were too strict and therefore we were not able to recruit more patients.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	subarachnoid hemorrhage	FENTANYL	targetBased	2	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01851720	0.2	GoF	protect	Inclusion criteria were too strict and therefore we were not able to recruit more patients.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL	targetBased	4	Terminated	01/05/2015	https://clinicaltrials.gov/study/NCT02388321	1	GoF	protect	Patients meeting inclusion criteria was low, and PI went to another institution.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL	targetBased	4	Terminated	01/05/2015	https://clinicaltrials.gov/study/NCT02388321	1	GoF	protect	Patients meeting inclusion criteria was low, and PI went to another institution.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b910cff4-22a4-4b39-b872-0bd1312f4d8b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b910cff4-22a4-4b39-b872-0bd1312f4d8b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	FENTANYL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00228605	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	FENTANYL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00228605	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bee6f20-2d81-4e03-908f-ec9b004f49d8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bee6f20-2d81-4e03-908f-ec9b004f49d8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b60b040-3ac0-4cb5-bb0a-3b4d1ff07480	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b60b040-3ac0-4cb5-bb0a-3b4d1ff07480	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e190303-00f3-4a23-bed0-39fea1d15ae0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e190303-00f3-4a23-bed0-39fea1d15ae0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	FENTANYL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00214955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	FENTANYL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00214955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cognitive impairment	FENTANYL	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00446420	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cognitive impairment	FENTANYL	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00446420	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain injury	FENTANYL	targetBased	2	Withdrawn	01/01/2010	https://clinicaltrials.gov/study/NCT01007773	0.2	GoF	protect	Study will not be intiated
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain injury	FENTANYL	targetBased	2	Withdrawn	01/01/2010	https://clinicaltrials.gov/study/NCT01007773	0.2	GoF	protect	Study will not be intiated
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4906457e-30ad-4da7-b3ac-bb9e6651a670	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	FENTANYL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4906457e-30ad-4da7-b3ac-bb9e6651a670	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	FENTANYL	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02314351	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	FENTANYL	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02314351	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	FENTANYL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00228605	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	FENTANYL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00228605	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT01774903	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT01774903	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00237341	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00237341	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00214942	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00228605	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00228605	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	ROSIGLITAZONE	targetBased	2	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00242593	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	ROSIGLITAZONE	targetBased	2	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00242593	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	ROSIGLITAZONE	targetBased	2	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00242593	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	ROSIGLITAZONE	targetBased	2	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00242593	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	ROSIGLITAZONE	targetBased	2	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00242593	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Cognitive impairment	ROSIGLITAZONE	targetBased	2	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00242593	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diabetic neuropathy	ROSIGLITAZONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00422955	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diabetic neuropathy	ROSIGLITAZONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00422955	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diabetic neuropathy	ROSIGLITAZONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00422955	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diabetic neuropathy	ROSIGLITAZONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00422955	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diabetic neuropathy	ROSIGLITAZONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00422955	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diabetic neuropathy	ROSIGLITAZONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00422955	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	ROSIGLITAZONE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00348309	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	ROSIGLITAZONE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00348309	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	ROSIGLITAZONE	targetBased	3	Completed	12/07/2006	https://clinicaltrials.gov/study/NCT00348140	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	ROSIGLITAZONE	targetBased	3	Completed	12/07/2006	https://clinicaltrials.gov/study/NCT00348140	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	ROSIGLITAZONE	targetBased	3	Completed	12/07/2006	https://clinicaltrials.gov/study/NCT00348140	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	ROSIGLITAZONE	targetBased	3	Completed	12/07/2006	https://clinicaltrials.gov/study/NCT00348140	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	ROSIGLITAZONE	targetBased	3	Completed	12/07/2006	https://clinicaltrials.gov/study/NCT00348140	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	ROSIGLITAZONE	targetBased	3	Completed	12/07/2006	https://clinicaltrials.gov/study/NCT00348140	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol drinking	NALTREXONE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00537745	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol drinking	NALTREXONE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00537745	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol drinking	NALTREXONE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01519063	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol drinking	NALTREXONE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01519063	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	orthostatic intolerance	NALTREXONE	targetBased	4	Not yet recruiting	01/01/2025	https://clinicaltrials.gov/study/NCT05363514	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	orthostatic intolerance	NALTREXONE	targetBased	4	Not yet recruiting	01/01/2025	https://clinicaltrials.gov/study/NCT05363514	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT05685225	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	25/08/2017	https://clinicaltrials.gov/study/NCT03194555	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	18/02/2017	https://clinicaltrials.gov/study/NCT06245902	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	27/06/2017	https://clinicaltrials.gov/study/NCT03185143	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	18/02/2017	https://clinicaltrials.gov/study/NCT03061734	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Charcot-Marie-Tooth disease	NALTREXONE	targetBased	3	Active, not recruiting	30/03/2021	https://clinicaltrials.gov/study/NCT04762758	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Charcot-Marie-Tooth disease	NALTREXONE	targetBased	3	Active, not recruiting	30/03/2021	https://clinicaltrials.gov/study/NCT04762758	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7658a2d-b7a9-4fb5-8d65-a20ca1b9ad1f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7658a2d-b7a9-4fb5-8d65-a20ca1b9ad1f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe97a3d-247d-4dda-a641-1a95196cd8d8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe97a3d-247d-4dda-a641-1a95196cd8d8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE	targetBased	4	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01179191	1	LoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE	targetBased	4	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01179191	1	LoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	NALTREXONE	targetBased	2	Recruiting	22/12/2020	https://clinicaltrials.gov/study/NCT04678895	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	NALTREXONE	targetBased	2	Recruiting	22/12/2020	https://clinicaltrials.gov/study/NCT04678895	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE	targetBased	4	Terminated	01/04/2010	https://clinicaltrials.gov/study/NCT01100437	1	LoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE	targetBased	4	Terminated	01/04/2010	https://clinicaltrials.gov/study/NCT01100437	1	LoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00420992	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00420992	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00650182	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00650182	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01428583	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01428583	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	orthostatic intolerance	NALTREXONE	targetBased	4	Not yet recruiting	01/01/2025	https://clinicaltrials.gov/study/NCT05363514	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	NALTREXONE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01415895	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	NALTREXONE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01415895	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Charcot-Marie-Tooth disease	NALTREXONE	targetBased	3	Active, not recruiting	30/03/2021	https://clinicaltrials.gov/study/NCT04762758	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol drinking	NALTREXONE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00537745	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol drinking	NALTREXONE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01519063	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Back pain	NALTREXONE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01415895	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	NALTREXONE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01415895	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	diabetic neuropathy	NALTREXONE	targetBased	2	Recruiting	22/12/2020	https://clinicaltrials.gov/study/NCT04678895	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALTREXONE	targetBased	4	Terminated	01/04/2010	https://clinicaltrials.gov/study/NCT01100437	1	LoF	protect	See termination reason in detailed description.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALTREXONE	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00650182	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALTREXONE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01428583	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALTREXONE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00420992	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02401750	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe97a3d-247d-4dda-a641-1a95196cd8d8	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7658a2d-b7a9-4fb5-8d65-a20ca1b9ad1f	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01415895	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00415597	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE	targetBased	4	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01179191	1	LoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	18/02/2017	https://clinicaltrials.gov/study/NCT06245902	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	18/02/2017	https://clinicaltrials.gov/study/NCT06245902	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	25/08/2017	https://clinicaltrials.gov/study/NCT03194555	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	25/08/2017	https://clinicaltrials.gov/study/NCT03194555	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	27/06/2017	https://clinicaltrials.gov/study/NCT03185143	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	27/06/2017	https://clinicaltrials.gov/study/NCT03185143	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT05685225	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT05685225	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	18/02/2017	https://clinicaltrials.gov/study/NCT03061734	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	NALTREXONE	targetBased	2	Completed	18/02/2017	https://clinicaltrials.gov/study/NCT03061734	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALTREXONE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01415895	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	NALTREXONE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01415895	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02684942	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02684942	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df4b24fc-db03-4ebf-a8ba-542f60e6d857	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df4b24fc-db03-4ebf-a8ba-542f60e6d857	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE	targetBased	4	Unknown status	01/07/2015	https://clinicaltrials.gov/study/NCT02493192	1	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	stroke	DEXTROAMPHETAMINE	targetBased	2	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT01905371	0.2		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	stroke	DEXTROAMPHETAMINE	targetBased	2	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02514044	0.2		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	amyotrophic lateral sclerosis	TRAZODONE	targetBased	2	Recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04302870	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	TRAZODONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000179	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	diabetic neuropathy	TRAZODONE	targetBased	2	Completed	22/11/2018	https://clinicaltrials.gov/study/NCT03749642	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	diabetic neuropathy	TRAZODONE	targetBased	2	Completed	16/05/2017	https://clinicaltrials.gov/study/NCT03202979	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	ALFENTANIL	targetBased	4	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00742807	1	GoF	protect	No investigator to follow-up
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	ALFENTANIL	targetBased	4	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00742807	1	GoF	protect	No investigator to follow-up
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	ALFENTANIL	targetBased	4	Completed	29/04/2022	https://clinicaltrials.gov/study/NCT05344911	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	ALFENTANIL	targetBased	4	Completed	29/04/2022	https://clinicaltrials.gov/study/NCT05344911	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain aneurysm	NEBIVOLOL	targetBased	4	Not yet recruiting	01/01/2025	https://clinicaltrials.gov/study/NCT06249802	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	NEBIVOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=673f5ad2-c09b-4a89-9407-efdadd007917	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	NEBIVOLOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb47560d-9e35-4b0f-b12b-6ea478684a5b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	NEBIVOLOL	targetBased	2	Completed	20/08/2018	https://clinicaltrials.gov/study/NCT03655964	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	METHADONE	targetBased	3	Withdrawn	01/09/2022	https://clinicaltrials.gov/study/NCT05325164	0.7	GoF	protect	Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	METHADONE	targetBased	3	Withdrawn	01/09/2022	https://clinicaltrials.gov/study/NCT05325164	0.7	GoF	protect	Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE	targetBased	4	Completed	12/01/2023	https://clinicaltrials.gov/study/NCT05581901	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE	targetBased	4	Completed	12/01/2023	https://clinicaltrials.gov/study/NCT05581901	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c363f90-c378-48ae-abbc-aeb25c9bf5cb	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c363f90-c378-48ae-abbc-aeb25c9bf5cb	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a4840d6-98e3-4523-81a0-ef0b3a47d0c2	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a4840d6-98e3-4523-81a0-ef0b3a47d0c2	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	METHADONE	targetBased	4	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02107339	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	METHADONE	targetBased	4	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02107339	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	METHADONE	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02775474	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	METHADONE	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02775474	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	METHADONE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01542645	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	METHADONE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01542645	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	METHADONE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02233452	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	METHADONE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02233452	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	METHADONE	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01205516	1	GoF	protect	Funding agency withdrew funding due to slow recruitment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	METHADONE	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01205516	1	GoF	protect	Funding agency withdrew funding due to slow recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	METHADONE	targetBased	3	Completed	06/09/2019	https://clinicaltrials.gov/study/NCT05235191	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	METHADONE	targetBased	3	Completed	06/09/2019	https://clinicaltrials.gov/study/NCT05235191	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	METHADONE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01429181	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	restless legs syndrome	METHADONE	targetBased	2	Recruiting	22/10/2022	https://clinicaltrials.gov/study/NCT04145674	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	restless legs syndrome	METHADONE	targetBased	2	Recruiting	22/10/2022	https://clinicaltrials.gov/study/NCT04145674	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	METHADONE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01559454	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	METHADONE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01559454	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	peripheral neuropathy	METHADONE	targetBased	2	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT05786599	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	peripheral neuropathy	METHADONE	targetBased	2	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT05786599	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	MIRTAZAPINE	targetBased	2	Enrolling by invitation	20/01/2022	https://clinicaltrials.gov/study/NCT05170919	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol drinking	OXYCODONE	targetBased	4	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02945293	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol drinking	OXYCODONE	targetBased	4	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02945293	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Neck pain	OXYCODONE	targetBased	3	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT02892591	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Neck pain	OXYCODONE	targetBased	3	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT02892591	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00822614	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00822614	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE	targetBased	2	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT05265052	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02660229	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02660229	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd9f9d6d-9a59-4f74-8fe7-685e0c3c5fd4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd9f9d6d-9a59-4f74-8fe7-685e0c3c5fd4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9847cc7-67a2-408d-93cf-f9cf420346dd	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9847cc7-67a2-408d-93cf-f9cf420346dd	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c428e0d-2882-45e6-976b-5ae1f8aa1867	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c428e0d-2882-45e6-976b-5ae1f8aa1867	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	OXYCODONE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01063868	0.7	GoF	protect	Business decision
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	OXYCODONE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01063868	0.7	GoF	protect	Business decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4833c5b9-649b-5e0a-e054-00144ff8d46c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4833c5b9-649b-5e0a-e054-00144ff8d46c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eaff86d-3b90-499e-b46f-316a35f5d811	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eaff86d-3b90-499e-b46f-316a35f5d811	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a9529a3-8922-6b50-e053-2995a90a4b08	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a9529a3-8922-6b50-e053-2995a90a4b08	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	metastasis	OXYCODONE	targetBased	4	Completed	04/01/2021	https://clinicaltrials.gov/study/NCT05468671	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	metastasis	OXYCODONE	targetBased	4	Completed	04/01/2021	https://clinicaltrials.gov/study/NCT05468671	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	OXYCODONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	OXYCODONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	OXYCODONE	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00315445	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	OXYCODONE	targetBased	3	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT02892591	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	OXYCODONE	targetBased	3	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT02892591	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	OXYCODONE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00771758	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	OXYCODONE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00771758	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	OXYCODONE	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02307305	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	OXYCODONE	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02307305	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	OXYCODONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	OXYCODONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	restless legs syndrome	OXYCODONE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01112644	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	restless legs syndrome	OXYCODONE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01112644	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Parkinson disease	OXYCODONE	targetBased	2	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT02601586	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Parkinson disease	OXYCODONE	targetBased	2	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT02601586	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Parkinson disease	OXYCODONE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01439100	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Parkinson disease	OXYCODONE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01439100	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Spinal cord injury	OXYCODONE	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT03906721	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Spinal cord injury	OXYCODONE	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT03906721	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01344720	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01344720	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01587274	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01587274	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	OXYCODONE	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00944697	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	OXYCODONE	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00944697	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	OXYCODONE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01063868	0.7	GoF	protect	Business decision
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	OXYCODONE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01063868	0.7	GoF	protect	Business decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	peripheral neuropathy	OXYCODONE	targetBased	4	Terminated	01/10/2011	https://clinicaltrials.gov/study/NCT01458015	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	peripheral neuropathy	OXYCODONE	targetBased	4	Terminated	01/10/2011	https://clinicaltrials.gov/study/NCT01458015	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pain	ESTRADIOL	targetBased	2	Not yet recruiting	05/04/2024	https://clinicaltrials.gov/study/NCT06279195	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pain	ESTRADIOL	targetBased	2	Not yet recruiting	05/04/2024	https://clinicaltrials.gov/study/NCT06279195	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pain	ESTRADIOL	targetBased	3	Completed	07/12/2017	https://clinicaltrials.gov/study/NCT03204318	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pain	ESTRADIOL	targetBased	3	Completed	07/12/2017	https://clinicaltrials.gov/study/NCT03204318	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTRADIOL	targetBased	2	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00066157	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTRADIOL	targetBased	2	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00066157	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	migraine disorder	ESTRADIOL	targetBased	2	Unknown status	01/10/2001	https://clinicaltrials.gov/study/NCT00204074	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	migraine disorder	ESTRADIOL	targetBased	2	Unknown status	01/10/2001	https://clinicaltrials.gov/study/NCT00204074	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTRADIOL	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01301183	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTRADIOL	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01301183	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	suicidal ideation	ESTRADIOL	targetBased	4	Completed	27/07/2018	https://clinicaltrials.gov/study/NCT03498313	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	suicidal ideation	ESTRADIOL	targetBased	4	Completed	27/07/2018	https://clinicaltrials.gov/study/NCT03498313	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	suicidal ideation	ESTRADIOL	targetBased	4	Recruiting	15/09/2020	https://clinicaltrials.gov/study/NCT04112368	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	suicidal ideation	ESTRADIOL	targetBased	4	Recruiting	15/09/2020	https://clinicaltrials.gov/study/NCT04112368	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	cerebrovascular disorder	ESTRADIOL	targetBased	4	Recruiting	13/06/2023	https://clinicaltrials.gov/study/NCT06253702	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	cerebrovascular disorder	ESTRADIOL	targetBased	4	Recruiting	13/06/2023	https://clinicaltrials.gov/study/NCT06253702	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	orthostatic intolerance	ESTRADIOL	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT01153581	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	orthostatic intolerance	ESTRADIOL	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT01153581	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	trigeminal neuralgia	SUFENTANIL	targetBased	4	Unknown status	15/05/2017	https://clinicaltrials.gov/study/NCT03152955	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	trigeminal neuralgia	SUFENTANIL	targetBased	4	Unknown status	15/05/2017	https://clinicaltrials.gov/study/NCT03152955	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01516268	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01516268	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/dzuveo	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/dzuveo	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01356732	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01356732	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	SUFENTANIL	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02085577	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	SUFENTANIL	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02085577	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	SUFENTANIL	targetBased	2	Withdrawn	01/01/2010	https://clinicaltrials.gov/study/NCT00943566	0.2	GoF	protect	funding for project discontinued
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	SUFENTANIL	targetBased	2	Withdrawn	01/01/2010	https://clinicaltrials.gov/study/NCT00943566	0.2	GoF	protect	funding for project discontinued
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	SUFENTANIL	targetBased	3	Recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03825198	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	SUFENTANIL	targetBased	3	Recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03825198	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	AMANTADINE	targetBased	3	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06052787	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	AMANTADINE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02321761	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	AMANTADINE	targetBased	2	Recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06253923	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	AMANTADINE	targetBased	2	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00970944	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	AMANTADINE	targetBased	4	Completed	30/09/2020	https://clinicaltrials.gov/study/NCT04527289	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		amyotrophic lateral sclerosis	AMANTADINE	targetBased	2	Recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04302870	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinsonism	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	AMANTADINE	targetBased	2	Recruiting	15/08/2018	https://clinicaltrials.gov/study/NCT03612921	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral infarction	AMANTADINE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00821691	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral palsy	AMANTADINE	targetBased	4	Terminated	28/02/2020	https://clinicaltrials.gov/study/NCT04273737	1	LoF	protect	PI left institution.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bced627-51e3-4e5c-a23c-30deb86ff37b	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a3e25d-80fa-479f-a419-d9487281deff	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0637f133-1f9d-48b3-b82f-a4e16f926cd6	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		stroke	AMANTADINE	targetBased	2	Recruiting	01/02/2022	https://clinicaltrials.gov/study/NCT05140148	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pain	CYCLOBENZAPRINE	targetBased	3	Completed	10/11/2017	https://clinicaltrials.gov/study/NCT02862977	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pain	CYCLOBENZAPRINE	targetBased	3	Terminated	05/10/2020	https://clinicaltrials.gov/study/NCT03127592	0.7	LoF	protect	recruitment difficulty
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pain	CYCLOBENZAPRINE	targetBased	3	Completed	08/03/2018	https://clinicaltrials.gov/study/NCT03025113	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cerebral palsy	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cerebral palsy	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06da53af-5b46-4e32-a64c-9677e27ae229	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	spinal cord disease	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	spinal cord disease	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06da53af-5b46-4e32-a64c-9677e27ae229	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	migraine disorder	CYCLOBENZAPRINE	targetBased	3	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01151787	0.7	LoF	protect	Study was never initiated under new location/provider group. Contract to continue was never signed between TEVA and Kennedy Headache Center
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Low back pain	CYCLOBENZAPRINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01587274	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Cognitive impairment	EPINEPHRINE	targetBased	2	Suspended	01/10/2014	https://clinicaltrials.gov/study/NCT02428062	0.2	GoF	protect	Pending Pilot study results evaluation
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	EPINEPHRINE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06059144	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02519023	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE	targetBased	4	Not yet recruiting	05/03/2021	https://clinicaltrials.gov/study/NCT04784104	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02526199	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb6d8fee-def4-4c96-9972-695e8cea8ea8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE	targetBased	4	Recruiting	01/12/2019	https://clinicaltrials.gov/study/NCT04577690	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL CITRATE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00459277	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL CITRATE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00459277	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL CITRATE	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00822614	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	FENTANYL CITRATE	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00822614	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39531d0c-db12-4627-81c9-6563076b637b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39531d0c-db12-4627-81c9-6563076b637b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4906457e-30ad-4da7-b3ac-bb9e6651a670	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4906457e-30ad-4da7-b3ac-bb9e6651a670	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL CITRATE	targetBased	4	Unknown status	17/08/2017	https://clinicaltrials.gov/study/NCT03296488	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL CITRATE	targetBased	4	Unknown status	17/08/2017	https://clinicaltrials.gov/study/NCT03296488	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	FENTANYL CITRATE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00463047	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	FENTANYL CITRATE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00463047	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	FENTANYL CITRATE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00214955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	FENTANYL CITRATE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00214955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cognitive impairment	FENTANYL CITRATE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00446420	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cognitive impairment	FENTANYL CITRATE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00446420	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4906457e-30ad-4da7-b3ac-bb9e6651a670	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	FENTANYL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4906457e-30ad-4da7-b3ac-bb9e6651a670	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL CITRATE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00214942	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	FENTANYL CITRATE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00214942	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pain	ETHINYL ESTRADIOL	targetBased	4	Recruiting	23/12/2021	https://clinicaltrials.gov/study/NCT05156879	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pain	ETHINYL ESTRADIOL	targetBased	4	Recruiting	23/12/2021	https://clinicaltrials.gov/study/NCT05156879	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	migraine disorder	ETHINYL ESTRADIOL	targetBased	3	Recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT04007874	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	migraine disorder	ETHINYL ESTRADIOL	targetBased	3	Recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT04007874	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ETHINYL ESTRADIOL	targetBased	2	Terminated	15/03/2016	https://clinicaltrials.gov/study/NCT03172533	0.2	GoF	protect	Difficulties in recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ETHINYL ESTRADIOL	targetBased	2	Terminated	15/03/2016	https://clinicaltrials.gov/study/NCT03172533	0.2	GoF	protect	Difficulties in recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ETHINYL ESTRADIOL	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01343771	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ETHINYL ESTRADIOL	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01343771	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	neural tube defect	ETHINYL ESTRADIOL	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00301587	0.7	GoF	protect	Company decision to not fund further development of women's health new drug development programs.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	neural tube defect	ETHINYL ESTRADIOL	targetBased	3	Withdrawn		https://clinicaltrials.gov/study/NCT00301587	0.7	GoF	protect	Company decision to not fund further development of women's health new drug development programs.
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	nervous system injury	DALFAMPRIDINE	targetBased	2	Active, not recruiting	05/06/2021	https://clinicaltrials.gov/study/NCT03701581	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	nervous system injury	DALFAMPRIDINE	targetBased	2	Active, not recruiting	05/06/2021	https://clinicaltrials.gov/study/NCT03701581	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	nervous system injury	DALFAMPRIDINE	targetBased	2	Active, not recruiting	05/06/2021	https://clinicaltrials.gov/study/NCT03701581	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	nervous system injury	DALFAMPRIDINE	targetBased	2	Active, not recruiting	05/06/2021	https://clinicaltrials.gov/study/NCT03701581	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Spinal cord injury	DALFAMPRIDINE	targetBased	3	Active, not recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03899584	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Spinal cord injury	DALFAMPRIDINE	targetBased	3	Active, not recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03899584	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	stroke	DALFAMPRIDINE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02422940	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	stroke	DALFAMPRIDINE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02422940	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	stroke	DALFAMPRIDINE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02422940	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Spinal cord injury	DALFAMPRIDINE	targetBased	3	Active, not recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03899584	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Spinal cord injury	DALFAMPRIDINE	targetBased	3	Active, not recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03899584	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Spinal cord injury	DALFAMPRIDINE	targetBased	3	Active, not recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03899584	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Spinal cord injury	DALFAMPRIDINE	targetBased	3	Active, not recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03899584	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Spinal cord injury	DALFAMPRIDINE	targetBased	3	Active, not recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03899584	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	short-term memory	DALFAMPRIDINE	targetBased	2	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT04652557	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	short-term memory	DALFAMPRIDINE	targetBased	2	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT04652557	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	short-term memory	DALFAMPRIDINE	targetBased	2	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT04652557	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	short-term memory	DALFAMPRIDINE	targetBased	2	Withdrawn	01/10/2020	https://clinicaltrials.gov/study/NCT04516603	0.2	LoF	protect	Changement of study design. Restart spring 2021.
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	short-term memory	DALFAMPRIDINE	targetBased	2	Withdrawn	01/10/2020	https://clinicaltrials.gov/study/NCT04516603	0.2	LoF	protect	Changement of study design. Restart spring 2021.
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	short-term memory	DALFAMPRIDINE	targetBased	2	Withdrawn	01/10/2020	https://clinicaltrials.gov/study/NCT04516603	0.2	LoF	protect	Changement of study design. Restart spring 2021.
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	short-term memory	DALFAMPRIDINE	targetBased	2	Withdrawn	01/10/2020	https://clinicaltrials.gov/study/NCT04516603	0.2	LoF	protect	Changement of study design. Restart spring 2021.
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	short-term memory	DALFAMPRIDINE	targetBased	2	Withdrawn	01/10/2020	https://clinicaltrials.gov/study/NCT04516603	0.2	LoF	protect	Changement of study design. Restart spring 2021.
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	short-term memory	DALFAMPRIDINE	targetBased	2	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT04652557	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	short-term memory	DALFAMPRIDINE	targetBased	2	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT04652557	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	carpal tunnel syndrome	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06294821	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	carpal tunnel syndrome	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06294821	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	carpal tunnel syndrome	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06294821	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	carpal tunnel syndrome	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06294821	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	carpal tunnel syndrome	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06294821	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	anterior ischemic optic neuropathy	DALFAMPRIDINE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01975324	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	anterior ischemic optic neuropathy	DALFAMPRIDINE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01975324	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	stroke	DALFAMPRIDINE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02422940	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	stroke	DALFAMPRIDINE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02422940	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	stroke	DALFAMPRIDINE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02422940	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	stroke	DALFAMPRIDINE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02422940	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	nervous system injury	DALFAMPRIDINE	targetBased	2	Active, not recruiting	05/06/2021	https://clinicaltrials.gov/study/NCT03701581	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	nervous system injury	DALFAMPRIDINE	targetBased	2	Active, not recruiting	05/06/2021	https://clinicaltrials.gov/study/NCT03701581	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	nervous system injury	DALFAMPRIDINE	targetBased	2	Active, not recruiting	05/06/2021	https://clinicaltrials.gov/study/NCT03701581	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	anterior ischemic optic neuropathy	DALFAMPRIDINE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01975324	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	anterior ischemic optic neuropathy	DALFAMPRIDINE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01975324	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	anterior ischemic optic neuropathy	DALFAMPRIDINE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01975324	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	short-term memory	DALFAMPRIDINE	targetBased	2	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT04652557	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	short-term memory	DALFAMPRIDINE	targetBased	2	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT04652557	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	short-term memory	DALFAMPRIDINE	targetBased	2	Withdrawn	01/10/2020	https://clinicaltrials.gov/study/NCT04516603	0.2	LoF	protect	Changement of study design. Restart spring 2021.
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	short-term memory	DALFAMPRIDINE	targetBased	2	Withdrawn	01/10/2020	https://clinicaltrials.gov/study/NCT04516603	0.2	LoF	protect	Changement of study design. Restart spring 2021.
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	anterior ischemic optic neuropathy	DALFAMPRIDINE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01975324	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	anterior ischemic optic neuropathy	DALFAMPRIDINE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01975324	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	carpal tunnel syndrome	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06294821	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	carpal tunnel syndrome	DALFAMPRIDINE	targetBased	2	Not yet recruiting	01/09/2024	https://clinicaltrials.gov/study/NCT06294821	0.2	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	TRIMETHADIONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AC02	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	childhood absence epilepsy	ETHOSUXIMIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00088452	0.7	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	Seizure	ETHOSUXIMIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00088452	0.7	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	neuropathic pain	ETHOSUXIMIDE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02100046	0.2	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	neuropathic pain	ETHOSUXIMIDE	targetBased	2	Recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04431778	0.2	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	ETHOSUXIMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7d4b2a4-2dae-4026-a381-9d534d36c6b3	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	ETHOSUXIMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AD51	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	ETHOSUXIMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb5577e2-e906-438f-b13d-e55709a0e7fd	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	ETHOSUXIMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e8e8ee-b19f-4b3f-a140-9c7391393e1c	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	ETHOSUXIMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a5cc930-0b36-48a8-9ad0-de633b208742	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	ETHOSUXIMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b8dd7cd-03a5-47a3-955a-03b6b08555b5	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	complex regional pain syndrome	ETHOSUXIMIDE	targetBased	2	Terminated	01/09/2008	https://clinicaltrials.gov/study/NCT00689585	0.2	LoF	protect	Recruitment difficult and enrolment low: decision was made to stop the study.
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	Seizure	METHSUXIMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	METHSUXIMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AD03	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Abdominal pain	ALBUTEROL	targetBased	3	Recruiting	01/07/2023	https://clinicaltrials.gov/study/NCT05653024	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	memory impairment	ALBUTEROL	targetBased	2	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01957293	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	OLANZAPINE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT00876772	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Huntington disease	OLANZAPINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	movement disorder	OLANZAPINE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	2	Enrolling by invitation	20/01/2022	https://clinicaltrials.gov/study/NCT05170919	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	2	Enrolling by invitation	20/01/2022	https://clinicaltrials.gov/study/NCT05170919	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	2	Enrolling by invitation	20/01/2022	https://clinicaltrials.gov/study/NCT05170919	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	2	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00260962	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	2	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00260962	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	2	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00260962	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	OLANZAPINE	targetBased	2	Enrolling by invitation	20/01/2022	https://clinicaltrials.gov/study/NCT05170919	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00592930	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	OLANZAPINE	targetBased	2	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00260962	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	movement disorder	OLANZAPINE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	movement disorder	OLANZAPINE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	movement disorder	OLANZAPINE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	movement disorder	OLANZAPINE	targetBased	4	Completed	01/07/2000	https://clinicaltrials.gov/study/NCT00621998	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	developmental disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Intellectual disability	OLANZAPINE	targetBased	3	Completed	01/07/1998	https://clinicaltrials.gov/study/NCT00065273	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Cognitive impairment	QUETIAPINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anorexia nervosa	QUETIAPINE	targetBased	2	Terminated	01/02/2007	https://clinicaltrials.gov/study/NCT00584688	0.2	LoF	protect	Lack of Enrollment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anorexia nervosa	QUETIAPINE	targetBased	2	Terminated	01/02/2007	https://clinicaltrials.gov/study/NCT00584688	0.2	LoF	protect	Lack of Enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anorexia nervosa	QUETIAPINE	targetBased	2	Terminated	01/02/2007	https://clinicaltrials.gov/study/NCT00584688	0.2	LoF	protect	Lack of Enrollment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anorexia nervosa	QUETIAPINE	targetBased	2	Terminated	01/02/2007	https://clinicaltrials.gov/study/NCT00584688	0.2	LoF	protect	Lack of Enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anorexia nervosa	QUETIAPINE	targetBased	2	Terminated	01/02/2007	https://clinicaltrials.gov/study/NCT00584688	0.2	LoF	protect	Lack of Enrollment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anorexia nervosa	QUETIAPINE	targetBased	2	Terminated	01/02/2007	https://clinicaltrials.gov/study/NCT00584688	0.2	LoF	protect	Lack of Enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	QUETIAPINE	targetBased	2	Terminated	23/10/2019	https://clinicaltrials.gov/study/NCT04164758	0.2	LoF	protect	Study enrollment impacted by COVID-19 pandemic and Sponsor terminated for business reasons
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	QUETIAPINE	targetBased	4	Recruiting	24/10/2022	https://clinicaltrials.gov/study/NCT04373317	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	concussion	QUETIAPINE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Cognitive impairment	QUETIAPINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Cognitive impairment	QUETIAPINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Cognitive impairment	QUETIAPINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Cognitive impairment	QUETIAPINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Cognitive impairment	QUETIAPINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Cognitive impairment	QUETIAPINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00654706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	concussion	QUETIAPINE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	concussion	QUETIAPINE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	concussion	QUETIAPINE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	concussion	QUETIAPINE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	concussion	QUETIAPINE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	concussion	QUETIAPINE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	QUETIAPINE	targetBased	4	Recruiting	24/10/2022	https://clinicaltrials.gov/study/NCT04373317	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	QUETIAPINE	targetBased	4	Recruiting	24/10/2022	https://clinicaltrials.gov/study/NCT04373317	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	QUETIAPINE	targetBased	4	Recruiting	24/10/2022	https://clinicaltrials.gov/study/NCT04373317	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	QUETIAPINE	targetBased	4	Recruiting	24/10/2022	https://clinicaltrials.gov/study/NCT04373317	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	QUETIAPINE	targetBased	4	Recruiting	24/10/2022	https://clinicaltrials.gov/study/NCT04373317	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	QUETIAPINE	targetBased	4	Recruiting	24/10/2022	https://clinicaltrials.gov/study/NCT04373317	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	QUETIAPINE	targetBased	2	Terminated	01/02/2007	https://clinicaltrials.gov/study/NCT00584688	0.2	LoF	protect	Lack of Enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Alzheimer disease	CARVEDILOL	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01354444	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	epilepsy	CARVEDILOL	targetBased	2	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00524134	0.2	LoF	protect	PI left the institution.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	PROCHLORPERAZINE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00364806	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	PROCHLORPERAZINE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00364806	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	PROCHLORPERAZINE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00364806	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	PROCHLORPERAZINE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00364806	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	PROCHLORPERAZINE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00364806	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	PROCHLORPERAZINE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00364806	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	KETAMINE	targetBased	2	Withdrawn	01/12/2008	https://clinicaltrials.gov/study/NCT00556387	0.2	LoF	protect	This study has been withdraw from the IRB. The PI has transferred to another university. The IND was transferred.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		retinopathy	KETAMINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01955135	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Low back pain	KETAMINE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02154438	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		attempted suicide	KETAMINE	targetBased	4	Enrolling by invitation	15/03/2021	https://clinicaltrials.gov/study/NCT04578938	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		attempted suicide	KETAMINE	targetBased	3	Recruiting	27/06/2022	https://clinicaltrials.gov/study/NCT04763343	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		attempted suicide	KETAMINE	targetBased	4	Terminated	19/12/2019	https://clinicaltrials.gov/study/NCT04154150	1	LoF	protect	Midway through this pilot study, funding was obtained to support a much larger study of the same interventions in this clinical population. Therefore the pilot study was halted so as not to compete with enrollment for the larger study.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cancer pain	KETAMINE	targetBased	2	Recruiting	01/06/2018	https://clinicaltrials.gov/study/NCT03362073	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		epilepsy	KETAMINE	targetBased	2	Recruiting	26/08/2022	https://clinicaltrials.gov/study/NCT05019885	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		epilepsy	KETAMINE	targetBased	3	Withdrawn	01/02/2014	https://clinicaltrials.gov/study/NCT02726867	0.7	LoF	protect	No participants enrolled
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		epilepsy	KETAMINE	targetBased	2	Withdrawn	04/05/2017	https://clinicaltrials.gov/study/NCT03115489	0.2	LoF	protect	Low eligibility of patients, no successful recruitment
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE	targetBased	4	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01168492	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE	targetBased	4	Terminated	01/05/2015	https://clinicaltrials.gov/study/NCT02388321	1	LoF	protect	Patients meeting inclusion criteria was low, and PI went to another institution.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE	targetBased	4	Completed	01/09/2022	https://clinicaltrials.gov/study/NCT05552391	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE	targetBased	4	Active, not recruiting	01/01/2015	https://clinicaltrials.gov/study/NCT02363270	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT02916927	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE	targetBased	4	Completed	06/11/2017	https://clinicaltrials.gov/study/NCT02753114	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		status epilepticus	KETAMINE	targetBased	3	Withdrawn	01/02/2014	https://clinicaltrials.gov/study/NCT02726867	0.7	LoF	protect	No participants enrolled
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		status epilepticus	KETAMINE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02431663	0.35	LoF	protect	Futility
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		status epilepticus	KETAMINE	targetBased	2	Recruiting	21/03/2023	https://clinicaltrials.gov/study/NCT05779657	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE	targetBased	2	Not yet recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04658420	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE	targetBased	2	Withdrawn	01/02/2022	https://clinicaltrials.gov/study/NCT05105061	0.2	LoF	protect	PI leaving institution
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE	targetBased	2	Withdrawn	01/04/2019	https://clinicaltrials.gov/study/NCT03502551	0.2	LoF	protect	Trial never received funding.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE	targetBased	3	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02299440	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01507181	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE	targetBased	3	Not yet recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05468840	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE	targetBased	4	Terminated	02/03/2017	https://clinicaltrials.gov/study/NCT02997722	1	LoF	protect	Staffing and space deficiencies prevented completion of the study.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		subarachnoid hemorrhage	KETAMINE	targetBased	2	Withdrawn	27/04/2023	https://clinicaltrials.gov/study/NCT05032118	0.2	LoF	protect	Institution change, no IRB approval
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		subarachnoid hemorrhage	KETAMINE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02636218	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		migraine disorder	KETAMINE	targetBased	4	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT03221569	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		trigeminal neuralgia	KETAMINE	targetBased	4	Unknown status	15/05/2017	https://clinicaltrials.gov/study/NCT03152955	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		complex regional pain syndrome	KETAMINE	targetBased	2	Terminated	24/03/2014	https://clinicaltrials.gov/study/NCT02094352	0.2	LoF	protect	The study was unable to enroll efficiently despite trying various technique.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		complex regional pain syndrome	KETAMINE	targetBased	2	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00579085	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		complex regional pain syndrome	KETAMINE	targetBased	2	Withdrawn	01/01/2024	https://clinicaltrials.gov/study/NCT05945147	0.2	LoF	protect	Lack of funding
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	KETAMINE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02233452	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	KETAMINE	targetBased	4	Recruiting	12/10/2023	https://clinicaltrials.gov/study/NCT05639322	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	KETAMINE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00961194	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	KETAMINE	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00798083	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	KETAMINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02467517	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	KETAMINE	targetBased	4	Completed	25/09/2017	https://clinicaltrials.gov/study/NCT03280017	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Chronic pain	KETAMINE	targetBased	2	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01755169	0.2	LoF	protect	Inability to enroll sufficient patients
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Chronic pain	KETAMINE	targetBased	3	Completed	01/05/2017	https://clinicaltrials.gov/study/NCT02920528	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Chronic pain	KETAMINE	targetBased	4	Suspended	18/08/2015	https://clinicaltrials.gov/study/NCT02729805	1	LoF	protect	Not enough patients
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Chronic pain	KETAMINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01296347	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Chronic pain	KETAMINE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02085577	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Chronic pain	KETAMINE	targetBased	4	Completed	25/09/2017	https://clinicaltrials.gov/study/NCT03280017	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Chronic pain	KETAMINE	targetBased	3	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02303847	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	KETAMINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06231563	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain aneurysm	ESMOLOL	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02455440	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cerebral arterial disease	ESMOLOL	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02455440	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	ESMOLOL	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02466542	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	ESMOLOL	targetBased	2	Terminated	09/09/2020	https://clinicaltrials.gov/study/NCT04356352	0.2	LoF	protect	feasibility of enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	ESMOLOL	targetBased	4	Not yet recruiting	01/11/2019	https://clinicaltrials.gov/study/NCT04086940	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	ESMOLOL	targetBased	4	Completed	19/01/2021	https://clinicaltrials.gov/study/NCT04752111	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00738192	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00738192	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AF01	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AF01	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00510666	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00510666	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUTORPHANOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AF01	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUTORPHANOL	targetBased	4	Recruiting	15/12/2019	https://clinicaltrials.gov/study/NCT04315935	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUTORPHANOL	targetBased	4	Recruiting	04/09/2020	https://clinicaltrials.gov/study/NCT04436224	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUTORPHANOL	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00510666	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUTORPHANOL	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00738192	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hereditary hemorrhagic telangiectasia	TAMOXIFEN CITRATE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00375622	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hereditary hemorrhagic telangiectasia	TAMOXIFEN CITRATE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00375622	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pain	TAMOXIFEN CITRATE	targetBased	2	Unknown status	01/11/2018	https://clinicaltrials.gov/study/NCT02801786	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pain	TAMOXIFEN CITRATE	targetBased	2	Unknown status	01/11/2018	https://clinicaltrials.gov/study/NCT02801786	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Cognitive impairment	TAMOXIFEN CITRATE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00687102	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Cognitive impairment	TAMOXIFEN CITRATE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00687102	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	amyotrophic lateral sclerosis	TAMOXIFEN CITRATE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00214110	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	amyotrophic lateral sclerosis	TAMOXIFEN CITRATE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00214110	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	amyotrophic lateral sclerosis	TAMOXIFEN CITRATE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01257581	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	amyotrophic lateral sclerosis	TAMOXIFEN CITRATE	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01257581	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	metastasis	TAMOXIFEN CITRATE	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	metastasis	TAMOXIFEN CITRATE	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	epilepsy	METHYLPHENIDATE	targetBased	4	Recruiting	14/08/2023	https://clinicaltrials.gov/study/NCT04419272	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Alzheimer disease	METHYLPHENIDATE	targetBased	4	Completed	01/11/2019	https://clinicaltrials.gov/study/NCT03811847	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Alzheimer disease	METHYLPHENIDATE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01117181	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Alzheimer disease	METHYLPHENIDATE	targetBased	3	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02346201	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Cognitive impairment	METHYLPHENIDATE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02326038	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	childhood apraxia of speech	METHYLPHENIDATE	targetBased	2	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05185583	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Parkinson disease	METHYLPHENIDATE	targetBased	4	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00526630	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Parkinson disease	METHYLPHENIDATE	targetBased	4	Terminated	01/12/2010	https://clinicaltrials.gov/study/NCT01244269	1	LoF	protect	Inadequate enrolment, protocol too challenging for participants, lack of observable benefit after analysis of 6 patients.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Parkinson disease	METHYLPHENIDATE	targetBased	2	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00359723	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	stroke	METHYLPHENIDATE	targetBased	4	Terminated	01/11/2006	https://clinicaltrials.gov/study/NCT00396058	1	LoF	protect	Recruitment of patients proved much too difficult based on the chosen criteria.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	brain injury	METHYLPHENIDATE	targetBased	2	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02227056	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	brain injury	METHYLPHENIDATE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02015949	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	brain injury	METHYLPHENIDATE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00035139	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Chronic pain	METHYLPHENIDATE	targetBased	2	Recruiting	02/02/2024	https://clinicaltrials.gov/study/NCT05285683	0.2	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	PHENSUXIMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AD02	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	internal carotid artery stenosis	FASUDIL	targetBased	2	Terminated	13/03/2008	https://clinicaltrials.gov/study/NCT00670202	0.2	LoF	protect	Slow enrollment
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	amyotrophic lateral sclerosis	FASUDIL	targetBased	2	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01935518	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	amyotrophic lateral sclerosis	FASUDIL	targetBased	2	Completed	20/02/2019	https://clinicaltrials.gov/study/NCT03792490	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	retinopathy of prematurity	FASUDIL	targetBased	2	Recruiting	02/06/2019	https://clinicaltrials.gov/study/NCT04191954	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	retinal vein occlusion	FASUDIL	targetBased	2	Unknown status	01/01/2018	https://clinicaltrials.gov/study/NCT03391219	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	Parkinson disease	FASUDIL	targetBased	2	Recruiting	11/09/2023	https://clinicaltrials.gov/study/NCT05931575	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	MEMANTINE	targetBased	4	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00462228	1	LoF	protect	The study was stopped due to a lack of additional subjects.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		amyotrophic lateral sclerosis	MEMANTINE	targetBased	2	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00353665	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		amyotrophic lateral sclerosis	MEMANTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00409721	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		amyotrophic lateral sclerosis	MEMANTINE	targetBased	2	Recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04302870	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		amyotrophic lateral sclerosis	MEMANTINE	targetBased	2	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT01020331	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		memory impairment	MEMANTINE	targetBased	4	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00283309	1	LoF	protect	Study finished enrollment but data was never sent for publishing.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Aphasia	MEMANTINE	targetBased	4	Unknown status	01/03/2005	https://clinicaltrials.gov/study/NCT00196703	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Aphasia	MEMANTINE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640198	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	MEMANTINE	targetBased	4	Unknown status	01/01/2010	https://clinicaltrials.gov/study/NCT01041313	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	MEMANTINE	targetBased	3	Terminated	04/05/2017	https://clinicaltrials.gov/study/NCT02950233	0.7	LoF	protect	Recruitment was slower than expected and study drug reached expiry
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	MEMANTINE	targetBased	4	Terminated	01/12/2009	https://clinicaltrials.gov/study/NCT01032759	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol drinking	MEMANTINE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01519063	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol drinking	MEMANTINE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00630955	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		migraine disorder	MEMANTINE	targetBased	3	Completed	15/02/2019	https://clinicaltrials.gov/study/NCT04698525	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Huntington disease	MEMANTINE	targetBased	4	Completed	23/11/2004	https://clinicaltrials.gov/study/NCT00652457	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Huntington disease	MEMANTINE	targetBased	2	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01458470	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neurotoxicity	MEMANTINE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00566852	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		frontotemporal dementia	MEMANTINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00594737	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		complex regional pain syndrome	MEMANTINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT02467556	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	MEMANTINE	targetBased	2	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01602185	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	MEMANTINE	targetBased	2	Not yet recruiting	15/02/2019	https://clinicaltrials.gov/study/NCT03686774	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	MEMANTINE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01536314	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE	targetBased	4	Unknown status	15/07/2017	https://clinicaltrials.gov/study/NCT03168997	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81496236-0a90-4265-8244-cba6a6b4f3ac	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00800709	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00476008	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8f5c20b-4573-44c5-89fc-4da11b2e1fe1	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00401167	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	MEMANTINE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00646204	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	MEMANTINE	targetBased	3	Recruiting	01/04/2019	https://clinicaltrials.gov/study/NCT03858270	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	MEMANTINE	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01108029	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Cognitive impairment	MEMANTINE	targetBased	2	Recruiting	06/12/2017	https://clinicaltrials.gov/study/NCT03342443	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Cognitive impairment	MEMANTINE	targetBased	3	Recruiting	22/02/2024	https://clinicaltrials.gov/study/NCT06275035	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Cognitive impairment	MEMANTINE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01902004	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		stroke	MEMANTINE	targetBased	4	Unknown status	01/03/2005	https://clinicaltrials.gov/study/NCT00196703	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		stroke	MEMANTINE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640198	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		developmental and epileptic encephalopathy 94	MEMANTINE	targetBased	4	Completed	07/02/2019	https://clinicaltrials.gov/study/NCT03779672	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	metastasis	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	metastasis	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	metastasis	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	metastasis	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	metastasis	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	metastasis	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	metastasis	GUANIDINE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00037869	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489476	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	migraine disorder	LOXAPINE	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00825500	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	epilepsy	EZOGABINE	targetBased	4	Terminated	27/03/2013	https://clinicaltrials.gov/study/NCT01607346	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	epilepsy	EZOGABINE	targetBased	4	Terminated	27/03/2013	https://clinicaltrials.gov/study/NCT01607346	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	epilepsy	EZOGABINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AX21	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	epilepsy	EZOGABINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AX21	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	epilepsy	EZOGABINE	targetBased	3	Completed	21/02/2011	https://clinicaltrials.gov/study/NCT01336621	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	epilepsy	EZOGABINE	targetBased	3	Terminated	29/08/2012	https://clinicaltrials.gov/study/NCT01648101	0.7		protect	Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	epilepsy	EZOGABINE	targetBased	3	Terminated	29/08/2012	https://clinicaltrials.gov/study/NCT01648101	0.7		protect	Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	amyotrophic lateral sclerosis	EZOGABINE	targetBased	2	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02450552	0.2		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	amyotrophic lateral sclerosis	EZOGABINE	targetBased	2	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02450552	0.2		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Seizure	EZOGABINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00235755	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Seizure	EZOGABINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Seizure	EZOGABINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Seizure	EZOGABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c60979b-489d-4e7b-8893-468ae00c44bb	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Seizure	EZOGABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c60979b-489d-4e7b-8893-468ae00c44bb	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Seizure	EZOGABINE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00232596	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Seizure	EZOGABINE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00232596	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Seizure	EZOGABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c60979b-489d-4e7b-8893-468ae00c44bb	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Seizure	EZOGABINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c60979b-489d-4e7b-8893-468ae00c44bb	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Seizure	EZOGABINE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00232596	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Seizure	EZOGABINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Seizure	EZOGABINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Seizure	EZOGABINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00235755	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Seizure	EZOGABINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00235755	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	epilepsy	EZOGABINE	targetBased	4	Terminated	27/03/2013	https://clinicaltrials.gov/study/NCT01607346	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	epilepsy	EZOGABINE	targetBased	4	Terminated	27/03/2013	https://clinicaltrials.gov/study/NCT01607346	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	epilepsy	EZOGABINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AX21	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	epilepsy	EZOGABINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AX21	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	epilepsy	EZOGABINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00310375	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	epilepsy	EZOGABINE	targetBased	3	Completed	21/02/2011	https://clinicaltrials.gov/study/NCT01336621	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	epilepsy	EZOGABINE	targetBased	3	Completed	21/02/2011	https://clinicaltrials.gov/study/NCT01336621	0.7		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	amyotrophic lateral sclerosis	EZOGABINE	targetBased	2	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02450552	0.2		protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	amyotrophic lateral sclerosis	EZOGABINE	targetBased	2	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02450552	0.2		protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	hereditary hemorrhagic telangiectasia	POMALIDOMIDE	targetBased	2	Completed	17/10/2019	https://clinicaltrials.gov/study/NCT03910244	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	radiculopathy	LENALIDOMIDE	targetBased	2	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00120120	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	complex regional pain syndrome	LENALIDOMIDE	targetBased	2	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00067743	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	metastasis	LENALIDOMIDE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00057616	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	BEFIRADOL	targetBased	2	Completed	09/11/2021	https://clinicaltrials.gov/study/NCT05148884	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	BEFIRADOL	targetBased	2	Completed	09/11/2021	https://clinicaltrials.gov/study/NCT05148884	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Parkinson disease	CLENBUTEROL	targetBased	2	Withdrawn	01/06/2024	https://clinicaltrials.gov/study/NCT04935762	0.2	GoF	protect	Sponsor Decision
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	amyotrophic lateral sclerosis	CLENBUTEROL	targetBased	2	Completed	10/02/2020	https://clinicaltrials.gov/study/NCT04245709	0.2	GoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	DABIGATRAN	targetBased	3	Recruiting	05/12/2019	https://clinicaltrials.gov/study/NCT03961334	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	DABIGATRAN	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00262600	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	DABIGATRAN	targetBased	3	Completed	03/06/2019	https://clinicaltrials.gov/study/NCT03996772	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL TARTRATE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00510666	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL TARTRATE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00510666	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL TARTRATE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00738192	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUTORPHANOL TARTRATE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00738192	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUTORPHANOL TARTRATE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00510666	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUTORPHANOL TARTRATE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00738192	1	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	restless legs syndrome	BUPROPION	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00621517	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01456936	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00770666	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01330043	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01574703	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT03362099	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION	targetBased	4	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00322205	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	suicidal ideation	BUPROPION	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01748955	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Huntington disease	BUPROPION	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01914965	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE	targetBased	4	Unknown status	17/08/2017	https://clinicaltrials.gov/study/NCT03296488	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE	targetBased	4	Unknown status	17/08/2017	https://clinicaltrials.gov/study/NCT03296488	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE	targetBased	4	Unknown status	24/10/2018	https://clinicaltrials.gov/study/NCT03786887	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE	targetBased	4	Unknown status	24/10/2018	https://clinicaltrials.gov/study/NCT03786887	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ad5e836-33bf-49c9-a530-296cff30d1c7	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d32eb5-6806-4aa4-8976-e3ba0fe871df	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03288428	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AF02	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE	targetBased	4	Unknown status	24/10/2018	https://clinicaltrials.gov/study/NCT03786887	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Low back pain	ORPHENADRINE	targetBased	3	Unknown status	01/01/2021	https://clinicaltrials.gov/study/NCT02985671	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Low back pain	ORPHENADRINE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02665286	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ORPHENADRINE	targetBased	4	Completed	11/04/2019	https://clinicaltrials.gov/study/NCT04835116	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ORPHENADRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ORPHENADRINE	targetBased	4	Completed	05/04/2021	https://clinicaltrials.gov/study/NCT05413902	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	ORPHENADRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AB02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cerebral infarction	SARPOGRELATE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00129805	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cerebral infarction	SARPOGRELATE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00147303	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	DOBUTAMINE	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02019810	0.2	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Spinal cord injury	IMATINIB	targetBased	2	Unknown status	01/04/2018	https://clinicaltrials.gov/study/NCT02363361	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	stroke	IMATINIB	targetBased	3	Recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03639922	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02025608	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02025608	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02025608	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02025608	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02025608	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02025608	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ebb3e0b-8fd5-4ac8-ba2f-abfcfc0c91ad	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ebb3e0b-8fd5-4ac8-ba2f-abfcfc0c91ad	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ebb3e0b-8fd5-4ac8-ba2f-abfcfc0c91ad	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00349531	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00349531	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00349531	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Alzheimer disease	PRAMIPEXOLE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01388478	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950bfa3-d42f-49c2-b4ca-8c8a1d95894c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950bfa3-d42f-49c2-b4ca-8c8a1d95894c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950bfa3-d42f-49c2-b4ca-8c8a1d95894c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950bfa3-d42f-49c2-b4ca-8c8a1d95894c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950bfa3-d42f-49c2-b4ca-8c8a1d95894c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2950bfa3-d42f-49c2-b4ca-8c8a1d95894c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT01515774	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT01515774	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT01515774	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60167d7c-469f-455a-a113-561841af5e59	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60167d7c-469f-455a-a113-561841af5e59	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60167d7c-469f-455a-a113-561841af5e59	1	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuroma	CAPSAICIN	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00130962	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99049768-d5e5-4479-84ea-bbd3123d3ffa	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e00ce082-5d08-4628-9b99-87ecd2ac43a6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e495f18f-4c42-4126-a4c2-f5641aa163a7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5dd4fefc-b70a-4850-819c-1cca6f28aa97	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10d1bcb7-c300-1145-e054-00144ff88e88	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db9a695-a41c-4867-8684-161c81abbe00	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	peripheral neuropathy	CAPSAICIN	targetBased	3	Not yet recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT05840562	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Morton Neuroma	CAPSAICIN	targetBased	2	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02283957	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Morton Neuroma	CAPSAICIN	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02678793	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	CAPSAICIN	targetBased	2	Completed	09/11/2017	https://clinicaltrials.gov/study/NCT03317613	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aab4f0b9-5b08-4ed7-b85b-93dcee5c50ad	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	CAPSAICIN	targetBased	4	Terminated	03/12/2018	https://clinicaltrials.gov/study/NCT03348735	1		protect	Low inclusion rate
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	CAPSAICIN	targetBased	3	Recruiting	13/07/2021	https://clinicaltrials.gov/study/NCT04967664	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab5a8fa3-2eb2-44fd-bf9b-a1ac114e0c9b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuralgia	CAPSAICIN	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00115310	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuralgia	CAPSAICIN	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuralgia	CAPSAICIN	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00300222	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuralgia	CAPSAICIN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00068081	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	facial pain	CAPSAICIN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00008476	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8d70a88-4ad9-4be3-9f4d-3771a28a1450	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bdaff52a-da42-47a8-bc4b-44cc1476fe26	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3a3796e-e71a-4da3-9441-32c971ef51bf	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e3e528-b7cd-e4b7-e053-2995a90a4029	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4afbd2a-7e8c-4ba3-9923-ebda3c23855e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Back pain	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4e61706-71b4-4bbd-8c8e-ad7565506e34	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	peripheral nervous system disease	CAPSAICIN	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00300222	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	peripheral nervous system disease	CAPSAICIN	targetBased	3	Terminated		https://clinicaltrials.gov/study/NCT00085761	0.7		protect	Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	peripheral nervous system disease	CAPSAICIN	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00064623	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	peripheral nervous system disease	CAPSAICIN	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00321672	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diabetic neuropathy	CAPSAICIN	targetBased	2	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT01125215	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diabetic neuropathy	CAPSAICIN	targetBased	4	Completed	10/01/2019	https://clinicaltrials.gov/study/NCT04238208	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diabetic neuropathy	CAPSAICIN	targetBased	3	Completed	04/11/2010	https://clinicaltrials.gov/study/NCT05029297	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diabetic neuropathy	CAPSAICIN	targetBased	3	Completed	19/01/2017	https://clinicaltrials.gov/study/NCT03113448	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diabetic neuropathy	CAPSAICIN	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01478607	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diabetic polyneuropathy	CAPSAICIN	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00993070	0.2		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5770c65f-dd52-4ba0-928e-495cfc12c587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5770c65f-dd52-4ba0-928e-495cfc12c587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9281b012-ee14-4992-ba6a-ae91180b6f95	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9281b012-ee14-4992-ba6a-ae91180b6f95	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ef44915-8e59-40d7-a43a-c1ea33bfdf53	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ef44915-8e59-40d7-a43a-c1ea33bfdf53	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00226421	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00930943	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00930943	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01206907	0.7	GoF	protect	The study is no longer required for the PREA for this product.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01206907	0.7	GoF	protect	The study is no longer required for the PREA for this product.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Suspended	11/03/2013	https://clinicaltrials.gov/study/NCT04681027	0.7	GoF	protect	Study Suspended 06Feb2020 per FDA Request
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Suspended	11/03/2013	https://clinicaltrials.gov/study/NCT04681027	0.7	GoF	protect	Study Suspended 06Feb2020 per FDA Request
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Suspended	11/03/2013	https://clinicaltrials.gov/study/NCT04681027	0.7	GoF	protect	Study Suspended 06Feb2020 per FDA Request
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00930943	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01206907	0.7	GoF	protect	The study is no longer required for the PREA for this product.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00225797	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Terminated	17/11/2008	https://clinicaltrials.gov/study/NCT00765856	0.7	GoF	protect	Terminated new protocol developed which incorporated Pharmacokinetics
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	OXYMORPHONE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00226421	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9be700c1-937a-180d-fb38-bc2aa85d20cf	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c4b8fab-3112-43a0-994a-591e5089f619	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27615b77-2550-4e46-87d9-b4d007a0e79f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ef44915-8e59-40d7-a43a-c1ea33bfdf53	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=468bc2c3-9af3-4db1-b079-f2b5b98e951d	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ca97412-1594-4a4e-b5e4-8593ffa1b242	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	smoking cessation	NALMEFENE	targetBased	2	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00202696	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	smoking cessation	NALMEFENE	targetBased	2	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00202696	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	smoking cessation	NALMEFENE	targetBased	2	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00202696	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	REMIFENTANIL	targetBased	4	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT02733835	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	REMIFENTANIL	targetBased	4	Unknown status	01/12/2016	https://clinicaltrials.gov/study/NCT02733835	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	REMIFENTANIL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00757198	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	REMIFENTANIL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00757198	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	REMIFENTANIL	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01419405	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	REMIFENTANIL	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01419405	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	REMIFENTANIL	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02031016	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	REMIFENTANIL	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02031016	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	metastasis	REMIFENTANIL	targetBased	4	Completed	04/01/2021	https://clinicaltrials.gov/study/NCT05468671	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	metastasis	REMIFENTANIL	targetBased	4	Completed	04/01/2021	https://clinicaltrials.gov/study/NCT05468671	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	internal carotid artery stenosis	REMIFENTANIL	targetBased	4	Completed	29/09/2017	https://clinicaltrials.gov/study/NCT03996148	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	internal carotid artery stenosis	REMIFENTANIL	targetBased	4	Completed	29/09/2017	https://clinicaltrials.gov/study/NCT03996148	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	internal carotid artery stenosis	REMIFENTANIL	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00335972	1	GoF	protect	Closed due to lack of enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	internal carotid artery stenosis	REMIFENTANIL	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00335972	1	GoF	protect	Closed due to lack of enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain injury	REMIFENTANIL	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02123355	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain injury	REMIFENTANIL	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02123355	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intelligence	REMIFENTANIL	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02123355	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intelligence	REMIFENTANIL	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02123355	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intelligence	REMIFENTANIL	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01375348	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intelligence	REMIFENTANIL	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01375348	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	stroke	REMIFENTANIL	targetBased	3	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02822144	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	stroke	REMIFENTANIL	targetBased	3	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02822144	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	stroke	LEVODOPA	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00102869	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	stroke	LEVODOPA	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00102869	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	stroke	LEVODOPA	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00102869	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	stroke	LEVODOPA	targetBased	4	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02346630	1	GoF	protect	We didn't receive the expected funding to support the study.
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	stroke	LEVODOPA	targetBased	4	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02346630	1	GoF	protect	We didn't receive the expected funding to support the study.
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	stroke	LEVODOPA	targetBased	4	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02346630	1	GoF	protect	We didn't receive the expected funding to support the study.
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	alcohol drinking	LEVODOPA	targetBased	4	Withdrawn	01/02/2023	https://clinicaltrials.gov/study/NCT04742348	1	GoF	protect	COVID-19 and expiration of funding
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	alcohol drinking	LEVODOPA	targetBased	4	Withdrawn	01/02/2023	https://clinicaltrials.gov/study/NCT04742348	1	GoF	protect	COVID-19 and expiration of funding
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	alcohol drinking	LEVODOPA	targetBased	4	Withdrawn	01/02/2023	https://clinicaltrials.gov/study/NCT04742348	1	GoF	protect	COVID-19 and expiration of funding
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Chronic pain	LEVODOPA	targetBased	2	Recruiting	02/02/2024	https://clinicaltrials.gov/study/NCT05285683	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Chronic pain	LEVODOPA	targetBased	2	Recruiting	02/02/2024	https://clinicaltrials.gov/study/NCT05285683	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Chronic pain	LEVODOPA	targetBased	2	Recruiting	02/02/2024	https://clinicaltrials.gov/study/NCT05285683	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	amblyopia	LEVODOPA	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01190813	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	amblyopia	LEVODOPA	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01190813	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	amblyopia	LEVODOPA	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01190813	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	amblyopia	LEVODOPA	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00789672	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	amblyopia	LEVODOPA	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00789672	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	amblyopia	LEVODOPA	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00789672	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anterior ischemic optic neuropathy	LEVODOPA	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00432393	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anterior ischemic optic neuropathy	LEVODOPA	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00432393	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anterior ischemic optic neuropathy	LEVODOPA	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00432393	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	LEVODOPA	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00625547	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	LEVODOPA	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00625547	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	LEVODOPA	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00625547	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	LEVODOPA	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00144209	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	LEVODOPA	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00144209	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	LEVODOPA	targetBased	3	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00144209	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	pain	LEVODOPA	targetBased	2	Withdrawn	01/11/2021	https://clinicaltrials.gov/study/NCT05087914	0.2	GoF	protect	Study was not started, therefore recruitment did not happen
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	pain	LEVODOPA	targetBased	2	Withdrawn	01/11/2021	https://clinicaltrials.gov/study/NCT05087914	0.2	GoF	protect	Study was not started, therefore recruitment did not happen
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	pain	LEVODOPA	targetBased	2	Withdrawn	01/11/2021	https://clinicaltrials.gov/study/NCT05087914	0.2	GoF	protect	Study was not started, therefore recruitment did not happen
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	pain	LEVODOPA	targetBased	2	Withdrawn	01/05/2014	https://clinicaltrials.gov/study/NCT02116790	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	pain	LEVODOPA	targetBased	2	Withdrawn	01/05/2014	https://clinicaltrials.gov/study/NCT02116790	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	pain	LEVODOPA	targetBased	2	Withdrawn	01/05/2014	https://clinicaltrials.gov/study/NCT02116790	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Spinal cord injury	LEVODOPA	targetBased	2	Suspended	19/06/2019	https://clinicaltrials.gov/study/NCT04000919	0.2	GoF	protect	PI left UofL and intends to reopen study at University of Alberta
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Spinal cord injury	LEVODOPA	targetBased	2	Suspended	19/06/2019	https://clinicaltrials.gov/study/NCT04000919	0.2	GoF	protect	PI left UofL and intends to reopen study at University of Alberta
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Spinal cord injury	LEVODOPA	targetBased	2	Suspended	19/06/2019	https://clinicaltrials.gov/study/NCT04000919	0.2	GoF	protect	PI left UofL and intends to reopen study at University of Alberta
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	retinopathy	LEVODOPA	targetBased	4	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00812760	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	retinopathy	LEVODOPA	targetBased	4	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00812760	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	retinopathy	LEVODOPA	targetBased	4	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00812760	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	LEVODOPA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0caee228-12c7-437c-9ea6-06b4e51722e1	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	LEVODOPA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0caee228-12c7-437c-9ea6-06b4e51722e1	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	LEVODOPA	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0caee228-12c7-437c-9ea6-06b4e51722e1	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	LEVODOPA	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	LEVODOPA	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	LEVODOPA	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Aphasia	LEVODOPA	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00102869	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Aphasia	LEVODOPA	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00102869	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Aphasia	LEVODOPA	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00102869	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Aphasia	LEVODOPA	targetBased	2	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01429077	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Aphasia	LEVODOPA	targetBased	2	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01429077	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Aphasia	LEVODOPA	targetBased	2	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01429077	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Back pain	LEVODOPA	targetBased	2	Withdrawn	01/10/2019	https://clinicaltrials.gov/study/NCT04082715	0.2	GoF	protect	we don't have enough research funding.
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Back pain	LEVODOPA	targetBased	2	Withdrawn	01/10/2019	https://clinicaltrials.gov/study/NCT04082715	0.2	GoF	protect	we don't have enough research funding.
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Back pain	LEVODOPA	targetBased	2	Withdrawn	01/10/2019	https://clinicaltrials.gov/study/NCT04082715	0.2	GoF	protect	we don't have enough research funding.
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Back pain	LEVODOPA	targetBased	4	Completed	24/02/2015	https://clinicaltrials.gov/study/NCT01951105	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Back pain	LEVODOPA	targetBased	4	Completed	24/02/2015	https://clinicaltrials.gov/study/NCT01951105	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Back pain	LEVODOPA	targetBased	4	Completed	24/02/2015	https://clinicaltrials.gov/study/NCT01951105	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Parkinson disease	CHOLECALCIFEROL	targetBased	4	Terminated	01/06/2007	https://clinicaltrials.gov/study/NCT00571285	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Parkinson disease	CHOLECALCIFEROL	targetBased	2	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00907972	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Parkinson disease	CHOLECALCIFEROL	targetBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01119131	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	neuropathic pain	CHOLECALCIFEROL	targetBased	2	Recruiting	19/12/2022	https://clinicaltrials.gov/study/NCT05259527	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	optic neuritis	CHOLECALCIFEROL	targetBased	2	Unknown status	01/07/2011	https://clinicaltrials.gov/study/NCT01465893	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	optic neuritis	CHOLECALCIFEROL	targetBased	2	Recruiting	23/11/2017	https://clinicaltrials.gov/study/NCT03302585	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	epilepsy	CHOLECALCIFEROL	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02890823	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	epilepsy	CHOLECALCIFEROL	targetBased	3	Unknown status	01/04/2018	https://clinicaltrials.gov/study/NCT03475225	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Cognitive impairment	CHOLECALCIFEROL	targetBased	2	Unknown status	01/11/2012	https://clinicaltrials.gov/study/NCT01708005	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Cognitive impairment	CHOLECALCIFEROL	targetBased	3	Recruiting	01/07/2016	https://clinicaltrials.gov/study/NCT02808676	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Abdominal pain	CHOLECALCIFEROL	targetBased	2	Not yet recruiting	01/07/2016	https://clinicaltrials.gov/study/NCT02839239	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	neurotoxicity	CHOLECALCIFEROL	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01499940	0.2	GoF	protect	Research cancelled - no funding identified.
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Huntington disease	TIAPRIDE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00632645	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPTAZINOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX05	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPTAZINOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX05	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	PROCYCLIDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA04	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	PROCYCLIDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA04	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	PROCYCLIDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA04	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	PROCYCLIDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA04	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	PROCYCLIDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA04	1	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ZUCAPSAICIN	targetBased	3	Not yet recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT01341548	0.7	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ZUCAPSAICIN	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00033839	0.7	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	ZUCAPSAICIN	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00069082	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	central nervous system leukemia	VINCRISTINE	targetBased	3	Active, not recruiting	29/02/2012	https://clinicaltrials.gov/study/NCT02883049	0.7	LoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	optic neuritis	FINGOLIMOD	targetBased	2	Terminated	01/08/2013	https://clinicaltrials.gov/study/NCT01757691	0.2	GoF	protect	Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	optic neuritis	FINGOLIMOD	targetBased	2	Terminated	01/08/2013	https://clinicaltrials.gov/study/NCT01757691	0.2	GoF	protect	Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	stroke	FINGOLIMOD	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02002390	0.2	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	stroke	FINGOLIMOD	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02002390	0.2	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	stroke	FINGOLIMOD	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02002390	0.2	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	chronic inflammatory demyelinating polyradiculoneuropathy	FINGOLIMOD	targetBased	3	Completed	22/12/2012	https://clinicaltrials.gov/study/NCT01625182	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	optic neuritis	FINGOLIMOD	targetBased	2	Terminated	01/08/2013	https://clinicaltrials.gov/study/NCT01757691	0.2	GoF	protect	Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	optic neuritis	FINGOLIMOD	targetBased	2	Terminated	01/08/2013	https://clinicaltrials.gov/study/NCT01757691	0.2	GoF	protect	Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	Cognitive impairment	FINGOLIMOD	targetBased	4	Terminated	16/02/2016	https://clinicaltrials.gov/study/NCT02575365	1	GoF	protect	The trial was terminated due to low enrollment.
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	Cognitive impairment	FINGOLIMOD	targetBased	4	Terminated	16/02/2016	https://clinicaltrials.gov/study/NCT02575365	1	GoF	protect	The trial was terminated due to low enrollment.
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	chronic inflammatory demyelinating polyradiculoneuropathy	FINGOLIMOD	targetBased	3	Completed	22/12/2012	https://clinicaltrials.gov/study/NCT01625182	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	chronic inflammatory demyelinating polyradiculoneuropathy	FINGOLIMOD	targetBased	3	Completed	22/12/2012	https://clinicaltrials.gov/study/NCT01625182	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	stroke	FINGOLIMOD	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02002390	0.2	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	stroke	FINGOLIMOD	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02002390	0.2	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	Cognitive impairment	FINGOLIMOD	targetBased	4	Terminated	16/02/2016	https://clinicaltrials.gov/study/NCT02575365	1	GoF	protect	The trial was terminated due to low enrollment.
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	amyotrophic lateral sclerosis	FINGOLIMOD	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	stroke	FINGOLIMOD	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT02002390	0.2	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	Cognitive impairment	FINGOLIMOD	targetBased	4	Terminated	16/02/2016	https://clinicaltrials.gov/study/NCT02575365	1	GoF	protect	The trial was terminated due to low enrollment.
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	chronic inflammatory demyelinating polyradiculoneuropathy	FINGOLIMOD	targetBased	3	Completed	22/12/2012	https://clinicaltrials.gov/study/NCT01625182	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	optic neuritis	FINGOLIMOD	targetBased	2	Terminated	01/08/2013	https://clinicaltrials.gov/study/NCT01757691	0.2	GoF	protect	Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	optic neuritis	FINGOLIMOD	targetBased	2	Terminated	01/08/2013	https://clinicaltrials.gov/study/NCT01757691	0.2	GoF	protect	Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	Cognitive impairment	FINGOLIMOD	targetBased	4	Terminated	16/02/2016	https://clinicaltrials.gov/study/NCT02575365	1	GoF	protect	The trial was terminated due to low enrollment.
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	Cognitive impairment	FINGOLIMOD	targetBased	4	Terminated	16/02/2016	https://clinicaltrials.gov/study/NCT02575365	1	GoF	protect	The trial was terminated due to low enrollment.
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	amyotrophic lateral sclerosis	FINGOLIMOD	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	amyotrophic lateral sclerosis	FINGOLIMOD	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	chronic inflammatory demyelinating polyradiculoneuropathy	FINGOLIMOD	targetBased	3	Completed	22/12/2012	https://clinicaltrials.gov/study/NCT01625182	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	chronic inflammatory demyelinating polyradiculoneuropathy	FINGOLIMOD	targetBased	3	Completed	22/12/2012	https://clinicaltrials.gov/study/NCT01625182	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	amyotrophic lateral sclerosis	FINGOLIMOD	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	amyotrophic lateral sclerosis	FINGOLIMOD	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	amyotrophic lateral sclerosis	FINGOLIMOD	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		epilepsy	FELBAMATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f522701-397a-11de-8a39-0800200c9a66	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		epilepsy	FELBAMATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AX10	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Seizure	FELBAMATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f522701-397a-11de-8a39-0800200c9a66	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	PARAMETHADIONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N03AC01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BIPERIDEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA02	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BIPERIDEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BIPERIDEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA02	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BIPERIDEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BIPERIDEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pain	DROPERIDOL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01432977	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	pain	DROPERIDOL	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02282956	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	pain	DROPERIDOL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01432977	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	pain	DROPERIDOL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01432977	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	pain	DROPERIDOL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01432977	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00041678	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00041678	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pain	ARIPIPRAZOLE	targetBased	4	Completed	10/11/2021	https://clinicaltrials.gov/study/NCT05103410	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT01438060	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00041678	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	drug-Induced dyskinesia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2008	https://clinicaltrials.gov/study/NCT00837707	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	ARIPIPRAZOLE	targetBased	3	Unknown status	01/03/2010	https://clinicaltrials.gov/study/NCT01082848	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00041678	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00041678	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT01438060	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT01438060	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00036114	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	GoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	ARGATROBAN	targetBased	4	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03740958	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	ARGATROBAN	targetBased	4	Completed	25/10/2017	https://clinicaltrials.gov/study/NCT03552354	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	SUMANIROLE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00058838	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	SUMANIROLE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00058838	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	SUMANIROLE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00036218	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	SUMANIROLE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00036218	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	SUMANIROLE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00036218	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	SUMANIROLE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00036218	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	SUMANIROLE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00036218	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	SUMANIROLE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00036218	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ETHOPROPAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA05	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ETHOPROPAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ETHOPROPAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA05	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ETHOPROPAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA05	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ETHOPROPAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA05	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	intracranial subdural hematoma	ISOFLURANE	targetBased	4	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03146104	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	subarachnoid hemorrhage	ISOFLURANE	targetBased	2	Completed	26/06/2020	https://clinicaltrials.gov/study/NCT05213832	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	subarachnoid hemorrhage	ISOFLURANE	targetBased	2	Completed	26/06/2020	https://clinicaltrials.gov/study/NCT05213832	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	intracranial subdural hematoma	ISOFLURANE	targetBased	4	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03146104	1		protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	2	Active, not recruiting	13/09/2019	https://clinicaltrials.gov/study/NCT04528706	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	2	Active, not recruiting	13/09/2019	https://clinicaltrials.gov/study/NCT04528706	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	2	Active, not recruiting	13/09/2019	https://clinicaltrials.gov/study/NCT04528706	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	2	Active, not recruiting	13/09/2019	https://clinicaltrials.gov/study/NCT04528706	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	2	Active, not recruiting	13/09/2019	https://clinicaltrials.gov/study/NCT04528706	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	2	Active, not recruiting	13/09/2019	https://clinicaltrials.gov/study/NCT04528706	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	3	Recruiting	12/07/2023	https://clinicaltrials.gov/study/NCT05819866	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	3	Recruiting	12/07/2023	https://clinicaltrials.gov/study/NCT05819866	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	3	Recruiting	12/07/2023	https://clinicaltrials.gov/study/NCT05819866	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	3	Recruiting	12/07/2023	https://clinicaltrials.gov/study/NCT05819866	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	3	Recruiting	12/07/2023	https://clinicaltrials.gov/study/NCT05819866	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	leukodystrophy	LERIGLITAZONE	targetBased	3	Recruiting	12/07/2023	https://clinicaltrials.gov/study/NCT05819866	0.7	GoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	stroke	TRAMIPROSATE	pathwayBased	2	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00056238	0.2	GoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	stroke	TRAMIPROSATE	pathwayBased	2	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00056238	0.2	GoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	stroke	TRAMIPROSATE	targetBased	2	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00056238	0.2	GoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	TRAMIPROSATE	pathwayBased	3	Unknown status	01/05/2006	https://clinicaltrials.gov/study/NCT00314912	0.7	GoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	TRAMIPROSATE	pathwayBased	3	Unknown status	01/05/2006	https://clinicaltrials.gov/study/NCT00314912	0.7	GoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	TRAMIPROSATE	targetBased	3	Unknown status	01/05/2006	https://clinicaltrials.gov/study/NCT00314912	0.7	GoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Cognitive impairment	TRAMIPROSATE	pathwayBased	4	Recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT05022186	1	GoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Cognitive impairment	TRAMIPROSATE	pathwayBased	4	Recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT05022186	1	GoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Cognitive impairment	TRAMIPROSATE	targetBased	4	Recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT05022186	1	GoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	restless legs syndrome	LEVETIRACETAM	targetBased	2	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00247364	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Alzheimer disease	LEVETIRACETAM	targetBased	2	Completed	16/10/2014	https://clinicaltrials.gov/study/NCT02002819	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Alzheimer disease	LEVETIRACETAM	targetBased	2	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04004702	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Alzheimer disease	LEVETIRACETAM	targetBased	2	Recruiting	22/08/2019	https://clinicaltrials.gov/study/NCT03875638	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	childhood epilepsy with centrotemporal spikes	LEVETIRACETAM	targetBased	4	Recruiting	20/06/2018	https://clinicaltrials.gov/study/NCT03490487	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	subarachnoid hemorrhage	LEVETIRACETAM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01137110	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	photosensitive epilepsy	LEVETIRACETAM	targetBased	2	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00894010	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Rolandic epilepsy	LEVETIRACETAM	targetBased	4	Terminated	02/08/2019	https://clinicaltrials.gov/study/NCT04610879	1	LoF	protect	Following the internal pilot, the study did not meet prespecified stop/go criteria for continuation.
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy with generalized tonic-clonic seizures	LEVETIRACETAM	targetBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT01150331	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy with generalized tonic-clonic seizures	LEVETIRACETAM	targetBased	3	Completed	10/08/2005	https://clinicaltrials.gov/study/NCT00150813	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy with generalized tonic-clonic seizures	LEVETIRACETAM	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00150787	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	polyneuropathy	LEVETIRACETAM	targetBased	2	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00156689	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	polyneuropathy	LEVETIRACETAM	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00286260	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	status epilepticus	LEVETIRACETAM	targetBased	2	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02920060	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	status epilepticus	LEVETIRACETAM	targetBased	2	Withdrawn	01/01/2008	https://clinicaltrials.gov/study/NCT00603135	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	status epilepticus	LEVETIRACETAM	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT01960075	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	status epilepticus	LEVETIRACETAM	targetBased	4	Enrolling by invitation	15/05/2023	https://clinicaltrials.gov/study/NCT06403150	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	status epilepticus	LEVETIRACETAM	targetBased	2	Completed	20/06/2021	https://clinicaltrials.gov/study/NCT04926844	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	status epilepticus	LEVETIRACETAM	targetBased	2	Unknown status	01/10/2006	https://clinicaltrials.gov/study/NCT00362141	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	status epilepticus	LEVETIRACETAM	targetBased	3	Withdrawn	01/02/2014	https://clinicaltrials.gov/study/NCT02726867	0.7	LoF	protect	No participants enrolled
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	partial epilepsy	LEVETIRACETAM	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00438451	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	partial epilepsy	LEVETIRACETAM	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00280696	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	partial epilepsy	LEVETIRACETAM	targetBased	4	Active, not recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT03689114	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	partial epilepsy	LEVETIRACETAM	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00855738	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	partial epilepsy	LEVETIRACETAM	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT02208492	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	intracerebral hemorrhage	LEVETIRACETAM	targetBased	3	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02631759	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	movement disorder	LEVETIRACETAM	targetBased	2	Unknown status	01/05/2006	https://clinicaltrials.gov/study/NCT00291733	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	movement disorder	LEVETIRACETAM	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00291213	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Parkinson disease	LEVETIRACETAM	targetBased	4	Withdrawn	01/12/2007	https://clinicaltrials.gov/study/NCT00584025	1	LoF	protect	Study withdrawn due to personnel limitations.
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Parkinson disease	LEVETIRACETAM	targetBased	2	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00160576	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Parkinson disease	LEVETIRACETAM	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00307450	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	drug-Induced dyskinesia	LEVETIRACETAM	targetBased	2	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00175955	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=925d34bb-235a-4655-b5bf-d1c3d93f5daa	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a781b4-da67-4650-a99b-593fc34465da	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8d09dcb-e267-4fc4-ba59-6a5b9aa654a3	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1918b4e-2238-4cbd-81be-61cae5481c88	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bb6ee93-27b0-46aa-ab78-445e076c47a3	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Seizure	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f2642ac-703f-4447-ab2c-2c15511e5a81	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	pain	LEVETIRACETAM	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00252954	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80f5349c-3910-4c69-9f56-cb552bf4f336	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d9e871-696d-45c6-98eb-052c8962bef5	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d818ef84-9b3e-434b-92d9-910cfa8af7da	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0815e947-ecc1-496f-9419-ebdb6a6f24c9	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4f7e6ed-992b-4217-82d8-658036d12faa	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	epilepsy	LEVETIRACETAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f691fe85-a3dd-40b8-83ac-c1fa27907e6a	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	oromandibular dystonia	LEVETIRACETAM	targetBased	2	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02199509	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Cognitive impairment	LEVETIRACETAM	targetBased	2	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01044758	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Cognitive impairment	LEVETIRACETAM	targetBased	2	Recruiting	22/08/2019	https://clinicaltrials.gov/study/NCT03875638	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT01976871	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT01976871	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT01976871	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT01976871	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT01976871	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT01976871	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROTIGOTINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/leganto	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROTIGOTINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/leganto	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	ROTIGOTINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/leganto	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	26/11/2012	https://clinicaltrials.gov/study/NCT01823770	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	26/11/2012	https://clinicaltrials.gov/study/NCT01823770	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	ROTIGOTINE	targetBased	4	Completed	26/11/2012	https://clinicaltrials.gov/study/NCT01823770	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Alzheimer disease	ROTIGOTINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03250741	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01744496	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01744496	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01744496	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01744496	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01744496	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01744496	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	pain	ROTIGOTINE	targetBased	2	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02123979	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01523301	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01523301	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	ROTIGOTINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01523301	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	ROTIGOTINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/leganto	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	ROTIGOTINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/leganto	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	ROTIGOTINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/leganto	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	stroke	ROTIGOTINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00663338	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PICLOZOTAN	targetBased	2	Completed	13/07/2007	https://clinicaltrials.gov/study/NCT00623363	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PICLOZOTAN	targetBased	2	Completed	13/07/2007	https://clinicaltrials.gov/study/NCT00623363	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	stroke	PICLOZOTAN	targetBased	2	Terminated	01/09/2004	https://clinicaltrials.gov/study/NCT00272909	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	stroke	PICLOZOTAN	targetBased	2	Terminated	01/09/2004	https://clinicaltrials.gov/study/NCT00272909	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	metastasis	FULVESTRANT	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	metastasis	FULVESTRANT	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	metastasis	FULVESTRANT	targetBased	3	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00241449	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	memory impairment	VILAZODONE	targetBased	2	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01828515	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	memory impairment	VILAZODONE	targetBased	2	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01828515	0.2	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Alzheimer disease	MODAFINIL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT01172145	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Parkinson disease	MODAFINIL	targetBased	2	Withdrawn	01/11/2016	https://clinicaltrials.gov/study/NCT02857244	0.2	LoF	protect	Site did not obtain LIRB approval due to medication usage.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Parkinson disease	MODAFINIL	targetBased	2	Completed	13/06/2017	https://clinicaltrials.gov/study/NCT03083132	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	cognition	MODAFINIL	targetBased	2	Recruiting	17/07/2019	https://clinicaltrials.gov/study/NCT03893032	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	stroke	MODAFINIL	targetBased	3	Terminated	01/10/2012	https://clinicaltrials.gov/study/NCT01800097	0.7	LoF	protect	Slow recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	THIETHYLPERAZINE	targetBased	2	Completed	24/11/2017	https://clinicaltrials.gov/study/NCT03417986	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	THIETHYLPERAZINE	targetBased	2	Completed	24/11/2017	https://clinicaltrials.gov/study/NCT03417986	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	THIETHYLPERAZINE	targetBased	2	Completed	24/11/2017	https://clinicaltrials.gov/study/NCT03417986	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	THIETHYLPERAZINE	targetBased	2	Completed	24/11/2017	https://clinicaltrials.gov/study/NCT03417986	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	THIETHYLPERAZINE	targetBased	2	Completed	24/11/2017	https://clinicaltrials.gov/study/NCT03417986	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	THIETHYLPERAZINE	targetBased	2	Completed	24/11/2017	https://clinicaltrials.gov/study/NCT03417986	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	LECOZOTAN	targetBased	2	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00277810	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	LECOZOTAN	targetBased	2	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00277810	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	LECOZOTAN	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00151333	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	LECOZOTAN	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00151333	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	LECOZOTAN	targetBased	2	Completed	06/10/2005	https://clinicaltrials.gov/study/NCT00151398	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	LECOZOTAN	targetBased	2	Completed	06/10/2005	https://clinicaltrials.gov/study/NCT00151398	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Cognitive impairment	PSILOCYBINE	targetBased	2	Recruiting	27/11/2023	https://clinicaltrials.gov/study/NCT06041152	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	PSILOCYBINE	targetBased	2	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06399263	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	PSILOCYBINE	targetBased	2	Recruiting	12/10/2022	https://clinicaltrials.gov/study/NCT05481736	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anorexia nervosa	PSILOCYBINE	targetBased	2	Completed	01/05/2021	https://clinicaltrials.gov/study/NCT04661514	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	temporal lobe epilepsy	NALUZOTAN	targetBased	2	Terminated	07/01/2011	https://clinicaltrials.gov/study/NCT01281956	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	temporal lobe epilepsy	NALUZOTAN	targetBased	2	Terminated	07/01/2011	https://clinicaltrials.gov/study/NCT01281956	0.2	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	migraine disorder	SB-705498	targetBased	2	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00269022	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Cognitive impairment	EPHEDRINE	targetBased	2	Suspended	01/10/2014	https://clinicaltrials.gov/study/NCT02428062	0.2	GoF	protect	Pending Pilot study results evaluation
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPHEDRINE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02062801	1	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	358940	targetBased	2	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00387140	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Alzheimer disease	SARACATINIB	targetBased	2	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02167256	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	alcohol drinking	SARACATINIB	targetBased	2	Completed	09/05/2017	https://clinicaltrials.gov/study/NCT02955186	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	central nervous system leukemia	DASATINIB	targetBased	3	Active, not recruiting	29/02/2012	https://clinicaltrials.gov/study/NCT02883049	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	brain disease	DASATINIB	targetBased	2	Withdrawn	01/05/2009	https://clinicaltrials.gov/study/NCT02661113	0.2	LoF	protect	Sponsor withdrew support; Study did not progress to Phase II (Phase I registration NCT00895960)
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02463825	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PIMOZIDE	targetBased	2	Recruiting	27/10/2017	https://clinicaltrials.gov/study/NCT03272503	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	DOMPERIDONE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT03022201	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	DOMPERIDONE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT03022201	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	DOMPERIDONE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT03022201	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	DOMPERIDONE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT03022201	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	DOMPERIDONE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT03022201	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	DOMPERIDONE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT03022201	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	cerebral infarction	NIMODIPINE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02248233	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	subarachnoid hemorrhage	NIMODIPINE	targetBased	3	Terminated	01/07/2016	https://clinicaltrials.gov/study/NCT02790632	0.35	LoF	protect	DMC review concluded study has a low probability of meeting its primary endpoint
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	subarachnoid hemorrhage	NIMODIPINE	targetBased	2	Completed	11/01/2020	https://clinicaltrials.gov/study/NCT04100824	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	NIMODIPINE	targetBased	2	Withdrawn	01/09/2015	https://clinicaltrials.gov/study/NCT02165644	0.2	LoF	protect	The PI is leaving the University of Florida.
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	pain	VASOPRESSIN	targetBased	3	Completed	29/10/2018	https://clinicaltrials.gov/study/NCT03636451	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Parkinson disease	DESMOPRESSIN	targetBased	4	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00806468	1	GoF	protect	lack of recruitment
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	pain	DESMOPRESSIN	targetBased	3	Unknown status	01/03/2012	https://clinicaltrials.gov/study/NCT01742689	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	intracerebral hemorrhage	DESMOPRESSIN	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT00961532	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	SARIZOTAN	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	SARIZOTAN	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105521	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105521	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105521	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105521	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	SARIZOTAN	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105508	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105521	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105521	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN	targetBased	3	Completed	30/09/2004	https://clinicaltrials.gov/study/NCT00105521	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	BIFEPRUNOX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00160147	0.7	GoF	protect	The study was discontinued prematurely on 25 February 2008 due to slow enrollment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	BIFEPRUNOX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00160147	0.7	GoF	protect	The study was discontinued prematurely on 25 February 2008 due to slow enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	BIFEPRUNOX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00160147	0.7	GoF	protect	The study was discontinued prematurely on 25 February 2008 due to slow enrollment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	BIFEPRUNOX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00160147	0.7	GoF	protect	The study was discontinued prematurely on 25 February 2008 due to slow enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	BIFEPRUNOX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00160147	0.7	GoF	protect	The study was discontinued prematurely on 25 February 2008 due to slow enrollment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	BIFEPRUNOX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00160147	0.7	GoF	protect	The study was discontinued prematurely on 25 February 2008 due to slow enrollment
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	BIFEPRUNOX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00160147	0.7	GoF	protect	The study was discontinued prematurely on 25 February 2008 due to slow enrollment
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	BIFEPRUNOX	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00160147	0.7	GoF	protect	The study was discontinued prematurely on 25 February 2008 due to slow enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Cognitive impairment	NOREPINEPHRINE	targetBased	2	Suspended	01/10/2014	https://clinicaltrials.gov/study/NCT02428062	0.2	GoF	protect	Pending Pilot study results evaluation
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	NOREPINEPHRINE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06059144	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	NOREPINEPHRINE	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02019810	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	neuropathic pain	HYDROCODONE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01400139	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566bd196-3c0c-4f05-9e2e-4803ad3126d4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566bd196-3c0c-4f05-9e2e-4803ad3126d4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7a9280e-e713-4773-b4bd-aabec9cff63a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7a9280e-e713-4773-b4bd-aabec9cff63a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b933d7c4-0766-4a27-93db-ed0ce6028306	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b933d7c4-0766-4a27-93db-ed0ce6028306	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01517295	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01517295	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00195728	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01240863	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01240863	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00314340	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00314340	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	HYDROCODONE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01400139	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	HYDROCODONE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01400139	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01789970	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00325949	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01922739	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01452529	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	HYDROCODONE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01364922	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01081912	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01223365	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01240863	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01517295	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00314340	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00195728	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	HYDROCODONE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01115569	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc123646-b0ac-4fd7-88fe-bee7cf10b205	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07b3ba11-6c4e-4fda-b322-cfbfd9f81021	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a344a83d-66e7-4f71-b819-1e636b089486	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4db32036-15bc-4ea0-9d0f-4760111a4462	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=930b3a2b-b79d-4290-b358-bd1bb214c96b	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41ebe34d-567d-4fea-9fcb-c93e990a7861	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01452529	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01452529	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01789970	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01789970	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01081912	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01081912	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01922739	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01922739	0.7	GoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	movement disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00926965	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cancer pain	ESKETAMINE	targetBased	2	Withdrawn	25/11/2020	https://clinicaltrials.gov/study/NCT04666623	0.2	LoF	protect	investigator decision
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ESKETAMINE	targetBased	4	Completed	14/02/2017	https://clinicaltrials.gov/study/NCT04459377	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ESKETAMINE	targetBased	4	Recruiting	19/04/2022	https://clinicaltrials.gov/study/NCT05289050	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ESKETAMINE	targetBased	4	Completed	01/02/2017	https://clinicaltrials.gov/study/NCT02994173	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ESKETAMINE	targetBased	4	Completed	14/06/2022	https://clinicaltrials.gov/study/NCT05414006	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ESKETAMINE	targetBased	4	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05515822	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ESKETAMINE	targetBased	4	Recruiting	12/04/2022	https://clinicaltrials.gov/study/NCT05299866	1	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	cerebral small vessel disease	EXENATIDE	targetBased	2	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05356104	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	cerebral small vessel disease	EXENATIDE	targetBased	2	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05356104	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	cerebral small vessel disease	EXENATIDE	targetBased	2	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT05356104	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	stroke	EXENATIDE	targetBased	2	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT02838589	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	stroke	EXENATIDE	targetBased	2	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT02838589	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	stroke	EXENATIDE	targetBased	2	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT02838589	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	brain injury	EXENATIDE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02058940	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	brain injury	EXENATIDE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02058940	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	brain injury	EXENATIDE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02058940	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Active, not recruiting	21/01/2020	https://clinicaltrials.gov/study/NCT04305002	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Active, not recruiting	21/01/2020	https://clinicaltrials.gov/study/NCT04305002	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Active, not recruiting	21/01/2020	https://clinicaltrials.gov/study/NCT04305002	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT01174810	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT01174810	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT01174810	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT01971242	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT01971242	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT01971242	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	3	Active, not recruiting	20/01/2020	https://clinicaltrials.gov/study/NCT04232969	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	3	Active, not recruiting	20/01/2020	https://clinicaltrials.gov/study/NCT04232969	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	EXENATIDE	targetBased	3	Active, not recruiting	20/01/2020	https://clinicaltrials.gov/study/NCT04232969	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Huntington disease	SRX246	targetBased	2	Completed	10/05/2016	https://clinicaltrials.gov/study/NCT02507284	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	neuropathic pain	OXYTOCIN	targetBased	2	Terminated	19/06/2014	https://clinicaltrials.gov/study/NCT02100956	0.2	GoF	protect	Cessation of funding period prior to completion, due to slow recruitment during the pandemic
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pain	OXYTOCIN	targetBased	2	Terminated	12/01/2017	https://clinicaltrials.gov/study/NCT03011307	0.2	GoF	protect	Cessation of funding period prior to completion, due to slow recruitment during the pandemic.
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pain	OXYTOCIN	targetBased	2	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02888574	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	pain	OXYTOCIN	targetBased	4	Recruiting	15/11/2021	https://clinicaltrials.gov/study/NCT05079841	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	frontotemporal dementia	OXYTOCIN	targetBased	2	Completed	12/09/2013	https://clinicaltrials.gov/study/NCT01937013	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	frontotemporal dementia	OXYTOCIN	targetBased	2	Active, not recruiting	31/01/2018	https://clinicaltrials.gov/study/NCT03260920	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Chronic pain	OXYTOCIN	targetBased	2	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02888574	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Chronic pain	OXYTOCIN	targetBased	4	Completed	08/08/2019	https://clinicaltrials.gov/study/NCT03935399	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Chronic pain	OXYTOCIN	targetBased	2	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT04903002	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Chronic pain	OXYTOCIN	targetBased	4	Completed	10/05/2019	https://clinicaltrials.gov/study/NCT03929367	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Chronic pain	OXYTOCIN	targetBased	2	Not yet recruiting	01/01/2025	https://clinicaltrials.gov/study/NCT04433741	0.2	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	subarachnoid hemorrhage	NICARDIPINE	targetBased	2	Completed	05/04/2020	https://clinicaltrials.gov/study/NCT04269408	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	intracerebral hemorrhage	NICARDIPINE	targetBased	3	Terminated	15/05/2011	https://clinicaltrials.gov/study/NCT01176565	0.35	LoF	protect	Planned interim analysis: no significant outcome differences between groups
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	intracranial vasospasm	NICARDIPINE	targetBased	4	Recruiting	29/08/2016	https://clinicaltrials.gov/study/NCT01996436	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	intracranial vasospasm	NICARDIPINE	targetBased	2	Terminated	01/08/2013	https://clinicaltrials.gov/study/NCT01810302	0.2	LoF	protect	Unable to secure drug.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	NICARDIPINE	targetBased	2	Completed	17/01/2020	https://clinicaltrials.gov/study/NCT04116112	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TRIHEXYPHENIDYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA01	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TRIHEXYPHENIDYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TRIHEXYPHENIDYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA01	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TRIHEXYPHENIDYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TRIHEXYPHENIDYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	pain	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	pain	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	dystonic disorder	TRIHEXYPHENIDYL	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00122044	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	dystonic disorder	TRIHEXYPHENIDYL	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00122044	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	dystonic disorder	TRIHEXYPHENIDYL	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00122044	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	dystonic disorder	TRIHEXYPHENIDYL	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00122044	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	dystonic disorder	TRIHEXYPHENIDYL	targetBased	2	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00122044	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	TRIHEXYPHENIDYL	targetBased	4	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT04523935	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	focal dystonia	AMLODIPINE	targetBased	2	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00015457	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7820d-471f-4ee2-9ec6-25d8d27c77de	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18686fa-be94-472e-8404-c69e6869ed10	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=003dd1ec-16f8-4f96-b6a8-c4689d35892a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE	targetBased	3	Completed	29/09/2018	https://clinicaltrials.gov/study/NCT03375515	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE	targetBased	3	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04785768	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE	targetBased	3	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04785768	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00766831	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00766831	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01621100	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01621100	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02035709	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02035709	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE	targetBased	4	Completed	11/11/2020	https://clinicaltrials.gov/study/NCT03592992	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE	targetBased	4	Completed	11/11/2020	https://clinicaltrials.gov/study/NCT03592992	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f26ababe-f6f0-443e-8d91-4d2a174675bc	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f26ababe-f6f0-443e-8d91-4d2a174675bc	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00631319	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01709721	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01709721	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE	targetBased	4	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02107339	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE	targetBased	4	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02107339	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00365898	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE	targetBased	3	Terminated	01/07/2005	https://clinicaltrials.gov/study/NCT00365898	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	HYDROMORPHONE	targetBased	3	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01986946	0.7	GoF	protect	Lack of recruitment.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	HYDROMORPHONE	targetBased	3	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01986946	0.7	GoF	protect	Lack of recruitment.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	HYDROMORPHONE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01207596	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	HYDROMORPHONE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01207596	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Abdominal pain	HYDROMORPHONE	targetBased	4	Completed	10/01/2018	https://clinicaltrials.gov/study/NCT03300674	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Abdominal pain	HYDROMORPHONE	targetBased	4	Completed	10/01/2018	https://clinicaltrials.gov/study/NCT03300674	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	HYDROMORPHONE	targetBased	4	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02389829	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	HYDROMORPHONE	targetBased	4	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02389829	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00398788	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00398788	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00411268	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00411268	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01455519	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01455519	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00549042	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00549042	0.7	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	partial epilepsy	NIFEDIPINE	targetBased	2	Recruiting	01/02/2021	https://clinicaltrials.gov/study/NCT03949478	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	epilepsy	NIFEDIPINE	targetBased	2	Recruiting	01/02/2021	https://clinicaltrials.gov/study/NCT03949478	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Alzheimer disease	NILOTINIB	targetBased	2	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02947893	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Alzheimer disease	NILOTINIB	targetBased	3	Not yet recruiting	01/02/2022	https://clinicaltrials.gov/study/NCT05143528	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Parkinson disease	NILOTINIB	targetBased	2	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02954978	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Parkinson disease	NILOTINIB	targetBased	2	Completed	16/10/2017	https://clinicaltrials.gov/study/NCT03205488	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	cerebellar ataxia	NILOTINIB	targetBased	2	Completed	19/11/2018	https://clinicaltrials.gov/study/NCT03932669	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	hearing loss	HYDROXYCHLOROQUINE	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06467526	0.2	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	neuropathic pain	ERGOCALCIFEROL	targetBased	2	Recruiting	19/12/2022	https://clinicaltrials.gov/study/NCT05259527	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	optic neuritis	ERGOCALCIFEROL	targetBased	2	Unknown status	01/07/2011	https://clinicaltrials.gov/study/NCT01465893	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	migraine disorder	ERGOCALCIFEROL	targetBased	2	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01225263	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Alzheimer disease	ERGOCALCIFEROL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01409694	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pain	ERGOCALCIFEROL	targetBased	3	Completed	11/07/2006	https://clinicaltrials.gov/study/NCT00365105	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pain	ERGOCALCIFEROL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02664857	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	restless legs syndrome	ERGOCALCIFEROL	targetBased	2	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02256215	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	diabetic neuropathy	ERGOCALCIFEROL	targetBased	2	Recruiting	03/11/2020	https://clinicaltrials.gov/study/NCT04689958	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	ALVIMOPAN	targetBased	4	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02785003	1	LoF	protect	Lack of Funding
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	ALVIMOPAN	targetBased	4	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02785003	1	LoF	protect	Lack of Funding
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	rhegmatogenous retinal detachment	ATROPINE	targetBased	4	Recruiting	25/07/2022	https://clinicaltrials.gov/study/NCT05331664	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	rhegmatogenous retinal detachment	ATROPINE	targetBased	4	Recruiting	25/07/2022	https://clinicaltrials.gov/study/NCT05331664	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	rhegmatogenous retinal detachment	ATROPINE	targetBased	4	Recruiting	25/07/2022	https://clinicaltrials.gov/study/NCT05331664	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	rhegmatogenous retinal detachment	ATROPINE	targetBased	4	Recruiting	25/07/2022	https://clinicaltrials.gov/study/NCT05331664	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	rhegmatogenous retinal detachment	ATROPINE	targetBased	4	Recruiting	25/07/2022	https://clinicaltrials.gov/study/NCT05331664	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	ATROPINE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	pain	ATROPINE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	pain	ATROPINE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	ATROPINE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	ATROPINE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	ATROPINE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02194088	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	ATROPINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	ATROPINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	ATROPINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	ATROPINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	ATROPINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	amblyopia	ATROPINE	targetBased	3	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00000170	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	amblyopia	ATROPINE	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00094614	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	amblyopia	ATROPINE	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00094614	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	amblyopia	ATROPINE	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00094614	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	amblyopia	ATROPINE	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00094614	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	amblyopia	ATROPINE	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00094614	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Cognitive impairment	ATROPINE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01845636	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Cognitive impairment	ATROPINE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01845636	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Cognitive impairment	ATROPINE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01845636	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Cognitive impairment	ATROPINE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01845636	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Cognitive impairment	ATROPINE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01845636	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	neuropathic pain	BUPRENORPHINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01298765	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	BUPRENORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	BUPRENORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	BUPRENORPHINE	targetBased	4	Recruiting	10/08/2022	https://clinicaltrials.gov/study/NCT05910190	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	BUPRENORPHINE	targetBased	4	Recruiting	10/08/2022	https://clinicaltrials.gov/study/NCT05910190	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUPRENORPHINE	targetBased	4	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04771689	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUPRENORPHINE	targetBased	4	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04771689	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=794aa355-66de-41b8-aedf-f2c40f6bc664	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=794aa355-66de-41b8-aedf-f2c40f6bc664	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUPRENORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AE01	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BUPRENORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AE01	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b25457a9-6237-4ba9-84dd-847b81cbcdae	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b25457a9-6237-4ba9-84dd-847b81cbcdae	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93902b00-6cbf-477d-9a3a-e47b2c45ff96	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93902b00-6cbf-477d-9a3a-e47b2c45ff96	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4	Suspended	01/02/2009	https://clinicaltrials.gov/study/NCT00916890	1	GoF	protect	difficulties in patients enrolment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4	Suspended	01/02/2009	https://clinicaltrials.gov/study/NCT00916890	1	GoF	protect	difficulties in patients enrolment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	BUPRENORPHINE	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00315445	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	BUPRENORPHINE	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00315445	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	BUPRENORPHINE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00315874	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	BUPRENORPHINE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00315874	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	BUPRENORPHINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01298765	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	BUPRENORPHINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01298765	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	restless legs syndrome	BUPRENORPHINE	targetBased	4	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT02138357	1	GoF	protect	No funding
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	restless legs syndrome	BUPRENORPHINE	targetBased	4	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT02138357	1	GoF	protect	No funding
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Back pain	BUPRENORPHINE	targetBased	3	Completed	01/12/1997	https://clinicaltrials.gov/study/NCT00315445	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Back pain	BUPRENORPHINE	targetBased	3	Completed	01/04/1997	https://clinicaltrials.gov/study/NCT00315874	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cancer pain	BUPRENORPHINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01809106	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cancer pain	BUPRENORPHINE	targetBased	4	Recruiting	10/08/2022	https://clinicaltrials.gov/study/NCT05910190	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01559454	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01675167	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00315887	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01256450	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Withdrawn	01/07/2012	https://clinicaltrials.gov/study/NCT01431742	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00346047	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00490919	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Terminated	01/02/2004	https://clinicaltrials.gov/study/NCT00313014	0.7	GoF	protect	Terminated early due to administrative reasons unrelated to efficacy or safety.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	restless legs syndrome	BUPRENORPHINE	targetBased	4	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT02138357	1	GoF	protect	No funding
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	2	Completed	19/10/2017	https://clinicaltrials.gov/study/NCT03026790	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	3	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00312195	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b25457a9-6237-4ba9-84dd-847b81cbcdae	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4	Suspended	01/02/2009	https://clinicaltrials.gov/study/NCT00916890	1	GoF	protect	difficulties in patients enrolment
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00313833	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93902b00-6cbf-477d-9a3a-e47b2c45ff96	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	3	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT01151098	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	BUPRENORPHINE	targetBased	2	Unknown status	01/04/2009	https://clinicaltrials.gov/study/NCT00612287	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUPRENORPHINE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01983111	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUPRENORPHINE	targetBased	4	Not yet recruiting	01/07/2022	https://clinicaltrials.gov/study/NCT04771689	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUPRENORPHINE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01298297	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUPRENORPHINE	targetBased	4	Recruiting	28/02/2023	https://clinicaltrials.gov/study/NCT05824832	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b25457a9-6237-4ba9-84dd-847b81cbcdae	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=794aa355-66de-41b8-aedf-f2c40f6bc664	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01559454	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01559454	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00346047	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00490919	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00490919	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00315887	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	BUPRENORPHINE	targetBased	3	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00315887	0.7	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	diabetic neuropathy	BICIFADINE	targetBased	2	Unknown status	01/09/2007	https://clinicaltrials.gov/study/NCT00553592	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Low back pain	BICIFADINE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00295724	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Low back pain	BICIFADINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00295711	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Low back pain	BICIFADINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00281645	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	AMANTADINE HYDROCHLORIDE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02321761	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	AMANTADINE HYDROCHLORIDE	targetBased	2	Recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06253923	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		brain injury	AMANTADINE HYDROCHLORIDE	targetBased	2	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00970944	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		amyotrophic lateral sclerosis	AMANTADINE HYDROCHLORIDE	targetBased	2	Recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04302870	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinsonism	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cerebral palsy	AMANTADINE HYDROCHLORIDE	targetBased	4	Terminated	28/02/2020	https://clinicaltrials.gov/study/NCT04273737	1	LoF	protect	PI left institution.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE HYDROCHLORIDE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00632762	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c74c9424-278d-4a52-8866-db66f6c3ac67	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63d9d4aa-5f92-45b0-98d0-d6ec38b727cb	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=076740b2-9a76-45e9-9d56-87e9f3b96e97	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be411327-5ac7-46df-b5e4-32a11b419b15	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	AMANTADINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0637f133-1f9d-48b3-b82f-a4e16f926cd6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AA08	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AA08	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547885	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547885	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a519a201-bcfd-4029-9bdf-fc3e03f975ac	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a519a201-bcfd-4029-9bdf-fc3e03f975ac	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	smoking cessation	nadolol	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01825122	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	nadolol	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcae071c-bd67-4fa9-be40-3325ebf04119	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	nadolol	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00910689	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	migraine disorder	METHYSERGIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02CA04	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	migraine disorder	METHYSERGIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02CA04	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Parkinson disease	ISRADIPINE	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02168842	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Parkinson disease	ISRADIPINE	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00909545	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Parkinson disease	ISRADIPINE	targetBased	2	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00753636	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	central nervous system leukemia	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	29/02/2012	https://clinicaltrials.gov/study/NCT02883049	0.7	LoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	Back pain	TERIPARATIDE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00343252	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac196ff5-9215-402b-bc57-69aa87f8bade	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	brain injury	PROPRANOLOL HYDROCHLORIDE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT03401515	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	movement disorder	PROPRANOLOL HYDROCHLORIDE	targetBased	2	Withdrawn	18/09/2017	https://clinicaltrials.gov/study/NCT03254186	0.2	LoF	protect	No participants
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=976077df-038b-4b01-bc4e-751cd70d4441	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db15690c-6f65-4ad1-845c-d337b8ab5f54	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46942e6e-73bb-4687-853a-e3ec2734cc70	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee09b4db-4d28-4748-a471-0f7b8c491f54	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e27c2424-0e18-4c10-aa3a-34bc28b5d681	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	migraine disorder	PROPRANOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa627be5-7fa9-4d12-8891-c8e058aebb79	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Alzheimer disease	NILVADIPINE	targetBased	3	Completed	24/04/2013	https://clinicaltrials.gov/study/NCT02017340	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DEZOCINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX03	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DEZOCINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX03	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DEZOCINE	targetBased	4	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT03014713	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DEZOCINE	targetBased	4	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT03014713	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DEZOCINE	targetBased	4	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05515822	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DEZOCINE	targetBased	4	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05515822	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	DEZOCINE	targetBased	4	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05515822	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	DEZOCINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX03	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	DEZOCINE	targetBased	4	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT03014713	1	LoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	amyotrophic lateral sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	amyotrophic lateral sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	amyotrophic lateral sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	amyotrophic lateral sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	amyotrophic lateral sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	amyotrophic lateral sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01786174	0.2	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION HYDROCHLORIDE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02050308	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION HYDROCHLORIDE	targetBased	2	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01111149	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION HYDROCHLORIDE	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00894166	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION HYDROCHLORIDE	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01456936	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION HYDROCHLORIDE	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01574703	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	BUPROPION HYDROCHLORIDE	targetBased	4	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00322205	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		amyotrophic lateral sclerosis	MEMANTINE HYDROCHLORIDE	targetBased	2	Recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04302870	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		frontotemporal dementia	MEMANTINE HYDROCHLORIDE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00594737	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-mylan	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81496236-0a90-4265-8244-cba6a6b4f3ac	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9f27baf-aa2a-443a-9ef5-e002d23407ba	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2335950c-be3b-4248-ad04-e9763aee47d2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a861df49-c5ee-40ba-9027-b2371b91f6f3	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8f5c20b-4573-44c5-89fc-4da11b2e1fe1	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		developmental and epileptic encephalopathy 94	MEMANTINE HYDROCHLORIDE	targetBased	4	Completed	07/02/2019	https://clinicaltrials.gov/study/NCT03779672	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c2b41c3-732c-477f-8790-0eecea43b2da	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c2b41c3-732c-477f-8790-0eecea43b2da	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0084d5bc-17d5-4c58-a791-7ab3bb4590b7	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MEPERIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0084d5bc-17d5-4c58-a791-7ab3bb4590b7	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		attempted suicide	KETAMINE HYDROCHLORIDE	targetBased	3	Recruiting	27/06/2022	https://clinicaltrials.gov/study/NCT04763343	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		epilepsy	KETAMINE HYDROCHLORIDE	targetBased	2	Recruiting	26/08/2022	https://clinicaltrials.gov/study/NCT05019885	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	10/05/2023	https://clinicaltrials.gov/study/NCT05855798	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	28/08/2017	https://clinicaltrials.gov/study/NCT02925858	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	01/09/2022	https://clinicaltrials.gov/study/NCT05552391	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT02817477	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	01/11/2022	https://clinicaltrials.gov/study/NCT05565664	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE HYDROCHLORIDE	targetBased	3	Not yet recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT05468840	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE HYDROCHLORIDE	targetBased	2	Not yet recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04658420	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		suicidal ideation	KETAMINE HYDROCHLORIDE	targetBased	2	Withdrawn	01/02/2022	https://clinicaltrials.gov/study/NCT05105061	0.2	LoF	protect	PI leaving institution
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		subarachnoid hemorrhage	KETAMINE HYDROCHLORIDE	targetBased	2	Withdrawn	27/04/2023	https://clinicaltrials.gov/study/NCT05032118	0.2	LoF	protect	Institution change, no IRB approval
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	KETAMINE HYDROCHLORIDE	targetBased	4	Recruiting	12/10/2023	https://clinicaltrials.gov/study/NCT05639322	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Chronic pain	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02085577	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	stroke	NALOXONE HYDROCHLORIDE	targetBased	4	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT05301712	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffa4a9b6-5770-4dc9-8151-78065bfc9e94	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffa4a9b6-5770-4dc9-8151-78065bfc9e94	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e2de757-cfe1-4731-93d1-36f80175ef33	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e2de757-cfe1-4731-93d1-36f80175ef33	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=643af9ce-549e-4102-932e-f4d995816cf1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=643af9ce-549e-4102-932e-f4d995816cf1	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffa4a9b6-5770-4dc9-8151-78065bfc9e94	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=643af9ce-549e-4102-932e-f4d995816cf1	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e2de757-cfe1-4731-93d1-36f80175ef33	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6aa52f1-0ebd-4312-8a18-99ea77928c51	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=911500d0-8894-4c08-a92e-85c834bc2b9a	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a28450a0-ac93-4235-b9a6-58cdf24773cb	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	stroke	NALOXONE HYDROCHLORIDE	targetBased	4	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT05301712	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	stroke	NALOXONE HYDROCHLORIDE	targetBased	4	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT05301712	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	childhood apraxia of speech	METHYLPHENIDATE HYDROCHLORIDE	targetBased	2	Recruiting	14/03/2022	https://clinicaltrials.gov/study/NCT05185583	0.2	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	DABIGATRAN ETEXILATE	targetBased	3	Completed	27/11/2014	https://clinicaltrials.gov/study/NCT02239120	0.7	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	DABIGATRAN ETEXILATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	DABIGATRAN ETEXILATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT02242305	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT02242305	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT02242305	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT02242305	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT02242305	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	2	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT02242292	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	2	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT02242292	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	2	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT02242292	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	2	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT02242292	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Abdominal pain	SCOPOLAMINE	targetBased	2	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT02242292	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	SCOPOLAMINE	targetBased	4	Not yet recruiting	01/01/2016	https://clinicaltrials.gov/study/NCT02618785	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	SCOPOLAMINE	targetBased	4	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03506763	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	pain	SCOPOLAMINE	targetBased	4	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03506763	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	pain	SCOPOLAMINE	targetBased	4	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03506763	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	SCOPOLAMINE	targetBased	4	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03506763	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	pain	SCOPOLAMINE	targetBased	4	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03506763	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	SCOPOLAMINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	SCOPOLAMINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	SCOPOLAMINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	SCOPOLAMINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	amyotrophic lateral sclerosis	SCOPOLAMINE	targetBased	2	Not yet recruiting	01/11/2020	https://clinicaltrials.gov/study/NCT04391361	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	SCOPOLAMINE	targetBased	3	Recruiting	27/04/2022	https://clinicaltrials.gov/study/NCT03616067	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	SCOPOLAMINE	targetBased	3	Recruiting	27/04/2022	https://clinicaltrials.gov/study/NCT03616067	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	SCOPOLAMINE	targetBased	3	Recruiting	27/04/2022	https://clinicaltrials.gov/study/NCT03616067	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	SCOPOLAMINE	targetBased	3	Recruiting	27/04/2022	https://clinicaltrials.gov/study/NCT03616067	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	SCOPOLAMINE	targetBased	3	Recruiting	27/04/2022	https://clinicaltrials.gov/study/NCT03616067	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	neuropathic pain	TERBUTALINE	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01582646	0.2	GoF	protect	difficulty of recruitment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	TERBUTALINE	targetBased	4	Unknown status	01/08/2012	https://clinicaltrials.gov/study/NCT01651962	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Huntington disease	PRIDOPIDINE	targetBased	3	Active, not recruiting	16/10/2020	https://clinicaltrials.gov/study/NCT04556656	0.7		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Huntington disease	PRIDOPIDINE	targetBased	3	Active, not recruiting	16/10/2020	https://clinicaltrials.gov/study/NCT04556656	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Huntington disease	PRIDOPIDINE	targetBased	3	Completed	24/04/2008	https://clinicaltrials.gov/study/NCT00665223	0.7		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Huntington disease	PRIDOPIDINE	targetBased	3	Completed	24/04/2008	https://clinicaltrials.gov/study/NCT00665223	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Huntington disease	PRIDOPIDINE	targetBased	3	Completed	24/04/2008	https://clinicaltrials.gov/study/NCT00665223	0.7		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Huntington disease	PRIDOPIDINE	targetBased	3	Completed	24/04/2008	https://clinicaltrials.gov/study/NCT00665223	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Huntington disease	PRIDOPIDINE	targetBased	3	Completed	24/04/2008	https://clinicaltrials.gov/study/NCT00665223	0.7		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Huntington disease	PRIDOPIDINE	targetBased	3	Completed	24/04/2008	https://clinicaltrials.gov/study/NCT00665223	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Active, not recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04297683	0.2		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Active, not recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04297683	0.2		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Active, not recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04297683	0.2		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Active, not recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04297683	0.2		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Active, not recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04297683	0.2		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Active, not recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04297683	0.2		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Completed	18/12/2020	https://clinicaltrials.gov/study/NCT04615923	0.2		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Completed	18/12/2020	https://clinicaltrials.gov/study/NCT04615923	0.2		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Completed	18/12/2020	https://clinicaltrials.gov/study/NCT04615923	0.2		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Completed	18/12/2020	https://clinicaltrials.gov/study/NCT04615923	0.2		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Completed	18/12/2020	https://clinicaltrials.gov/study/NCT04615923	0.2		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	amyotrophic lateral sclerosis	PRIDOPIDINE	targetBased	2	Completed	18/12/2020	https://clinicaltrials.gov/study/NCT04615923	0.2		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PRIDOPIDINE	targetBased	2	Terminated	22/05/2019	https://clinicaltrials.gov/study/NCT03922711	0.2		protect	COVID-19
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PRIDOPIDINE	targetBased	2	Terminated	22/05/2019	https://clinicaltrials.gov/study/NCT03922711	0.2		protect	COVID-19
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PRIDOPIDINE	targetBased	2	Terminated	22/05/2019	https://clinicaltrials.gov/study/NCT03922711	0.2		protect	COVID-19
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PRIDOPIDINE	targetBased	2	Terminated	22/05/2019	https://clinicaltrials.gov/study/NCT03922711	0.2		protect	COVID-19
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PRIDOPIDINE	targetBased	2	Terminated	22/05/2019	https://clinicaltrials.gov/study/NCT03922711	0.2		protect	COVID-19
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PRIDOPIDINE	targetBased	2	Terminated	22/05/2019	https://clinicaltrials.gov/study/NCT03922711	0.2		protect	COVID-19
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	radiculopathy	Z160	targetBased	2	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01655849	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Lewy body dementia	NELOTANSERIN	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02640729	0.2	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	restless legs syndrome	SUVOREXANT	targetBased	2	Unknown status	01/02/2019	https://clinicaltrials.gov/study/NCT03755310	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	restless legs syndrome	SUVOREXANT	targetBased	2	Unknown status	01/02/2019	https://clinicaltrials.gov/study/NCT03755310	0.2	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Alzheimer disease	SUVOREXANT	targetBased	2	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT04629547	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Alzheimer disease	SUVOREXANT	targetBased	2	Recruiting	25/05/2022	https://clinicaltrials.gov/study/NCT04629547	0.2	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	smoking cessation	SUVOREXANT	targetBased	2	Recruiting	23/08/2021	https://clinicaltrials.gov/study/NCT04234997	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	smoking cessation	SUVOREXANT	targetBased	2	Recruiting	23/08/2021	https://clinicaltrials.gov/study/NCT04234997	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	intracerebral hemorrhage	LABETALOL HYDROCHLORIDE	targetBased	2	Recruiting	01/08/2011	https://clinicaltrials.gov/study/NCT02281838	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	intracerebral hemorrhage	LABETALOL HYDROCHLORIDE	targetBased	2	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00963976	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	intracerebral hemorrhage	NICARDIPINE HYDROCHLORIDE	targetBased	3	Terminated	15/05/2011	https://clinicaltrials.gov/study/NCT01176565	0.35	LoF	protect	Planned interim analysis: no significant outcome differences between groups
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	intracranial vasospasm	NICARDIPINE HYDROCHLORIDE	targetBased	2	Terminated	01/08/2013	https://clinicaltrials.gov/study/NCT01810302	0.2	LoF	protect	Unable to secure drug.
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b1fca78-1bc0-43cd-be4b-ae118196042b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9de8e37-5827-4ea5-a060-5c2e1311c45b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9de8e37-5827-4ea5-a060-5c2e1311c45b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9de8e37-5827-4ea5-a060-5c2e1311c45b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9de8e37-5827-4ea5-a060-5c2e1311c45b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9de8e37-5827-4ea5-a060-5c2e1311c45b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE MESYLATE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE MESYLATE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE MESYLATE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE MESYLATE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE MESYLATE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE MESYLATE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE MESYLATE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE MESYLATE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE MESYLATE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE MESYLATE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	ORPHENADRINE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e41b33e-f71f-4a5e-b88f-cdfefb2bee20	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Spinal cord injury	BUSPIRONE HYDROCHLORIDE	targetBased	2	Recruiting	22/12/2020	https://clinicaltrials.gov/study/NCT04458324	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Spinal cord injury	BUSPIRONE HYDROCHLORIDE	targetBased	2	Recruiting	22/12/2020	https://clinicaltrials.gov/study/NCT04458324	0.2	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18686fa-be94-472e-8404-c69e6869ed10	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=322f926c-99ac-49f8-9cc5-584594f2891f	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cdb9d61-5bbc-4026-a449-fec8c9ce5c65	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cdb9d61-5bbc-4026-a449-fec8c9ce5c65	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cdb9d61-5bbc-4026-a449-fec8c9ce5c65	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cdb9d61-5bbc-4026-a449-fec8c9ce5c65	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cdb9d61-5bbc-4026-a449-fec8c9ce5c65	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cdb9d61-5bbc-4026-a449-fec8c9ce5c65	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=414cd6c4-4926-4dfc-93c4-f04f4b7eeac3	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=414cd6c4-4926-4dfc-93c4-f04f4b7eeac3	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=414cd6c4-4926-4dfc-93c4-f04f4b7eeac3	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc1f418c-f229-4bf0-88a6-1b2c84a18041	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc1f418c-f229-4bf0-88a6-1b2c84a18041	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc1f418c-f229-4bf0-88a6-1b2c84a18041	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00485069	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00485069	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00485069	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00485069	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00485069	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00485069	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb0fae45-f54f-4c68-ac72-9396d9874ca4	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb0fae45-f54f-4c68-ac72-9396d9874ca4	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb0fae45-f54f-4c68-ac72-9396d9874ca4	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e565a1d-8886-437b-8e61-031455732a5c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e565a1d-8886-437b-8e61-031455732a5c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	ROPINIROLE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e565a1d-8886-437b-8e61-031455732a5c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	diabetic autonomic neuropathy	BROMOCRIPTINE MESYLATE	targetBased	4	Completed	05/10/2015	https://clinicaltrials.gov/study/NCT02682901	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	ALFENTANIL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00742807	1	GoF	protect	No investigator to follow-up
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	ALFENTANIL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2008	https://clinicaltrials.gov/study/NCT00742807	1	GoF	protect	No investigator to follow-up
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Parkinson disease	DESMOPRESSIN ACETATE	targetBased	4	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00806468	1	GoF	protect	lack of recruitment
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	intracerebral hemorrhage	DESMOPRESSIN ACETATE	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT00961532	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cerebral palsy	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cerebral palsy	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06da53af-5b46-4e32-a64c-9677e27ae229	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	spinal cord disease	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06da53af-5b46-4e32-a64c-9677e27ae229	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	spinal cord disease	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	migraine disorder	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	3	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01151787	0.7	LoF	protect	Study was never initiated under new location/provider group. Contract to continue was never signed between TEVA and Kennedy Headache Center
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	brain injury	SEVOFLURANE	targetBased	2	Terminated	01/12/2011	https://clinicaltrials.gov/study/NCT01374633	0.2		protect	Sponsor decision
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	brain injury	SEVOFLURANE	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02123355	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	brain aneurysm	SEVOFLURANE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02455440	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	brain aneurysm	SEVOFLURANE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01722409	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	brain aneurysm	SEVOFLURANE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02455440	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	brain aneurysm	SEVOFLURANE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01722409	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Back pain	SEVOFLURANE	targetBased	3	Recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03825198	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	internal carotid artery stenosis	SEVOFLURANE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02609087	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	internal carotid artery stenosis	SEVOFLURANE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02609087	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Back pain	SEVOFLURANE	targetBased	3	Recruiting	01/08/2019	https://clinicaltrials.gov/study/NCT03825198	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	intelligence	SEVOFLURANE	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02123355	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	subarachnoid hemorrhage	SEVOFLURANE	targetBased	2	Withdrawn	01/11/2015	https://clinicaltrials.gov/study/NCT02946437	0.2		protect	Patients failed to be enrolled because of tight exclusion criteria.
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	subarachnoid hemorrhage	SEVOFLURANE	targetBased	2	Withdrawn	01/11/2015	https://clinicaltrials.gov/study/NCT02946437	0.2		protect	Patients failed to be enrolled because of tight exclusion criteria.
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	memory impairment	SEVOFLURANE	targetBased	4	Withdrawn	01/06/2007	https://clinicaltrials.gov/study/NCT00541918	1		protect	study suspended due to staff indisposition
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	cerebral arterial disease	SEVOFLURANE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02455440	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	pain	SEVOFLURANE	targetBased	4	Completed	23/12/2016	https://clinicaltrials.gov/study/NCT03058341	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	pain	SEVOFLURANE	targetBased	4	Completed	27/08/2018	https://clinicaltrials.gov/study/NCT03597997	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	pain	SEVOFLURANE	targetBased	4	Completed	01/10/2020	https://clinicaltrials.gov/study/NCT04567160	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	pain	SEVOFLURANE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00420693	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	pain	SEVOFLURANE	targetBased	4	Recruiting	22/07/2020	https://clinicaltrials.gov/study/NCT04002271	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	pain	SEVOFLURANE	targetBased	3	Completed	20/01/2020	https://clinicaltrials.gov/study/NCT03841812	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	intelligence	SEVOFLURANE	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02123355	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	brain injury	SEVOFLURANE	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02123355	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	brain injury	SEVOFLURANE	targetBased	2	Terminated	01/12/2011	https://clinicaltrials.gov/study/NCT01374633	0.2		protect	Sponsor decision
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	pain	SEVOFLURANE	targetBased	4	Completed	01/10/2020	https://clinicaltrials.gov/study/NCT04567160	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	pain	SEVOFLURANE	targetBased	4	Completed	27/08/2018	https://clinicaltrials.gov/study/NCT03597997	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	pain	SEVOFLURANE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00420693	0.2		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	pain	SEVOFLURANE	targetBased	4	Completed	23/12/2016	https://clinicaltrials.gov/study/NCT03058341	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	pain	SEVOFLURANE	targetBased	3	Completed	20/01/2020	https://clinicaltrials.gov/study/NCT03841812	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	pain	SEVOFLURANE	targetBased	4	Recruiting	22/07/2020	https://clinicaltrials.gov/study/NCT04002271	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	retinopathy	SEVOFLURANE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01955135	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	cerebral arterial disease	SEVOFLURANE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02455440	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	retinopathy	SEVOFLURANE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01955135	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	memory impairment	SEVOFLURANE	targetBased	4	Withdrawn	01/06/2007	https://clinicaltrials.gov/study/NCT00541918	1		protect	study suspended due to staff indisposition
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	internal carotid artery stenosis	DESFLURANE	targetBased	4	Completed	29/09/2017	https://clinicaltrials.gov/study/NCT03996148	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	internal carotid artery stenosis	DESFLURANE	targetBased	4	Completed	29/09/2017	https://clinicaltrials.gov/study/NCT03996148	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	pain	CHLOROTRIANISENE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00390130	1		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ef44915-8e59-40d7-a43a-c1ea33bfdf53	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ef44915-8e59-40d7-a43a-c1ea33bfdf53	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=557e9610-62d7-42bf-90c1-44215bd8c1f8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=557e9610-62d7-42bf-90c1-44215bd8c1f8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c4136e8-c2dc-4ea0-9c65-f2d1c57d1171	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE HYDROCHLORIDE	targetBased	3	Suspended	11/03/2013	https://clinicaltrials.gov/study/NCT04681027	0.7	GoF	protect	Study Suspended 06Feb2020 per FDA Request
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYMORPHONE HYDROCHLORIDE	targetBased	3	Suspended	11/03/2013	https://clinicaltrials.gov/study/NCT04681027	0.7	GoF	protect	Study Suspended 06Feb2020 per FDA Request
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	OXYMORPHONE HYDROCHLORIDE	targetBased	3	Suspended	11/03/2013	https://clinicaltrials.gov/study/NCT04681027	0.7	GoF	protect	Study Suspended 06Feb2020 per FDA Request
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5770c65f-dd52-4ba0-928e-495cfc12c587	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=285e60f8-2404-47d0-a171-a4f075d6f418	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9281b012-ee14-4992-ba6a-ae91180b6f95	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=468bc2c3-9af3-4db1-b079-f2b5b98e951d	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ca97412-1594-4a4e-b5e4-8593ffa1b242	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	OXYMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10d4a5d9-9cb8-4dcf-9836-34c377990128	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	amyotrophic lateral sclerosis	TRAZODONE HYDROCHLORIDE	targetBased	2	Recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04302870	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE HYDROCHLORIDE	targetBased	4	Terminated	29/07/2017	https://clinicaltrials.gov/study/NCT02989597	1	GoF	protect	Due to personnel loss and logistical issues the study was unable to be completed as planned.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE HYDROCHLORIDE	targetBased	4	Terminated	29/07/2017	https://clinicaltrials.gov/study/NCT02989597	1	GoF	protect	Due to personnel loss and logistical issues the study was unable to be completed as planned.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=052cc172-e3f8-436a-ad92-234c3b7b4e38	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=052cc172-e3f8-436a-ad92-234c3b7b4e38	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a36705c4-867f-41f1-94c9-78b8b31836ce	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a36705c4-867f-41f1-94c9-78b8b31836ce	1	GoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	internal carotid artery stenosis	LITHIUM CARBONATE	targetBased	3	Recruiting	20/11/2021	https://clinicaltrials.gov/study/NCT05126238	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	Huntington disease	LITHIUM CARBONATE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00095355	0.2	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	carotid artery disease	LITHIUM CARBONATE	targetBased	3	Recruiting	20/11/2021	https://clinicaltrials.gov/study/NCT05126238	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	frontotemporal dementia	LITHIUM CARBONATE	targetBased	2	Completed	27/01/2017	https://clinicaltrials.gov/study/NCT02862210	0.2	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	stroke	LITHIUM CARBONATE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01112813	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	amyotrophic lateral sclerosis	LITHIUM CARBONATE	targetBased	3	Recruiting	09/08/2021	https://clinicaltrials.gov/study/NCT06008249	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	amyotrophic lateral sclerosis	LITHIUM CARBONATE	targetBased	2	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00925847	0.2	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	amyotrophic lateral sclerosis	LITHIUM CARBONATE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00790582	0.2	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	Huntington disease	LITHIUM CARBONATE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00095355	0.2	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	carotid artery disease	LITHIUM CARBONATE	targetBased	3	Recruiting	20/11/2021	https://clinicaltrials.gov/study/NCT05126238	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	Cognitive impairment	LITHIUM CARBONATE	targetBased	4	Active, not recruiting	01/09/2017	https://clinicaltrials.gov/study/NCT03185208	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	Cognitive impairment	LITHIUM CARBONATE	targetBased	4	Active, not recruiting	01/09/2017	https://clinicaltrials.gov/study/NCT03185208	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	Alzheimer disease	LITHIUM CARBONATE	targetBased	2	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00088387	0.2	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	Alzheimer disease	LITHIUM CARBONATE	targetBased	2	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00088387	0.2	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	frontotemporal dementia	LITHIUM CARBONATE	targetBased	2	Completed	27/01/2017	https://clinicaltrials.gov/study/NCT02862210	0.2	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	internal carotid artery stenosis	LITHIUM CARBONATE	targetBased	3	Recruiting	20/11/2021	https://clinicaltrials.gov/study/NCT05126238	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	stroke	LITHIUM CARBONATE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01112813	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	amyotrophic lateral sclerosis	LITHIUM CARBONATE	targetBased	2	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00925847	0.2	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	amyotrophic lateral sclerosis	LITHIUM CARBONATE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00790582	0.2	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	amyotrophic lateral sclerosis	LITHIUM CARBONATE	targetBased	3	Recruiting	09/08/2021	https://clinicaltrials.gov/study/NCT06008249	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	low tension glaucoma	TIMOLOL MALEATE	targetBased	2	Completed	15/09/2021	https://clinicaltrials.gov/study/NCT04857827	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE HYDROCHLORIDE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02660229	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	OXYCODONE HYDROCHLORIDE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02660229	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46ff6f79-385d-4c47-ae0e-78930642da13	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46ff6f79-385d-4c47-ae0e-78930642da13	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b82495ce-8d77-4e12-a064-274a88448ba3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b82495ce-8d77-4e12-a064-274a88448ba3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5990fc7-ac15-4dab-abda-eaf45c6d4985	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5990fc7-ac15-4dab-abda-eaf45c6d4985	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566ef74d-5c0b-49bf-9619-e757d16431ef	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566ef74d-5c0b-49bf-9619-e757d16431ef	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eaff86d-3b90-499e-b46f-316a35f5d811	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eaff86d-3b90-499e-b46f-316a35f5d811	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a22b4011-322d-4b61-9349-1b32e1f3a361	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a22b4011-322d-4b61-9349-1b32e1f3a361	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE HYDROCHLORIDE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01427283	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE HYDROCHLORIDE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01427283	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE HYDROCHLORIDE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01427270	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODONE HYDROCHLORIDE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01427270	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Parkinson disease	ORPHENADRINE HYDROCHLORIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN LACTATE	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN LACTATE	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN LACTATE	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN LACTATE	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	brain injury	BIPERIDEN LACTATE	targetBased	3	Terminated	31/01/2018	https://clinicaltrials.gov/study/NCT01048138	0.7	LoF	protect	Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	CABERGOLINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00625547	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	CABERGOLINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00625547	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	CABERGOLINE	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00627003	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	CABERGOLINE	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00627003	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	CABERGOLINE	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00627003	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	CABERGOLINE	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00627003	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	CABERGOLINE	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00627003	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	CABERGOLINE	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00627003	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	CABERGOLINE	targetBased	4	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00174239	1	GoF	protect	See Detailed Description for termination reason.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	CABERGOLINE	targetBased	4	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00174239	1	GoF	protect	See Detailed Description for termination reason.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	CABERGOLINE	targetBased	4	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00174239	1	GoF	protect	See Detailed Description for termination reason.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	CABERGOLINE	targetBased	4	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00174239	1	GoF	protect	See Detailed Description for termination reason.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	CABERGOLINE	targetBased	4	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00174239	1	GoF	protect	See Detailed Description for termination reason.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	CABERGOLINE	targetBased	4	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00174239	1	GoF	protect	See Detailed Description for termination reason.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca3fe6e9-21ad-4fba-a602-e1c364cf3981	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95a33c9b-79a6-47c7-8433-fc217950b88f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df9801fc-03fe-41da-a6b3-0f76788217c9	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=243a6aea-0f48-42a9-a85e-ff247ab94336	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f0c092b-08db-4e8f-136a-456e0e7bec14	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace223cc-458e-4455-a64e-83e5cbf95f9a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36adb32c-638c-4d6e-b66a-1a1c35174ce6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36adb32c-638c-4d6e-b66a-1a1c35174ce6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdea5078-b6d3-4c2b-981b-398bb1fadc40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdea5078-b6d3-4c2b-981b-398bb1fadc40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c681ff1-9279-465a-ac3a-619d4d7b1552	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c681ff1-9279-465a-ac3a-619d4d7b1552	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=057def74-f06c-4a0b-97e5-6d77c03c5735	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d53bf9b7-1652-4287-a0c1-e89f6f0cb7f1	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9b11cbf-7585-4532-868f-5686f028679f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4ed06cd-20a1-4b6d-ba8a-0a2a71e9a0ff	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8ff3132-fd89-49ff-8623-971f01289df7	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90663fb4-62a6-438c-a474-acf40d706094	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca3fe6e9-21ad-4fba-a602-e1c364cf3981	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca3fe6e9-21ad-4fba-a602-e1c364cf3981	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a58819b8-a52c-44a7-9ab0-c74480d98506	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a58819b8-a52c-44a7-9ab0-c74480d98506	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66305a0c-caf8-414a-a30b-3ab7b73086e1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	migraine disorder	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66305a0c-caf8-414a-a30b-3ab7b73086e1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03288428	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03288428	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee8fe2ea-a6c7-485e-bea9-1b94ff66b05c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee8fe2ea-a6c7-485e-bea9-1b94ff66b05c	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02445599	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ad5e836-33bf-49c9-a530-296cff30d1c7	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	09/12/2022	https://clinicaltrials.gov/study/NCT05565235	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Unknown status	24/10/2018	https://clinicaltrials.gov/study/NCT03786887	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Unknown status	17/08/2017	https://clinicaltrials.gov/study/NCT03296488	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	15/01/2018	https://clinicaltrials.gov/study/NCT03826316	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Charcot-Marie-Tooth disease	NALTREXONE HYDROCHLORIDE	targetBased	3	Active, not recruiting	30/03/2021	https://clinicaltrials.gov/study/NCT04762758	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Charcot-Marie-Tooth disease	NALTREXONE HYDROCHLORIDE	targetBased	3	Active, not recruiting	30/03/2021	https://clinicaltrials.gov/study/NCT04762758	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7658a2d-b7a9-4fb5-8d65-a20ca1b9ad1f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7658a2d-b7a9-4fb5-8d65-a20ca1b9ad1f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01179191	1	LoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01179191	1	LoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe97a3d-247d-4dda-a641-1a95196cd8d8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe97a3d-247d-4dda-a641-1a95196cd8d8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE HYDROCHLORIDE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00420992	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE HYDROCHLORIDE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00420992	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE HYDROCHLORIDE	targetBased	4	Terminated	01/04/2010	https://clinicaltrials.gov/study/NCT01100437	1	LoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	NALTREXONE HYDROCHLORIDE	targetBased	4	Terminated	01/04/2010	https://clinicaltrials.gov/study/NCT01100437	1	LoF	protect	See termination reason in detailed description.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Charcot-Marie-Tooth disease	NALTREXONE HYDROCHLORIDE	targetBased	3	Active, not recruiting	30/03/2021	https://clinicaltrials.gov/study/NCT04762758	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALTREXONE HYDROCHLORIDE	targetBased	4	Terminated	01/04/2010	https://clinicaltrials.gov/study/NCT01100437	1	LoF	protect	See termination reason in detailed description.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	NALTREXONE HYDROCHLORIDE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00420992	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00415597	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01179191	1	LoF	protect	See termination reason in detailed description.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe97a3d-247d-4dda-a641-1a95196cd8d8	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	NALTREXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7658a2d-b7a9-4fb5-8d65-a20ca1b9ad1f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL HYDROCHLORIDE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00264485	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL HYDROCHLORIDE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00264485	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL HYDROCHLORIDE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00266539	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	FENTANYL HYDROCHLORIDE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00266539	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL CITRATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/dzuveo	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL CITRATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/dzuveo	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL CITRATE	targetBased	4	Terminated	27/09/2021	https://clinicaltrials.gov/study/NCT04716413	1	GoF	protect	Terminated early due to funding, lack of participants
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL CITRATE	targetBased	4	Terminated	27/09/2021	https://clinicaltrials.gov/study/NCT04716413	1	GoF	protect	Terminated early due to funding, lack of participants
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b580f3d-e3b5-4086-b093-87a980631147	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	SUFENTANIL CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b580f3d-e3b5-4086-b093-87a980631147	1	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	stroke	ARMODAFINIL	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01896128	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	brain injury	ARMODAFINIL	targetBased	3	Terminated	30/04/2009	https://clinicaltrials.gov/study/NCT00893789	0.7	LoF	protect	Study has been stopped by sponsor decision.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	brain injury	ARMODAFINIL	targetBased	3	Terminated	31/08/2009	https://clinicaltrials.gov/study/NCT00983437	0.7	LoF	protect	Study has been stopped by sponsor decision
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea53a18-71d1-445b-b108-5d23bcd3bf24	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=293d9505-b688-43dd-8b34-507e6a1c0fd3	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=293d9505-b688-43dd-8b34-507e6a1c0fd3	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=293d9505-b688-43dd-8b34-507e6a1c0fd3	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=293d9505-b688-43dd-8b34-507e6a1c0fd3	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	BENZTROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=293d9505-b688-43dd-8b34-507e6a1c0fd3	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peripheral nervous system disease	BENZTROPINE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00000793	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Back pain	BENZTROPINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT00964886	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Cognitive impairment	LISDEXAMFETAMINE	targetBased	4	Completed	22/09/2017	https://clinicaltrials.gov/study/NCT03187353	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	cognition	LISDEXAMFETAMINE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01977625	1		protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	cerebral palsy	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	METHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA03	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	METHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	METHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA03	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	METHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	METHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N04AA03	1	LoF	protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	stroke	UROKINASE	targetBased	3	Completed	18/05/2018	https://clinicaltrials.gov/study/NCT03541668	0.7		protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	stroke	UROKINASE	targetBased	3	Completed	10/08/2018	https://clinicaltrials.gov/study/NCT03578822	0.7		protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	stroke	UROKINASE	targetBased	2	Completed	28/09/2021	https://clinicaltrials.gov/study/NCT04516993	0.2		protect
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	PLAU	Urokinase-type plasminogen activator	subarachnoid hemorrhage	UROKINASE	targetBased	4	Recruiting	28/03/2024	https://clinicaltrials.gov/study/NCT06284642	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	stroke	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/12/1993	https://clinicaltrials.gov/study/NCT00026039	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	stroke	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/12/1993	https://clinicaltrials.gov/study/NCT00026039	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	memory impairment	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000176	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Parkinson disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00234676	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Parkinson disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00234676	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT00018343	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT00018343	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00006399	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00006399	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00000177	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00000177	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000176	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000176	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	brain injury	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00973674	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	brain injury	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00973674	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	brain injury	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00973674	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00088153	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01343771	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Recruiting	28/08/2020	https://clinicaltrials.gov/study/NCT03875378	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00310791	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00088153	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00088153	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Recruiting	28/08/2020	https://clinicaltrials.gov/study/NCT03875378	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Recruiting	28/08/2020	https://clinicaltrials.gov/study/NCT03875378	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01343771	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01343771	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00310791	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anorexia nervosa	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00310791	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	memory impairment	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000176	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	memory impairment	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000176	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00006399	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000176	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00000177	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Alzheimer disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT00018343	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Parkinson disease	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00234676	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	stroke	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/12/1993	https://clinicaltrials.gov/study/NCT00026039	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	NEBIVOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=673f5ad2-c09b-4a89-9407-efdadd007917	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stroke	NEBIVOLOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb47560d-9e35-4b0f-b12b-6ea478684a5b	1	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Parkinson disease	NILOTINIB HYDROCHLORIDE MONOHYDRATE	targetBased	2	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02954978	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e921054f-b3f1-4624-8edd-f6628c6f0fd9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4c911f3-484b-44fa-833e-2d970d39be8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4c911f3-484b-44fa-833e-2d970d39be8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TAPENTADOL	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00455520	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TAPENTADOL	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00455520	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TAPENTADOL	targetBased	3	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01041859	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TAPENTADOL	targetBased	3	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01041859	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TAPENTADOL	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01063868	0.7	GoF	protect	Business decision
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TAPENTADOL	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01063868	0.7	GoF	protect	Business decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aac7e48-f10c-4623-8fb5-1d74d5e22520	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aac7e48-f10c-4623-8fb5-1d74d5e22520	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a13367-b5f0-4255-ae6a-8f558d90cd07	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a13367-b5f0-4255-ae6a-8f558d90cd07	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT06269770	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT06269770	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TAPENTADOL	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TAPENTADOL	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TAPENTADOL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00771758	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TAPENTADOL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00771758	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TAPENTADOL	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TAPENTADOL	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01352741	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01352741	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4c911f3-484b-44fa-833e-2d970d39be8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4c911f3-484b-44fa-833e-2d970d39be8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aac7e48-f10c-4623-8fb5-1d74d5e22520	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aac7e48-f10c-4623-8fb5-1d74d5e22520	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01352741	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01352741	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01838616	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	TAPENTADOL	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01063868	0.7	GoF	protect	Business decision
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	TAPENTADOL	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01063868	0.7	GoF	protect	Business decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	peripheral neuropathy	TAPENTADOL	targetBased	4	Terminated	01/10/2011	https://clinicaltrials.gov/study/NCT01458015	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	peripheral neuropathy	TAPENTADOL	targetBased	4	Terminated	01/10/2011	https://clinicaltrials.gov/study/NCT01458015	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec2dd06c-0c6f-4e37-b75e-edc4f70646e2	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec2dd06c-0c6f-4e37-b75e-edc4f70646e2	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c33315-90c9-4a73-bf1d-bca70c7e0ff5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c33315-90c9-4a73-bf1d-bca70c7e0ff5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a6953cd-9d64-4443-b7db-5aef2c81324d	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a6953cd-9d64-4443-b7db-5aef2c81324d	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a13367-b5f0-4255-ae6a-8f558d90cd07	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a13367-b5f0-4255-ae6a-8f558d90cd07	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aac7e48-f10c-4623-8fb5-1d74d5e22520	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aac7e48-f10c-4623-8fb5-1d74d5e22520	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TAPENTADOL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TAPENTADOL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40671852-846e-4bc1-8e15-1f71add24414	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40671852-846e-4bc1-8e15-1f71add24414	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4c911f3-484b-44fa-833e-2d970d39be8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4c911f3-484b-44fa-833e-2d970d39be8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aac7e48-f10c-4623-8fb5-1d74d5e22520	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TAPENTADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aac7e48-f10c-4623-8fb5-1d74d5e22520	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL HYDROCHLORIDE	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00986180	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TAPENTADOL HYDROCHLORIDE	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00986180	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e6ea237-c085-4f22-bfe1-b0c7c116aa67	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e6ea237-c085-4f22-bfe1-b0c7c116aa67	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b3adfad-5f99-4add-bcdc-069d0a0da418	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b3adfad-5f99-4add-bcdc-069d0a0da418	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Neck pain	TRAMADOL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT01843660	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Neck pain	TRAMADOL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT01843660	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00942565	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00942565	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9893b6c0-fe47-4e56-8857-d3a5a888b9fd	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9893b6c0-fe47-4e56-8857-d3a5a888b9fd	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee7179b7-6a08-4eeb-a787-5d697b02c4a2	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee7179b7-6a08-4eeb-a787-5d697b02c4a2	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TRAMADOL	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00634543	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TRAMADOL	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00634543	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TRAMADOL	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00210847	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TRAMADOL	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00210847	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2347726f-7755-7026-426c-6f7741776179	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2347726f-7755-7026-426c-6f7741776179	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52375cd0-c3c3-49d6-94d0-c065b0fb8f2b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52375cd0-c3c3-49d6-94d0-c065b0fb8f2b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f799e5c-f782-4f3d-bdb6-52bd413a19cf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f799e5c-f782-4f3d-bdb6-52bd413a19cf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TRAMADOL	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00290901	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TRAMADOL	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00290901	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TRAMADOL	targetBased	4	Terminated	01/03/2005	https://clinicaltrials.gov/study/NCT00210561	1	GoF	protect	Study was stopped shortly after initiation due to change in strategic direction of the company; no safety concerns were observed that impacted this decision.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	TRAMADOL	targetBased	4	Terminated	01/03/2005	https://clinicaltrials.gov/study/NCT00210561	1	GoF	protect	Study was stopped shortly after initiation due to change in strategic direction of the company; no safety concerns were observed that impacted this decision.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TRAMADOL	targetBased	3	Completed	11/07/2022	https://clinicaltrials.gov/study/NCT05324059	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TRAMADOL	targetBased	3	Completed	11/07/2022	https://clinicaltrials.gov/study/NCT05324059	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TRAMADOL	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02307305	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	TRAMADOL	targetBased	2	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02307305	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Abdominal pain	TRAMADOL	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02465255	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Abdominal pain	TRAMADOL	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02465255	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT01843660	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT01843660	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL	targetBased	4	Completed	17/09/2020	https://clinicaltrials.gov/study/NCT05170841	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL	targetBased	4	Completed	17/09/2020	https://clinicaltrials.gov/study/NCT05170841	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL	targetBased	4	Terminated	01/03/2005	https://clinicaltrials.gov/study/NCT00210561	1	GoF	protect	Study was stopped shortly after initiation due to change in strategic direction of the company; no safety concerns were observed that impacted this decision.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL	targetBased	4	Terminated	01/03/2005	https://clinicaltrials.gov/study/NCT00210561	1	GoF	protect	Study was stopped shortly after initiation due to change in strategic direction of the company; no safety concerns were observed that impacted this decision.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Shoulder pain	TRAMADOL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT01843660	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Shoulder pain	TRAMADOL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT01843660	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04785768	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04785768	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bfbba46-1979-4797-a29e-d67718131686	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bfbba46-1979-4797-a29e-d67718131686	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d33b072-0755-4b8c-9558-2551306756a3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d33b072-0755-4b8c-9558-2551306756a3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c88f81ac-1643-4c08-ae2c-63cbe956db7e	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01709721	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01709721	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Terminated	11/03/2017	https://clinicaltrials.gov/study/NCT02321319	0.7	GoF	protect	Business decision - product discontinued
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Terminated	11/03/2017	https://clinicaltrials.gov/study/NCT02321319	0.7	GoF	protect	Business decision - product discontinued
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01709747	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01709747	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01986946	0.7	GoF	protect	Lack of recruitment.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01986946	0.7	GoF	protect	Lack of recruitment.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00398788	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROMORPHONE HYDROCHLORIDE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00398788	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fd73b94-8e76-4274-8259-7c353bc1a32d	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fd73b94-8e76-4274-8259-7c353bc1a32d	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58c2975a-47bd-4d3c-9cfe-9ea59f3f31ca	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58c2975a-47bd-4d3c-9cfe-9ea59f3f31ca	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32224ed4-4fd7-4ea2-b36c-506f4d00bf77	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32224ed4-4fd7-4ea2-b36c-506f4d00bf77	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00634543	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic neuropathy	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00634543	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=429ff009-936b-1e4c-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=429ff009-936b-1e4c-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5285f056-c32c-4e7a-bec6-3a726aa23d5a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5285f056-c32c-4e7a-bec6-3a726aa23d5a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9899985f-649f-4bcc-890f-0f4800227929	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9899985f-649f-4bcc-890f-0f4800227929	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	17/09/2020	https://clinicaltrials.gov/study/NCT05170841	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	17/09/2020	https://clinicaltrials.gov/study/NCT05170841	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL HYDROCHLORIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00662558	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	TRAMADOL HYDROCHLORIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00662558	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b66b68ce-fa1f-4d7d-9700-eee30eca3837	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b66b68ce-fa1f-4d7d-9700-eee30eca3837	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	intracerebral hemorrhage	CLEVIDIPINE	targetBased	4	Withdrawn	15/06/2017	https://clinicaltrials.gov/study/NCT03300479	1	LoF	protect	No patient enrolled. No study conduct due to lack of human resources.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	stroke	CLEVIDIPINE	targetBased	3	Recruiting	01/11/2021	https://clinicaltrials.gov/study/NCT05175547	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Alzheimer disease	FORMOTEROL	targetBased	2	Withdrawn	01/01/2023	https://clinicaltrials.gov/study/NCT02500784	0.2	GoF	protect	Funding ran out before study started, prior PI left institution.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fab28f67-9dfa-4bf7-8758-c0c4b6aef56a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67578b56-7540-487e-1fba-481255620e78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82b5bf2c-7dc9-40bd-9fb4-b5b1b5be0470	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a60cb55-530a-41ee-bc78-971eaf9f0850	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pain	EPINEPHRINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02a845c3-4521-4926-e397-25ab536e7cf6	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	XALIPRODEN	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00104013	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	XALIPRODEN	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00104013	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	XALIPRODEN	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00103649	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	XALIPRODEN	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00103649	0.7	GoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	DABIGATRAN ETEXILATE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5db7f199-8752-4d24-85f7-e34ca8f4d02e	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	stroke	DABIGATRAN ETEXILATE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	epilepsy	SUVECALTAMIDE	targetBased	2	Completed	25/02/2018	https://clinicaltrials.gov/study/NCT03406702	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	2	Completed	30/04/2011	https://clinicaltrials.gov/study/NCT01343966	0.2	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	2	Completed	30/04/2011	https://clinicaltrials.gov/study/NCT01343966	0.2	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	targetBased	2	Completed	30/04/2011	https://clinicaltrials.gov/study/NCT01343966	0.2	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	3	Terminated	11/04/2018	https://clinicaltrials.gov/study/NCT03491150	0.35	LoF	protect	This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	3	Terminated	11/04/2018	https://clinicaltrials.gov/study/NCT03491150	0.35	LoF	protect	This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	targetBased	3	Terminated	11/04/2018	https://clinicaltrials.gov/study/NCT03491150	0.35	LoF	protect	This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	3	Terminated	29/03/2017	https://clinicaltrials.gov/study/NCT03114657	0.35	LoF	protect	This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	3	Terminated	29/03/2017	https://clinicaltrials.gov/study/NCT03114657	0.35	LoF	protect	This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	targetBased	3	Terminated	29/03/2017	https://clinicaltrials.gov/study/NCT03114657	0.35	LoF	protect	This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	3	Terminated	22/03/2016	https://clinicaltrials.gov/study/NCT02670083	0.35	LoF	protect	This study was discontinued due to an interim analysis in this study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	3	Terminated	22/03/2016	https://clinicaltrials.gov/study/NCT02670083	0.35	LoF	protect	This study was discontinued due to an interim analysis in this study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	targetBased	3	Terminated	22/03/2016	https://clinicaltrials.gov/study/NCT02670083	0.35	LoF	protect	This study was discontinued due to an interim analysis in this study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	2	Completed	31/08/2011	https://clinicaltrials.gov/study/NCT01397578	0.2	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	2	Completed	31/08/2011	https://clinicaltrials.gov/study/NCT01397578	0.2	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	targetBased	2	Completed	31/08/2011	https://clinicaltrials.gov/study/NCT01397578	0.2	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	2	Completed	10/06/2019	https://clinicaltrials.gov/study/NCT03977584	0.2	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	2	Completed	10/06/2019	https://clinicaltrials.gov/study/NCT03977584	0.2	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	targetBased	2	Completed	10/06/2019	https://clinicaltrials.gov/study/NCT03977584	0.2	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	2	Completed	07/12/2012	https://clinicaltrials.gov/study/NCT01723826	0.2	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	pathwayBased	2	Completed	07/12/2012	https://clinicaltrials.gov/study/NCT01723826	0.2	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	CRENEZUMAB	targetBased	2	Completed	07/12/2012	https://clinicaltrials.gov/study/NCT01723826	0.2	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	targetBased	3	Terminated	06/06/2018	https://clinicaltrials.gov/study/NCT03444870	0.35		protect	Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early-stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	pathwayBased	3	Completed	30/11/2010	https://clinicaltrials.gov/study/NCT01224106	0.7		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	pathwayBased	3	Completed	30/11/2010	https://clinicaltrials.gov/study/NCT01224106	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	targetBased	3	Completed	30/11/2010	https://clinicaltrials.gov/study/NCT01224106	0.7		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	pathwayBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02051608	0.7		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	pathwayBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02051608	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02051608	0.7		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	pathwayBased	3	Terminated	22/05/2020	https://clinicaltrials.gov/study/NCT04339413	0.35		protect	Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	pathwayBased	3	Terminated	22/05/2020	https://clinicaltrials.gov/study/NCT04339413	0.35		protect	Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	GANTENERUMAB	targetBased	3	Terminated	22/05/2020	https://clinicaltrials.gov/study/NCT04339413	0.35		protect	Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	PONEZUMAB	pathwayBased	2	Completed	05/12/2008	https://clinicaltrials.gov/study/NCT00722046	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	PONEZUMAB	pathwayBased	2	Completed	05/12/2008	https://clinicaltrials.gov/study/NCT00722046	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	PONEZUMAB	targetBased	2	Completed	05/12/2008	https://clinicaltrials.gov/study/NCT00722046	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	PONEZUMAB	pathwayBased	2	Completed	06/08/2009	https://clinicaltrials.gov/study/NCT00945672	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	PONEZUMAB	pathwayBased	2	Completed	06/08/2009	https://clinicaltrials.gov/study/NCT00945672	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	PONEZUMAB	targetBased	2	Completed	06/08/2009	https://clinicaltrials.gov/study/NCT00945672	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	pathwayBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00904683	0.7		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	pathwayBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00904683	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00904683	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	targetBased	3	Terminated	01/06/2016	https://clinicaltrials.gov/study/NCT02760602	0.35		protect	Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to participants with prodromal AD as defined by study protocol.
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	pathwayBased	3	Terminated	01/12/2010	https://clinicaltrials.gov/study/NCT01127633	0.35		protect	Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	pathwayBased	3	Terminated	01/12/2010	https://clinicaltrials.gov/study/NCT01127633	0.35		protect	Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	targetBased	3	Terminated	01/12/2010	https://clinicaltrials.gov/study/NCT01127633	0.35		protect	Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	pathwayBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00905372	0.7		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	pathwayBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00905372	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	SOLANEZUMAB	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00905372	0.7		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Cognitive impairment	SOLANEZUMAB	pathwayBased	3	Completed	28/02/2014	https://clinicaltrials.gov/study/NCT02008357	0.7		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Cognitive impairment	SOLANEZUMAB	pathwayBased	3	Completed	28/02/2014	https://clinicaltrials.gov/study/NCT02008357	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Cognitive impairment	SOLANEZUMAB	targetBased	3	Completed	28/02/2014	https://clinicaltrials.gov/study/NCT02008357	0.7		protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	metastasis	TRASTUZUMAB EMTANSINE	targetBased	2	Recruiting	16/10/2008	https://clinicaltrials.gov/study/NCT00781612	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	macular degeneration	REGORAFENIB	targetBased	2	Terminated	01/10/2014	https://clinicaltrials.gov/study/NCT02222207	0.2	LoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	stroke	LEVOSIMENDAN	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00698763	0.2	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	stroke	LEVOSIMENDAN	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00698763	0.2	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	amyotrophic lateral sclerosis	LEVOSIMENDAN	targetBased	3	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT03948178	0.35	GoF	protect	This was an open label extension for patients completing the REFALS study (3119002; NCT03505021). Study 3119002 showed lack of efficacy of ODM109 so the sponsor decided to terminate this study
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	amyotrophic lateral sclerosis	LEVOSIMENDAN	targetBased	3	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT03948178	0.35	GoF	protect	This was an open label extension for patients completing the REFALS study (3119002; NCT03505021). Study 3119002 showed lack of efficacy of ODM109 so the sponsor decided to terminate this study
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	amyotrophic lateral sclerosis	LEVOSIMENDAN	targetBased	3	Completed	21/06/2018	https://clinicaltrials.gov/study/NCT03505021	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	amyotrophic lateral sclerosis	LEVOSIMENDAN	targetBased	3	Completed	21/06/2018	https://clinicaltrials.gov/study/NCT03505021	0.7	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	transient ischemic attack	LEVOSIMENDAN	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00698763	0.2	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	transient ischemic attack	LEVOSIMENDAN	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00698763	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5add9c2f-421d-44ec-952d-95c3ff0a31e4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5add9c2f-421d-44ec-952d-95c3ff0a31e4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a519a201-bcfd-4029-9bdf-fc3e03f975ac	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a519a201-bcfd-4029-9bdf-fc3e03f975ac	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63841f53-a567-4102-80b5-3565d9b52373	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DIHYDROCODEINE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63841f53-a567-4102-80b5-3565d9b52373	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE SULFATE	targetBased	3	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04785768	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE SULFATE	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00822614	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE SULFATE	targetBased	3	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00822614	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE SULFATE	targetBased	3	Recruiting	22/04/2019	https://clinicaltrials.gov/study/NCT03967327	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE SULFATE	targetBased	3	Recruiting	22/04/2019	https://clinicaltrials.gov/study/NCT03967327	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE SULFATE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02660229	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cancer pain	MORPHINE SULFATE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02660229	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=872ceecb-1f14-7a43-7451-e4650a01fbd9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=872ceecb-1f14-7a43-7451-e4650a01fbd9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1798cf82-9893-4de2-89a5-2fa4f229a5c5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1798cf82-9893-4de2-89a5-2fa4f229a5c5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE SULFATE	targetBased	4	Terminated	01/11/2011	https://clinicaltrials.gov/study/NCT02143141	1	GoF	protect	feasibility of population needed to complete study
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	MORPHINE SULFATE	targetBased	4	Terminated	01/11/2011	https://clinicaltrials.gov/study/NCT02143141	1	GoF	protect	feasibility of population needed to complete study
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c847554-3b4b-4d24-a145-2ef7e9b83699	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c847554-3b4b-4d24-a145-2ef7e9b83699	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca2e2b04-c12c-4957-a93e-f8bbe554a8be	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca2e2b04-c12c-4957-a93e-f8bbe554a8be	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadc3fdb-8edc-44cd-aaea-89e68aaf9a04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadc3fdb-8edc-44cd-aaea-89e68aaf9a04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	MORPHINE SULFATE	targetBased	4	Completed	16/01/2019	https://clinicaltrials.gov/study/NCT03761277	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Back pain	MORPHINE SULFATE	targetBased	4	Completed	16/01/2019	https://clinicaltrials.gov/study/NCT03761277	1	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Cognitive impairment	DAVUNETIDE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00404014	0.2	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Cognitive impairment	DAVUNETIDE	targetBased	2	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00422981	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Parkinson disease	DROXIDOPA	targetBased	2	Unknown status	01/05/2016	https://clinicaltrials.gov/study/NCT02812147	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Parkinson disease	DROXIDOPA	targetBased	2	Recruiting	17/08/2018	https://clinicaltrials.gov/study/NCT03567447	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Parkinson disease	DROXIDOPA	targetBased	4	Completed	18/04/2017	https://clinicaltrials.gov/study/NCT03115827	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00407095	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00407095	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00269516	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00269516	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00335374	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00335374	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00332917	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00332917	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00134251	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00134251	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00269516	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00269516	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00269516	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00269516	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00269516	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00269516	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00406588	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00406588	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00332917	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00332917	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00332917	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00134251	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00134251	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	PARDOPRUNOX	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00134251	0.7	GoF	protect
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	PLA2G7	Platelet-activating factor acetylhydrolase	Alzheimer disease	RILAPLADIB	targetBased	2	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01428453	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALDEMEDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALDEMEDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	subarachnoid hemorrhage	BARICITINIB	targetBased	2	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT06439615	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	brain injury	BARICITINIB	targetBased	2	Not yet recruiting	01/10/2023	https://clinicaltrials.gov/study/NCT06065046	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	BREXPIPRAZOLE	targetBased	3	Completed	11/10/2018	https://clinicaltrials.gov/study/NCT03594123	0.7	GoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	intracerebral hemorrhage	DIMETHYL FUMARATE	targetBased	2	Withdrawn	01/06/2021	https://clinicaltrials.gov/study/NCT04890379	0.2	LoF	protect	There are no sufficient patients in the hospital.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	LECOZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00151333	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Alzheimer disease	LECOZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00151333	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	neuropathic pain	RALFINAMIDE	targetBased	2	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00736151	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	RALFINAMIDE	targetBased	3	Completed	20/03/2009	https://clinicaltrials.gov/study/NCT01019824	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	RALFINAMIDE	targetBased	2	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00736151	0.2	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	pain	RALFINAMIDE	targetBased	3	Completed	20/03/2009	https://clinicaltrials.gov/study/NCT01019824	0.7	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	diabetic neuropathy	FILOREXANT	targetBased	2	Completed	26/03/2012	https://clinicaltrials.gov/study/NCT01564459	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	diabetic neuropathy	FILOREXANT	targetBased	2	Completed	26/03/2012	https://clinicaltrials.gov/study/NCT01564459	0.2	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	smoking cessation	DULAGLUTIDE	targetBased	2	Completed	26/06/2017	https://clinicaltrials.gov/study/NCT03204396	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	smoking cessation	DULAGLUTIDE	targetBased	2	Completed	26/06/2017	https://clinicaltrials.gov/study/NCT03204396	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	smoking cessation	DULAGLUTIDE	targetBased	2	Completed	26/06/2017	https://clinicaltrials.gov/study/NCT03204396	0.2	GoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00479557	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00479557	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	targetBased	2	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00479557	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00498602	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00498602	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	targetBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00498602	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00752232	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00752232	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00752232	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Terminated	01/12/2010	https://clinicaltrials.gov/study/NCT01238991	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Terminated	01/12/2010	https://clinicaltrials.gov/study/NCT01238991	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	targetBased	2	Terminated	01/12/2010	https://clinicaltrials.gov/study/NCT01238991	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT00960531	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT00960531	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	targetBased	2	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT00960531	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01284387	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01284387	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01284387	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00959192	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00959192	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	targetBased	2	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00959192	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01227564	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	pathwayBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01227564	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VANUTIDE CRIDIFICAR	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01227564	0.2		protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	Back pain	PARATHYROID HORMONE	targetBased	4	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00713258	1	GoF	protect	Slow enrolment
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	stroke	PLASMINOGEN	targetBased	3	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02002325	0.7		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	stroke	PLASMINOGEN	targetBased	3	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02002325	0.7		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Terminated	30/11/2015	https://clinicaltrials.gov/study/NCT02565511	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Terminated	30/11/2015	https://clinicaltrials.gov/study/NCT02565511	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	targetBased	2	Terminated	30/11/2015	https://clinicaltrials.gov/study/NCT02565511	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00795418	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00795418	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	targetBased	2	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00795418	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01097096	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01097096	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	targetBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01097096	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00733863	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00733863	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	targetBased	2	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00733863	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00956410	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00956410	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	targetBased	2	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00956410	0.2		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01023685	0.2		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	pathwayBased	2	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01023685	0.2		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	AMILOMOTIDE	targetBased	2	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01023685	0.2		protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	LIXISENATIDE	targetBased	2	Completed	13/06/2018	https://clinicaltrials.gov/study/NCT03439943	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	LIXISENATIDE	targetBased	2	Completed	13/06/2018	https://clinicaltrials.gov/study/NCT03439943	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	LIXISENATIDE	targetBased	2	Completed	13/06/2018	https://clinicaltrials.gov/study/NCT03439943	0.2	GoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	BAPINEUZUMAB	pathwayBased	3	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT00937352	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	BAPINEUZUMAB	targetBased	3	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT00937352	0.7		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	BAPINEUZUMAB	pathwayBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00575055	0.7		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	BAPINEUZUMAB	pathwayBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00575055	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	BAPINEUZUMAB	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00575055	0.7		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	BAPINEUZUMAB	pathwayBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00574132	0.7		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	BAPINEUZUMAB	pathwayBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00574132	0.7		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	BAPINEUZUMAB	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00574132	0.7		protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	SEMAGLUTIDE	targetBased	3	Active, not recruiting	18/05/2021	https://clinicaltrials.gov/study/NCT04777409	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	SEMAGLUTIDE	targetBased	3	Active, not recruiting	18/05/2021	https://clinicaltrials.gov/study/NCT04777409	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	SEMAGLUTIDE	targetBased	3	Active, not recruiting	18/05/2021	https://clinicaltrials.gov/study/NCT04777409	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	SEMAGLUTIDE	targetBased	3	Active, not recruiting	20/06/2023	https://clinicaltrials.gov/study/NCT05891496	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	SEMAGLUTIDE	targetBased	3	Active, not recruiting	20/06/2023	https://clinicaltrials.gov/study/NCT05891496	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	SEMAGLUTIDE	targetBased	3	Active, not recruiting	20/06/2023	https://clinicaltrials.gov/study/NCT05891496	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	pseudotumor cerebri	SEMAGLUTIDE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06361823	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	pseudotumor cerebri	SEMAGLUTIDE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06361823	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	pseudotumor cerebri	SEMAGLUTIDE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06361823	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	SEMAGLUTIDE	targetBased	2	Not yet recruiting	02/01/2019	https://clinicaltrials.gov/study/NCT03659682	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	SEMAGLUTIDE	targetBased	2	Not yet recruiting	02/01/2019	https://clinicaltrials.gov/study/NCT03659682	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	SEMAGLUTIDE	targetBased	2	Not yet recruiting	02/01/2019	https://clinicaltrials.gov/study/NCT03659682	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00626418	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00626418	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00626418	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00626418	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00626418	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00626418	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00834327	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00834327	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00834327	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00834327	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00834327	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	APLINDORE	targetBased	2	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00834327	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00623324	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00623324	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00623324	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00623324	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00623324	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00623324	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00809302	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00809302	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00809302	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00809302	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00809302	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	APLINDORE	targetBased	2	Terminated	01/12/2008	https://clinicaltrials.gov/study/NCT00809302	0.2	GoF	protect	Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Alzheimer disease	NERAMEXANE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00090116	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT02249403	0.2	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT02249403	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT02249403	0.2	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT02249403	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT02249403	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/05/1999	https://clinicaltrials.gov/study/NCT02248116	0.2	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/05/1999	https://clinicaltrials.gov/study/NCT02248116	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/05/1999	https://clinicaltrials.gov/study/NCT02248116	0.2	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/05/1999	https://clinicaltrials.gov/study/NCT02248116	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/05/1999	https://clinicaltrials.gov/study/NCT02248116	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/12/1999	https://clinicaltrials.gov/study/NCT02249351	0.2	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/12/1999	https://clinicaltrials.gov/study/NCT02249351	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/12/1999	https://clinicaltrials.gov/study/NCT02249351	0.2	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/12/1999	https://clinicaltrials.gov/study/NCT02249351	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	TALSACLIDINE	targetBased	2	Terminated	01/12/1999	https://clinicaltrials.gov/study/NCT02249351	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	PIMAVANSERIN	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02035553	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN	targetBased	3	Recruiting	27/09/2023	https://clinicaltrials.gov/study/NCT06068465	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00550238	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN	targetBased	4	Recruiting	24/10/2022	https://clinicaltrials.gov/study/NCT04373317	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00477672	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00658567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	neurodegenerative disease	PIMAVANSERIN	targetBased	3	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03575052	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	neurodegenerative disease	PIMAVANSERIN	targetBased	3	Completed	17/07/2018	https://clinicaltrials.gov/study/NCT03623321	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00009048	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	movement disorder	SARIZOTAN HYDROCHLORIDE	targetBased	2	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00314288	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXEGOL OXALATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c02665d-05d2-4e99-b403-c270de543ebe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXEGOL OXALATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c02665d-05d2-4e99-b403-c270de543ebe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXEGOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c02665d-05d2-4e99-b403-c270de543ebe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXEGOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c02665d-05d2-4e99-b403-c270de543ebe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXEGOL	targetBased	4	Completed	01/10/2017	https://clinicaltrials.gov/study/NCT03235739	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALOXEGOL	targetBased	4	Completed	01/10/2017	https://clinicaltrials.gov/study/NCT03235739	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain injury	NALOXEGOL	targetBased	3	Recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05008926	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	brain injury	NALOXEGOL	targetBased	3	Recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05008926	0.7	LoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	intracranial meningioma	CAPIVASERTIB	targetBased	2	Recruiting	01/08/2015	https://clinicaltrials.gov/study/NCT02523014	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	diabetic polyneuropathy	CEBRANOPADOL	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00878293	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CEBRANOPADOL	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00872885	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CEBRANOPADOL	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00872885	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CEBRANOPADOL	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06423703	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CEBRANOPADOL	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06423703	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	CEBRANOPADOL	targetBased	2	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01725087	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CEBRANOPADOL	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00872885	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CEBRANOPADOL	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06423703	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	CEBRANOPADOL	targetBased	2	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01725087	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	CEBRANOPADOL	targetBased	2	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01725087	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	CEBRANOPADOL	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00878293	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diabetic polyneuropathy	CEBRANOPADOL	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00878293	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OLICERIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OLICERIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OLICERIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce167984-8b9d-40b7-84ce-d0f33fff1eaa	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OLICERIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce167984-8b9d-40b7-84ce-d0f33fff1eaa	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OLICERIDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX07	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OLICERIDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AX07	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Alzheimer disease	PIMAVANSERIN TARTRATE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02035553	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN TARTRATE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00477672	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN TARTRATE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00550238	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN TARTRATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN TARTRATE	targetBased	3	Recruiting	27/09/2023	https://clinicaltrials.gov/study/NCT06068465	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN TARTRATE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00658567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Parkinson disease	PIMAVANSERIN TARTRATE	targetBased	3	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01174004	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALDEMEDINE TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	NALDEMEDINE TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16	1	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	ADUCANUMAB	pathwayBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf	1		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	ADUCANUMAB	pathwayBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf	1		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	ADUCANUMAB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf	1		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	ADUCANUMAB	targetBased	3	Active, not recruiting	02/06/2022	https://clinicaltrials.gov/study/NCT05310071	0.7		protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	ADUCANUMAB	pathwayBased	3	Terminated	13/08/2015	https://clinicaltrials.gov/study/NCT02477800	0.7		protect	Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	ADUCANUMAB	pathwayBased	3	Terminated	13/08/2015	https://clinicaltrials.gov/study/NCT02477800	0.7		protect	Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	ADUCANUMAB	targetBased	3	Terminated	13/08/2015	https://clinicaltrials.gov/study/NCT02477800	0.7		protect	Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BENZHYDROCODONE HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BENZHYDROCODONE HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s000lbl.pdf	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BENZHYDROCODONE HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BENZHYDROCODONE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	BENZHYDROCODONE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s000lbl.pdf	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	BENZHYDROCODONE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s000lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=688fa4d7-de12-4930-8bc5-0169297c1da6	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ebb3e0b-8fd5-4ac8-ba2f-abfcfc0c91ad	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ebb3e0b-8fd5-4ac8-ba2f-abfcfc0c91ad	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	restless legs syndrome	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ebb3e0b-8fd5-4ac8-ba2f-abfcfc0c91ad	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d441add2-b30c-414d-a645-8b40a13b67fc	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d441add2-b30c-414d-a645-8b40a13b67fc	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d441add2-b30c-414d-a645-8b40a13b67fc	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d441add2-b30c-414d-a645-8b40a13b67fc	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d441add2-b30c-414d-a645-8b40a13b67fc	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d441add2-b30c-414d-a645-8b40a13b67fc	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf89d9ae-decf-4078-8c97-59a6f199ad24	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf89d9ae-decf-4078-8c97-59a6f199ad24	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf89d9ae-decf-4078-8c97-59a6f199ad24	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b15a21d-cde6-4c9f-b9b2-b747ded70931	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b15a21d-cde6-4c9f-b9b2-b747ded70931	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	PRAMIPEXOLE DIHYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b15a21d-cde6-4c9f-b9b2-b747ded70931	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	concussion	QUETIAPINE FUMARATE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	concussion	QUETIAPINE FUMARATE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	concussion	QUETIAPINE FUMARATE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	concussion	QUETIAPINE FUMARATE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	concussion	QUETIAPINE FUMARATE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	concussion	QUETIAPINE FUMARATE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	concussion	QUETIAPINE FUMARATE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06333990	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking cessation	CENTANAFADINE	targetBased	2	Completed	15/09/2021	https://clinicaltrials.gov/study/NCT05066724	0.2	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Lewy body dementia	MEVIDALEN	targetBased	2	Completed	09/11/2017	https://clinicaltrials.gov/study/NCT03305809	0.2	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Lewy body dementia	MEVIDALEN	targetBased	2	Completed	09/11/2017	https://clinicaltrials.gov/study/NCT03305809	0.2	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Lewy body dementia	MEVIDALEN	targetBased	2	Completed	09/11/2017	https://clinicaltrials.gov/study/NCT03305809	0.2	GoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	metastasis	MOTEXAFIN GADOLINIUM	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00054795	0.7	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	metastasis	MOTEXAFIN GADOLINIUM	targetBased	2	Terminated		https://clinicaltrials.gov/study/NCT00121420	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Ocular pain	SAF312	targetBased	2	Completed	21/04/2021	https://clinicaltrials.gov/study/NCT04630158	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Ocular pain	SAF312	targetBased	2	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02961062	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	SAF312	targetBased	2	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00986882	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Neurogenic bladder	SAF312	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01598103	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	AZD1386	targetBased	2	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00976534	0.2	LoF	protect	The study was terminated due to results in another study (NCT00878501).
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pain	AZD1386	targetBased	2	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00672646	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	neuropathic pain	AZD1386	targetBased	2	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00976534	0.2	LoF	protect	The study was terminated due to results in another study (NCT00878501).
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	low tension glaucoma	AMA0076	targetBased	2	Completed	06/03/2017	https://clinicaltrials.gov/study/NCT03106532	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	DB959	targetBased	2	Completed	01/03/2021	https://clinicaltrials.gov/study/NCT04251182	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	DB959	targetBased	2	Completed	01/03/2021	https://clinicaltrials.gov/study/NCT04251182	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	DB959	targetBased	2	Completed	01/03/2021	https://clinicaltrials.gov/study/NCT04251182	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	DB959	targetBased	2	Completed	01/03/2021	https://clinicaltrials.gov/study/NCT04251182	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	DB959	targetBased	2	Completed	01/03/2021	https://clinicaltrials.gov/study/NCT04251182	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Alzheimer disease	DB959	targetBased	2	Completed	01/03/2021	https://clinicaltrials.gov/study/NCT04251182	0.2	GoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Alzheimer disease	LEMBOREXANT	targetBased	2	Recruiting	11/03/2024	https://clinicaltrials.gov/study/NCT06274528	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Alzheimer disease	LEMBOREXANT	targetBased	2	Recruiting	11/03/2024	https://clinicaltrials.gov/study/NCT06274528	0.2	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Alzheimer disease	LEMBOREXANT	targetBased	2	Withdrawn	01/03/2023	https://clinicaltrials.gov/study/NCT05728736	0.2	LoF	protect	Study was terminated due to enrollment difficulties and the inability to obtain necessary study supplies. Five participants signed consent; however, no one was randomized. The study was officially terminated with the funding source on 10/04/2023.
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Alzheimer disease	LEMBOREXANT	targetBased	2	Withdrawn	01/03/2023	https://clinicaltrials.gov/study/NCT05728736	0.2	LoF	protect	Study was terminated due to enrollment difficulties and the inability to obtain necessary study supplies. Five participants signed consent; however, no one was randomized. The study was officially terminated with the funding source on 10/04/2023.
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	epilepsy	LEMBOREXANT	targetBased	3	Recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06262594	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	epilepsy	LEMBOREXANT	targetBased	3	Recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06262594	0.7	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	neuropathic pain	ABT-639	targetBased	2	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01589432	0.2	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	neuropathic pain	ABT-639	targetBased	2	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01345045	0.2	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Parkinson disease	TAVAPADON	targetBased	3	Active, not recruiting	06/01/2020	https://clinicaltrials.gov/study/NCT04223193	0.7	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Parkinson disease	TAVAPADON	targetBased	3	Active, not recruiting	06/01/2020	https://clinicaltrials.gov/study/NCT04223193	0.7	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Parkinson disease	TAVAPADON	targetBased	3	Completed	27/10/2020	https://clinicaltrials.gov/study/NCT04542499	0.7	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Parkinson disease	TAVAPADON	targetBased	3	Completed	27/10/2020	https://clinicaltrials.gov/study/NCT04542499	0.7	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Parkinson disease	TAVAPADON	targetBased	3	Completed	27/10/2020	https://clinicaltrials.gov/study/NCT04542499	0.7	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Parkinson disease	TAVAPADON	targetBased	3	Active, not recruiting	13/12/2019	https://clinicaltrials.gov/study/NCT04201093	0.7	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Parkinson disease	TAVAPADON	targetBased	3	Active, not recruiting	13/12/2019	https://clinicaltrials.gov/study/NCT04201093	0.7	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Parkinson disease	TAVAPADON	targetBased	3	Active, not recruiting	13/12/2019	https://clinicaltrials.gov/study/NCT04201093	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	cerebral palsy	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737	1	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Ocular pain	SYL-1001	targetBased	2	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02455999	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		diabetic neuropathy	INDANTADOL	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00375960	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain	INDANTADOL	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00375960	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		neuropathic pain	INDANTADOL	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00794430	0.2	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	LECANEMAB	targetBased	3	Recruiting	14/07/2020	https://clinicaltrials.gov/study/NCT04468659	0.7	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	LECANEMAB	pathwayBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf	1	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	LECANEMAB	pathwayBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf	1	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	LECANEMAB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf	1	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	LECANEMAB	pathwayBased	3	Active, not recruiting	27/03/2019	https://clinicaltrials.gov/study/NCT03887455	0.7	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	LECANEMAB	pathwayBased	3	Active, not recruiting	27/03/2019	https://clinicaltrials.gov/study/NCT03887455	0.7	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	LECANEMAB	targetBased	3	Active, not recruiting	27/03/2019	https://clinicaltrials.gov/study/NCT03887455	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DEXTROMORAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AC01	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	DEXTROMORAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AC01	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	DEXTROMORAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02AC01	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	neuropathic pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01400139	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6222b0cf-7222-41c3-bdfc-5f799a8ef394	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6222b0cf-7222-41c3-bdfc-5f799a8ef394	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT03605914	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT03605914	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7510a9ec-6ef0-4610-8dce-8286a043d09c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7510a9ec-6ef0-4610-8dce-8286a043d09c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01115569	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01115569	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01400139	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neuropathic pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01400139	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01452529	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01081912	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Chronic pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01115569	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59e7db61-9ce5-416c-b576-87babe94dbdf	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5eef594-08e6-41ca-a2b6-16fe989a649a	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c29b97e9-8097-4d87-a420-ccf5aec8274a	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d321f279-a696-495d-932e-ea3e18c6c88a	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=681d604f-6b33-4d7c-93ae-a5458062ced9	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1367be54-3417-4a53-9c70-8d93007d26c3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01452529	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01452529	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01081912	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	HYDROCODONE BITARTRATE	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01081912	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Low back pain	AXOMADOL	targetBased	2	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01043263	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	AXOMADOL	targetBased	2	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01043263	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	AXOMADOL	targetBased	2	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01043263	0.2	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Alzheimer disease	TESOFENSINE	targetBased	2	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00153010	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Parkinson disease	TESOFENSINE	targetBased	2	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00148512	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Parkinson disease	TESOFENSINE	targetBased	2	Completed	01/08/2000	https://clinicaltrials.gov/study/NCT00006077	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Parkinson disease	TESOFENSINE	targetBased	2	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00148486	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE NAPSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE NAPSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE NAPSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e106abb-8b1d-4d83-8b42-fc46cfde113e	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE NAPSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e106abb-8b1d-4d83-8b42-fc46cfde113e	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE NAPSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4cf33260-5a78-4207-b113-a9d6771811a3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	PROPOXYPHENE NAPSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4cf33260-5a78-4207-b113-a9d6771811a3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE TEREPHTHALATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=946b4df5-f1dc-42a7-acb9-1d2543c9bb44	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	OXYCODONE TEREPHTHALATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=946b4df5-f1dc-42a7-acb9-1d2543c9bb44	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	DIFELIKEFALIN	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00877799	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	DIFELIKEFALIN	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02542384	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	DIFELIKEFALIN	targetBased	2	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01789476	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	DIFELIKEFALIN	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01361568	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	MK-7622	targetBased	2	Terminated	22/10/2013	https://clinicaltrials.gov/study/NCT01852110	0.2	GoF	protect	Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	MK-7622	targetBased	2	Terminated	22/10/2013	https://clinicaltrials.gov/study/NCT01852110	0.2	GoF	protect	Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	MK-7622	targetBased	2	Terminated	22/10/2013	https://clinicaltrials.gov/study/NCT01852110	0.2	GoF	protect	Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	MK-7622	targetBased	2	Terminated	22/10/2013	https://clinicaltrials.gov/study/NCT01852110	0.2	GoF	protect	Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Alzheimer disease	MK-7622	targetBased	2	Terminated	22/10/2013	https://clinicaltrials.gov/study/NCT01852110	0.2	GoF	protect	Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	LIRAGLUTIDE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT01843075	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	LIRAGLUTIDE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT01843075	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Alzheimer disease	LIRAGLUTIDE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT01843075	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	smoking cessation	LIRAGLUTIDE	targetBased	2	Completed	29/11/2018	https://clinicaltrials.gov/study/NCT03712098	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	smoking cessation	LIRAGLUTIDE	targetBased	2	Completed	29/11/2018	https://clinicaltrials.gov/study/NCT03712098	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	smoking cessation	LIRAGLUTIDE	targetBased	2	Completed	29/11/2018	https://clinicaltrials.gov/study/NCT03712098	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	LIRAGLUTIDE	targetBased	2	Completed	03/04/2017	https://clinicaltrials.gov/study/NCT02953665	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	LIRAGLUTIDE	targetBased	2	Completed	03/04/2017	https://clinicaltrials.gov/study/NCT02953665	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	LIRAGLUTIDE	targetBased	2	Completed	03/04/2017	https://clinicaltrials.gov/study/NCT02953665	0.2	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Parkinson disease	VODOBATINIB	targetBased	2	Active, not recruiting	18/02/2019	https://clinicaltrials.gov/study/NCT03655236	0.2	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	photosensitive epilepsy	APINOCALTAMIDE	targetBased	2	Completed	06/10/2017	https://clinicaltrials.gov/study/NCT03239691	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f317cd06-2851-4a52-86d3-6efde3a4c243	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f317cd06-2851-4a52-86d3-6efde3a4c243	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5819bdf7-300e-45b8-8f3a-447b53656293	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5819bdf7-300e-45b8-8f3a-447b53656293	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f317cd06-2851-4a52-86d3-6efde3a4c243	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	pain	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5819bdf7-300e-45b8-8f3a-447b53656293	1	GoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	pathwayBased	2	Completed	18/12/2017	https://clinicaltrials.gov/study/NCT03367403	0.2	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	pathwayBased	2	Completed	18/12/2017	https://clinicaltrials.gov/study/NCT03367403	0.2	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	targetBased	2	Completed	18/12/2017	https://clinicaltrials.gov/study/NCT03367403	0.2	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	pathwayBased	3	Active, not recruiting	19/06/2020	https://clinicaltrials.gov/study/NCT04437511	0.7	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	pathwayBased	3	Active, not recruiting	19/06/2020	https://clinicaltrials.gov/study/NCT04437511	0.7	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	targetBased	3	Active, not recruiting	19/06/2020	https://clinicaltrials.gov/study/NCT04437511	0.7	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	pathwayBased	3	Recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT05026866	0.7	LoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	pathwayBased	3	Recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT05026866	0.7	LoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	DONANEMAB	targetBased	3	Recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT05026866	0.7	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3)	MAPK10	MAPK10	Mitogen-activated protein kinase 10	hearing loss	BRIMAPITIDE, C-TERMINAL ACID	targetBased	3	Terminated	01/06/2016	https://clinicaltrials.gov/study/NCT02809118	0.7	LoF	protect	Availability of relevant new efficacy data from another study
Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3)	MAPK10	MAPK10	Mitogen-activated protein kinase 10	hearing loss	BRIMAPITIDE, C-TERMINAL ACID	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00802425	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3)	MAPK10	MAPK10	Mitogen-activated protein kinase 10	hearing loss	BRIMAPITIDE, C-TERMINAL ACID	targetBased	3	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02561091	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Parkinson disease	RADOTINIB	targetBased	2	Recruiting	09/09/2021	https://clinicaltrials.gov/study/NCT04691661	0.2	LoF	protect
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	HTT	Huntingtin	Huntington disease	TOMINERSEN	targetBased	3	Completed	23/01/2019	https://clinicaltrials.gov/study/NCT03761849	0.7	LoF	protect
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	HTT	Huntingtin	Huntington disease	TOMINERSEN	targetBased	3	Completed	23/01/2019	https://clinicaltrials.gov/study/NCT03761849	0.7	LoF	protect
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	HTT	Huntingtin	Huntington disease	TOMINERSEN	targetBased	3	Completed	23/01/2019	https://clinicaltrials.gov/study/NCT03761849	0.7	LoF	protect
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	HTT	Huntingtin	Huntington disease	TOMINERSEN	targetBased	3	Completed	23/01/2019	https://clinicaltrials.gov/study/NCT03761849	0.7	LoF	protect
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	HTT	Huntingtin	Huntington disease	TOMINERSEN	targetBased	3	Completed	23/04/2019	https://clinicaltrials.gov/study/NCT03842969	0.7	LoF	protect
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	HTT	Huntingtin	Huntington disease	TOMINERSEN	targetBased	3	Completed	23/04/2019	https://clinicaltrials.gov/study/NCT03842969	0.7	LoF	protect
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	HTT	Huntingtin	Huntington disease	TOMINERSEN	targetBased	3	Completed	23/04/2019	https://clinicaltrials.gov/study/NCT03842969	0.7	LoF	protect
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	HTT	Huntingtin	Huntington disease	TOMINERSEN	targetBased	3	Completed	23/04/2019	https://clinicaltrials.gov/study/NCT03842969	0.7	LoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	TRHR	Thyrotropin-releasing hormone receptor	cerebellar ataxia	ROVATIRELIN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT01970124	0.7	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	TRHR	Thyrotropin-releasing hormone receptor	cerebellar ataxia	ROVATIRELIN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT01970124	0.7	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	TRHR	Thyrotropin-releasing hormone receptor	cerebellar ataxia	ROVATIRELIN	targetBased	3	Completed	15/11/2016	https://clinicaltrials.gov/study/NCT02889302	0.7	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	TRHR	Thyrotropin-releasing hormone receptor	cerebellar ataxia	ROVATIRELIN	targetBased	3	Completed	15/11/2016	https://clinicaltrials.gov/study/NCT02889302	0.7	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	TRHR	Thyrotropin-releasing hormone receptor	cerebellar ataxia	ROVATIRELIN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT01970111	0.7	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	TRHR	Thyrotropin-releasing hormone receptor	cerebellar ataxia	ROVATIRELIN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT01970111	0.7	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	TRHR	Thyrotropin-releasing hormone receptor	cerebellar ataxia	ROVATIRELIN	targetBased	3	Completed	09/10/2013	https://clinicaltrials.gov/study/NCT01970098	0.7	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	TRHR	Thyrotropin-releasing hormone receptor	cerebellar ataxia	ROVATIRELIN	targetBased	3	Completed	09/10/2013	https://clinicaltrials.gov/study/NCT01970098	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODEGOL	targetBased	3	Completed	14/04/2015	https://clinicaltrials.gov/study/NCT02367820	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODEGOL	targetBased	3	Completed	14/04/2015	https://clinicaltrials.gov/study/NCT02367820	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODEGOL	targetBased	3	Completed	11/03/2015	https://clinicaltrials.gov/study/NCT02362672	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Chronic pain	OXYCODEGOL	targetBased	3	Completed	11/03/2015	https://clinicaltrials.gov/study/NCT02362672	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODEGOL	targetBased	3	Completed	11/03/2015	https://clinicaltrials.gov/study/NCT02362672	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODEGOL	targetBased	3	Completed	11/03/2015	https://clinicaltrials.gov/study/NCT02362672	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODEGOL	targetBased	3	Completed	14/04/2015	https://clinicaltrials.gov/study/NCT02367820	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Low back pain	OXYCODEGOL	targetBased	3	Completed	14/04/2015	https://clinicaltrials.gov/study/NCT02367820	0.7	GoF	protect
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	TILAVONEMAB	pathwayBased	2	Completed	26/01/2017	https://clinicaltrials.gov/study/NCT02880956	0.2	LoF	protect
qHTS Assay for Tau Filament Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	TILAVONEMAB	targetBased	2	Completed	26/01/2017	https://clinicaltrials.gov/study/NCT02880956	0.2	LoF	protect
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	TILAVONEMAB	pathwayBased	2	Completed	26/01/2017	https://clinicaltrials.gov/study/NCT02880956	0.2	LoF	protect
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	ZAGOTENEMAB	pathwayBased	2	Completed	30/04/2018	https://clinicaltrials.gov/study/NCT03518073	0.2	LoF	protect
qHTS Assay for Tau Filament Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	ZAGOTENEMAB	targetBased	2	Completed	30/04/2018	https://clinicaltrials.gov/study/NCT03518073	0.2	LoF	protect
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	ZAGOTENEMAB	pathwayBased	2	Completed	30/04/2018	https://clinicaltrials.gov/study/NCT03518073	0.2	LoF	protect
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	SNCA	Alpha-synuclein	Parkinson disease	PRASINEZUMAB	pathwayBased	2	Active, not recruiting	05/05/2021	https://clinicaltrials.gov/study/NCT04777331	0.2		protect
qHTS of alpha-syn Inhibitors	SNCA	SNCA	Alpha-synuclein	Parkinson disease	PRASINEZUMAB	pathwayBased	2	Active, not recruiting	05/05/2021	https://clinicaltrials.gov/study/NCT04777331	0.2		protect
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	SNCA	Alpha-synuclein	Parkinson disease	PRASINEZUMAB	pathwayBased	2	Active, not recruiting	27/06/2017	https://clinicaltrials.gov/study/NCT03100149	0.2		protect
qHTS of alpha-syn Inhibitors	SNCA	SNCA	Alpha-synuclein	Parkinson disease	PRASINEZUMAB	pathwayBased	2	Active, not recruiting	27/06/2017	https://clinicaltrials.gov/study/NCT03100149	0.2		protect
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	SEMORINEMAB	pathwayBased	2	Completed	25/01/2019	https://clinicaltrials.gov/study/NCT03828747	0.2	LoF	protect
qHTS Assay for Tau Filament Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	SEMORINEMAB	targetBased	2	Completed	25/01/2019	https://clinicaltrials.gov/study/NCT03828747	0.2	LoF	protect
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	SEMORINEMAB	pathwayBased	2	Completed	25/01/2019	https://clinicaltrials.gov/study/NCT03828747	0.2	LoF	protect
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	EPAS1	Endothelial PAS domain-containing protein 1	von Hippel-Lindau disease	BELZUTIFAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	peripheral neuropathy	ZICONOTIDE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01373983	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	neuropathic pain	ZICONOTIDE	targetBased	4	Completed	03/11/2016	https://clinicaltrials.gov/study/NCT03321955	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	pain	ZICONOTIDE	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00047749	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	pain	ZICONOTIDE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00076544	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	pain	ZICONOTIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N02BG08	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	low tension glaucoma	NETARSUDIL	targetBased	4	Not yet recruiting	01/08/2021	https://clinicaltrials.gov/study/NCT04981886	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	low tension glaucoma	NETARSUDIL	targetBased	4	Recruiting	13/06/2024	https://clinicaltrials.gov/study/NCT06449352	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TAK-071	targetBased	2	Completed	21/10/2020	https://clinicaltrials.gov/study/NCT04334317	0.2	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TAK-071	targetBased	2	Completed	21/10/2020	https://clinicaltrials.gov/study/NCT04334317	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TAK-071	targetBased	2	Completed	21/10/2020	https://clinicaltrials.gov/study/NCT04334317	0.2	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TAK-071	targetBased	2	Completed	21/10/2020	https://clinicaltrials.gov/study/NCT04334317	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Parkinson disease	TAK-071	targetBased	2	Completed	21/10/2020	https://clinicaltrials.gov/study/NCT04334317	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	MESDOPETAM	targetBased	2	Completed	29/10/2020	https://clinicaltrials.gov/study/NCT04435431	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	MESDOPETAM	targetBased	2	Completed	29/10/2020	https://clinicaltrials.gov/study/NCT04435431	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	MESDOPETAM	targetBased	2	Completed	29/10/2020	https://clinicaltrials.gov/study/NCT04435431	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease	MESDOPETAM	targetBased	2	Completed	12/04/2018	https://clinicaltrials.gov/study/NCT03368170	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease	MESDOPETAM	targetBased	2	Completed	12/04/2018	https://clinicaltrials.gov/study/NCT03368170	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease	MESDOPETAM	targetBased	2	Completed	12/04/2018	https://clinicaltrials.gov/study/NCT03368170	0.2	LoF	protect
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	BEPRANEMAB	pathwayBased	2	Active, not recruiting	09/06/2021	https://clinicaltrials.gov/study/NCT04867616	0.2	LoF	protect
qHTS Assay for Tau Filament Binding	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	BEPRANEMAB	targetBased	2	Active, not recruiting	09/06/2021	https://clinicaltrials.gov/study/NCT04867616	0.2	LoF	protect
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	MAPT	Microtubule-associated protein, Microtubule-associated protein tau	Alzheimer disease	BEPRANEMAB	pathwayBased	2	Active, not recruiting	09/06/2021	https://clinicaltrials.gov/study/NCT04867616	0.2	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	pathwayBased	2	Active, not recruiting	30/09/2020	https://clinicaltrials.gov/study/NCT04693520	0.2	GoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	pathwayBased	2	Active, not recruiting	30/09/2020	https://clinicaltrials.gov/study/NCT04693520	0.2	GoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	targetBased	2	Active, not recruiting	30/09/2020	https://clinicaltrials.gov/study/NCT04693520	0.2	GoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	pathwayBased	3	Enrolling by invitation	02/04/2024	https://clinicaltrials.gov/study/NCT06304883	0.7	GoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	pathwayBased	3	Enrolling by invitation	02/04/2024	https://clinicaltrials.gov/study/NCT06304883	0.7	GoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	targetBased	3	Enrolling by invitation	02/04/2024	https://clinicaltrials.gov/study/NCT06304883	0.7	GoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	pathwayBased	3	Active, not recruiting	19/05/2021	https://clinicaltrials.gov/study/NCT04770220	0.7	GoF	protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	pathwayBased	3	Active, not recruiting	19/05/2021	https://clinicaltrials.gov/study/NCT04770220	0.7	GoF	protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Alzheimer disease	VALILTRAMIPROSATE	targetBased	3	Active, not recruiting	19/05/2021	https://clinicaltrials.gov/study/NCT04770220	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	NLY-01	targetBased	2	Active, not recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04154072	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	NLY-01	targetBased	2	Active, not recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04154072	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Parkinson disease	NLY-01	targetBased	2	Active, not recruiting	27/02/2020	https://clinicaltrials.gov/study/NCT04154072	0.2	GoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	PTK2	Focal adhesion kinase 1	intracranial meningioma	GSK-2256098	targetBased	2	Recruiting	01/08/2015	https://clinicaltrials.gov/study/NCT02523014	0.2	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	subarachnoid hemorrhage		targetBased	3	Not yet recruiting	01/08/2020	https://clinicaltrials.gov/study/NCT04532333	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	diabetic neuropathy		targetBased	2	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01893125	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease		targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Parkinson disease		targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease		targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Parkinson disease		targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease		targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Parkinson disease		targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01770145	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease		targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02549573	1	GoF	protect	Subject enrollment is unsatisfactory
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease		targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02549573	1	GoF	protect	Subject enrollment is unsatisfactory
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease		targetBased	4	Terminated	01/01/2016	https://clinicaltrials.gov/study/NCT02549573	1	GoF	protect	Subject enrollment is unsatisfactory
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Parkinson disease		targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Parkinson disease		targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Parkinson disease		targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c	1	GoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

drTarget portfolio target-disease associations for nervous system

DrTarget’s AI-Driven Insights into Nervous System Disorders

Our approach enables:

✔ Target discovery for drug repurposing✔ Prioritization of high-confidence gene-disease associations✔ Identification of novel therapeutic opportunities

This dataset supports drug discovery oriented to precision medicine efforts, offering valuable insights into neurodegenerative and neurological disorders.

Check best scored target-disease associations in table by selecting scores, genes or diseases:

Some of these associations have also gone through clinical trials.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

✔ Target discovery for drug repurposing
✔ Prioritization of high-confidence gene-disease associations
✔ Identification of novel therapeutic opportunities